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Summary 		
2	
CLRs are vital for orchestrating anti-fungal immunity. These receptors are expressed 
on myeloid immune cells and induce robust anti-A.f. responses including phagocytosis, 
cytokine and chemokine release, respiratory burst, and inflammasome activation. The 
role of Dectin-1 has been thoroughly investigated; however, the CLRs requirement 
during anti-A.f. response is controversial. The impact of Dectin-2, Mcl and Mincle 
during anti-A.f. immunity is not well understood. A.f. is complex and poses many 
challenges for the immune system. PRR collaboration is likely required for A.f. 
clearance. Collaboration between TLRs and CLRs has been identified. Recently, the first 
CLR:CLR collaboration was demonstrated between Dectin-1 and Dectin-2; however, 
this was not in response to A.f.. The research in this thesis describes many novel 
interactions between CLRs and A.f. and seeks to further the understanding of the 
complex collaborative anti-A.f. immune response.  
 
Firstly, a novel role for NE inducing Dectin-1 Isoform A cleavage was described. This 
impaired A.f. recognition and the anti-A.f. response. CF patients possess high airway 
NE activity and experience a severe A.f. disease burden. My research suggests blocking 
the action of NE in CF patient’s airway may restore Dectin-1 expression and improve 
patient’s anti-A.f. immune response.  
 
Secondly, in vivo CLR KO and DKO models were used to elicit alveolar macrophages 
reliance on CLRs when generating anti-A.f. responses. My research suggests Dectin-1 
might exclusively be required during early anti-A.f. responses. Unfortunately, 
discrepancies between the sex and microbiome of mice restricted the conclusions 
drawn from in vivo CLR KO and DKO A.f. infection experiments.  
 
Finally, I identified novel risk factors that can be used to stratify patients according to 
their susceptibility to A.f. infection. A.f. disease incidence and mortality rates are 
unacceptably high in immune-suppressed patients. Patients are often prophylactically 
treated with inadequate anti-fungal therapeutics. Stratifying patients according to 
their A.f. disease susceptibility would allow a personalised medicine approach and 
reduce unnecessary treatment. 	  
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A.f.   – Aspergillus fumigatus 
A.f. EG  – Aspergillus fumigatus early germlings 
A.f. HY  – Aspergillus fumigatus hyphae 
A.f. RC  – Aspergillus fumigatus resting conidia 
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AS   – Aspergillus sensitisation 
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BMDM  – Bone marrow derived macrophage 
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M-CSF   – Macrophage colony stimulating factor 
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TH   – Type T helper 
TLR   – Toll-like receptor 
TNF   – Tumour necrosis factor 
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Introduction 	 	
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1.1: Aspergillus fumigatus 
 
 
1.1.1: The fungi 
  
Aspergillus fumigatus (A.f.) is an ubiquitous fungus with an essential environmental 
role in recycling carbon and nitrogen. The fungus survives and grows on organic debris 
found in soil, its natural ecological niche [1, 2]. A.f. has a complicated life cycle typically 
replicating via asexual reproduction and the formation of conidiophores. Three 
important steps distinguish the A.f. life cycle and generate four distinct fungal 
morphologies as displayed in figure 1.1. Appropriately warm and moist environmental 
conditions activate resting conidia (RC) and initiate isotropic wall growth. Water and 
nutrient uptake allows RC to swell and develop in to swollen conidia (SC). The polarised 
growth of SC results in germ tubes and early germlings (EG). Germ tubes continue 
polarised growth and develop into hyphae and new mycelium (HY). Fully developed 
HY provide the structure required for the formation of conidiophores and growth and 
release of RC [3].   
8	
 
 
 
Figure 1.1: A.f. life cycle steps and morphologies. (A) 1x106/ml A.f. RC were grown in 
RPMI supplemented with Polymixin B at 37oC 5% CO2. Images were taken of the A.f. 
conidia at 6 hours to display SC, 10 hours to display EG and 24 hours to display HY. All 
images are the same resolution; therefore, 200μm measurement bar present in the 
RC & SC image is the correct dimension for all images.   
A	
RC	&	SC	
EG	
HY	
SC 
RC	
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A.f. sporulates abundantly with every conidial head producing thousands of RC, 2-3μm 
in diameter. The produced RC are particularly environmentally resistant withstanding 
temperature ranges from 0-99oC for prolonged periods whilst maintaining viability. RC 
can germinate and successfully initiate fungal growth between 20-50oC, temperatures 
regularly encountered in decaying vegetation [4]. A.f. doesn’t possess an elaborate 
mechanism for RC distribution; instead, RC are manually released by disturbances in 
the air and rely exclusively on air currents for dissemination. Due to their small size RC 
remain buoyant for long periods of time allowing the fungi to spread extensively. It is 
estimated humans worldwide will inhale at least several hundred A.f. RC each day [1, 
5].  
 
Recently a sexual reproduction cycle has been described for A.f.. 215 genes implicated 
in sexual reproduction were detected and isolates of “complimentary mating types” 
were demonstrated to undergo genetic recombination over a period of 6 months. This 
allowed for the generation of progeny with increased virulence and resistance to anti-
fungal therapeutics. A sexual reproduction cycle may explain the diversity between 
A.f. genotypes despite the predominantly clonal, asexual reproduction cycle [6].  
 
 
1.1.2: A.f. disease in immune-compromised individuals  
 
Until recently, A.f. has been described as a weak pathogen responsible primarily for 
allergic-type disease caused by the repeated inhalation of high quantities of A.f. RC. 
Even in this scenario, A.f. could only grow and invade lung tissue in individuals with 
pre-existing immune-compromised lung cavities resulting from infections such as 
tuberculosis [1]. Healthy individuals exposed to typical quantities of A.f. RC do not 
experience any disease or symptoms as RC are very efficiently cleared from the lungs, 
see figure 1.2 (A). Inhaled RC that have escaped mucociliary clearance and been 
deposited within the bronchioles or alveolar spaces are rapidly recognised and 
phagocytosed by lung-resident alveolar macrophages. RC that evade both the 
mucociliary and alveolar macrophage front-line immune response begin to germinate 
and initiate a robust neutrophil-driven anti-fungal immune response. In healthy 
10	
individuals this robust immune response culminates in the efficient pathology-free 
clearance of all A.f. from the lung before RC can germinate into HY [2, 4]. 
 
With the extensive use of modern immune-suppressing therapeutics, a very clear 
pathogenic role for A.f. has been identified in patients with compromised immune 
systems. Two distinct risk factors for A.f. disease, termed invasive Aspergillosis (IA), 
linked with immune-suppression have been described, see figure 1.2 (A & B). The first 
risk factor is prolonged neutropenia, this is often induced by intensive chemotherapy 
treatment. The second risk factor is the use of corticosteroids to treat graft versus host 
disease in allogeneic transplant patients. Both these risk factors greatly increase the 
likelihood of IA [7-9].  
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Figure 1.2: A.f. disease course is dependent on host immune-capability. (A) Graph 
describing the different A.f. disease courses associated with neutropenia, 
corticosteroid treatment/cystic fibrosis (CF) disease and a healthy immune system. 
(Red line) Acute disease that typically becomes systemic resulting from a lack of 
neutrophil recruitment and response. (Orange line) Chronic disease resulting from a 
limited anti-A.f. immune response, A.f. is retained within the lung but a chronic 
inflammatory setting is generated. (Green line) No A.f. disease ensues as inhaled 
conidia are rapidly and efficiently cleared from the lung. (B) (Red box) A.f. 
unchallenged extensive growth in a neutropenia-associated disease course. (Orange 
box) Some A.f. germination results from the limited anti-A.f. immune response (Purple 
– neutrophils, Blue - macrophage) but extensive HY growth is perturbed. Figure 
adapted from [4]. 
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When A.f. is not efficiently removed from the lung it is able to germinate and grow 
into HY. Unperturbed A.f. growth disseminates the fungi throughout the lungs with 
the potential to culminate in a catastrophic invasion of the blood stream. This type of 
IA typically presents in neutropenic patients. Neutropenia is a common side effect of 
patients undergoing chemotherapy or radiotherapy for haematological malignancies. 
A lack of neutrophil recruitment, migration and anti-A.f. immune response allows 
unperturbed A.f. growth and minimal fungal killing. In neutropenic patients, large A.f. 
HY structures physically penetrate through lung tissue and result in the formation of a 
highly inflamed lung setting. If the inflammation is not resolved local tissue infarction 
and necrosis ensues, further impairing any anti-A.f. immune response. As A.f. 
continues to experience unperturbed growth, HY gain access to the host’s vasculature 
by penetrating through the endothelial lining of lung blood vessels. This HY angio-
invasion leads to the dispersion of HY fragments into the blood stream. HY fragments 
are carried around the vasculature of the host regularly invading back through the 
endothelium at multiple sites of slowed blood flow; therefore, systemically 
disseminating the A.f. infection. HY invasion back out of the blood vessel from the 
lumen to the abluminal side of the endothelium causes massive local tissue infarction 
and thrombosis. This localised damage generates multiple enlarging areas of necrosis 
providing ideal conditions for further A.f. growth into the surrounding tissue. At the 
point of systemic dissemination and growth of A.f. in multiple locations the prognosis 
is bleak for the individual. Multiple enlarging sites of thrombosis, infarction, 
inflammation and necrosis eventually conclude in multiple organ failure and death [10, 
11]. 
 
The disease course of A.f. infections in patients receiving corticosteroid therapies is 
very different to the systemic-type disease often encountered in neutropenic patients. 
Corticosteroid therapies are routinely used in allogeneic transplant patients to 
prophylactically prevent or treat graft versus host disease. IA presents as the use of 
corticosteroids significantly impairs the host anti-fungal response. Corticosteroids 
have a drastic impact on alveolar macrophage function reducing or blocking 
phagocytosis, oxidative burst, the production of cytokines and chemokines and 
cellular migration [12]. The inability of alveolar macrophages to phagocytose A.f. RC 
13	
when treated with corticosteroids has been well described [13]. As RC escape the 
alveolar-macrophage driven early immune response in patients treated with 
corticosteroids, A.f. germination and the development of HY structures in the lung 
ensue. Despite the corticosteroid-induced lack of phagocytosis, alveolar macrophages 
can still recognise pathogens. A weakened cytokine and chemokine response has been 
described in these patients [14]. A weakened anti-A.f. response likely results in limited 
recruitment of neutrophils and monocytes to the lung. Corticosteroids do not impact 
the ability of neutrophils to migrate, degranulate and release arachidonic acid 
metabolites. Therefore limited neutrophil recruitment can still result in perturbation 
of HY growth and A.f. killing, thereby retaining corticosteroid-associated A.f. disease 
in the lung. However, the lack of A.f. RC phagocytosis by alveolar macrophages permits 
regular RC germination, which eventually leads to the robust recruitment of 
neutrophils creating a chronic neutrophil-driven inflammatory environment [15-17]. A 
persistent inflammatory lung environment leads to local tissue infarction, thrombosis, 
necrosis and eventually fibrosis. This concludes in reduced lung function, which is 
often fatal to the host. Cause of death from corticosteroid-induced A.f. infections are 
generally regarded as a diminished lung function rather than A.f. infection itself [4].  
  
 
1.1.3: A.f. disease in immune-competent individuals 
 
A.f. can also cause pathology in immune-competent individuals with an underlying 
airway disease. Allergic bronchopulmonary Aspergillosis (ABPA) is a pulmonary disease 
impacting asthma and cystic fibrosis (CF) patients. Pathology results from 
hypersensitivity developed against inhaled A.f. RC. As previously mentioned, upon RC 
inhalation and deposition in the lung, conidia are rapidly phagocytosed and cleared by 
alveolar macrophages. Should RC evade this response a robust neutrophil response is 
generated and results in RC clearance. It is hypothesised that underlying airway 
disease dampens and curtails the local lung innate and adaptive immune response; 
therefore, inefficient RC clearance occurs permitting the germination of RC into HY. As 
the immune response is still present, although reduced, A.f. persists in the lung causing 
local pathology but is challenged enough so that the infection is retained within the 
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lung [18]. Angio-invasion and systemic A.f. infections are not encountered in immune 
competent patients even with the presence of underlying airway disease. Long-term 
persistent A.f. infections and their accompanying inflammation culminate in scarring 
and fibrosis of the airway epithelia and lung, exacerbating underlying airway disease 
and reducing lung function. Patients with CF have been extensively described to suffer 
severe morbidity and mortality from A.f. infections [19].  
 
 
1.1.4: Cystic fibrosis and A.f. disease 
 
CF is an autosomal recessive disorder caused by mutations in the CFTR gene. Mutation 
results in the CFTR protein misfolding leading to premature degradation and failure to 
reach the cell surface [20]. CF disease primarily impacts the airway mucosal glands, as 
this is where expression of the CFTR is most abundant [21]. The CFTR is responsible for 
transporting Cl- across the epithelia; a defective CFTR leads to an absence of Cl- 
transport and a lack of proper control over mucus secretion. This concludes in the thick 
deposition of mucus within the airway that is poorly cleared and retained for much 
longer than healthy mucus. The long-term presence of thick mucus radically alters 
airway homeostasis. Importantly the action of the mucociliary escalator, a crucial 
component of the immune system responsible for trapping and clearing inhaled 
pathogens, is drastically reduced [20, 22, 23].  
 
CF patients struggle with recurrent and chronic pulmonary infections such as ABPA 
and Aspergillus bronchitis. This is linked to their inability to mount an appropriate, 
robust immune response in the airway leading to an absence of pathogen clearance 
and an inability to resolve inflammation in a timely manner. From early childhood 
onwards bacterial and fungal infections are regularly acquired and associated with a 
profound, intense neutrophil response [24-26]. Neutrophils represent ~70% of the 
inflammatory cell population in CF patient’s lungs compared to ~1% in healthy lungs 
[27].  
Bacterial and fungal pathogens become trapped in thick mucus, avoid clearance and 
are retained in the airway providing a constant stimulus for the immune system. A 
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large neutrophil-driven immune response is generated; however, recruited cells are 
also retained in mucus further contributing to the inflammatory setting [25]. The CF 
airway is characterised by prolonged primary inflammation typically associated with 
an acute infection. This inflammatory response is unable to mature and promote a 
macrophage-driven more appropriate chronic response. The airway epithelia-
pathogen interactions have been suggested to be the key orchestrator in driving the 
pro-inflammatory response [28]. A.f.-associated disease may occur as inhaled RC 
become trapped in thick mucus avoiding immune clearance and germinate. A robust 
neutrophil-driven immune response is generated and recruited neutrophils perturb 
HY growth whilst also becoming stuck in thick mucus. Retained neutrophils persist in 
a chronically active state driving inflammation in the airway. As A.f. and neutrophils 
are not efficiently cleared and inflammation is not resolved, a state of chronic A.f. 
infection and immune response is created.  
 
Declining lung function in CF patients has been associated with profound neutrophil 
inflammation and the presence of high quantities of neutrophil-derived serine 
proteases [27]. Neutrophils, when recruited to the airway or lung are activated and 
combat pathogens such as A.f. using phagocytosis, serine proteases, DNA NETosis and 
reactive oxygen species. A key facet of the neutrophil anti-microbial response is the 
ability to release serine proteases [29]. This is particularly of interest during A.f. 
infections. These enzymes degrade microbial polypeptides or amino acids liberated 
during phagocytosis. When neutrophils are appropriately regulated, serine proteases 
are an important anti-microbial defence mechanism. However, when poorly 
regulated, serine proteases can be very damaging to the host. Three main proteases 
have been implicated in causing pathology in the CF airway: neutrophil elastase (NE), 
proteinase 3 and cathepsin G. The mature forms of these proteases are stored in 
granules within the neutrophil cytoplasm, ready for release upon pathogen 
recognition [27].  
 
High levels of NE have specifically been identified from CF patients struggling with A.f. 
disease. This serine protease is thought to drive inflammation in the CF airway. NE is 
released following neutrophil activation or necrosis and elevated quantities of NE have 
16	
been linked to high neutrophil infiltration within the CF airway [30, 31]. CF patient 
neutrophils release greater quantities of NE when compared to healthy control 
patient’s neutrophils; this is despite both sets of neutrophils containing similar 
quantities of NE [31]. The action of CF patient neutrophils to release large quantities 
of NE is likely due to the highly inflammatory setting their neutrophils are chronically 
exposed to. A poorly regulated neutrophil-NE response is widely accepted as a key 
contributor to CF airway pathology [27].  
 
The main impact NE conveys over the CF airway is the degradation and impairment of 
the host immune response via two distinct mechanisms. Firstly, the cleavage of 
pathogen PAMPS aids pathogen immune evasion. For example, NE cleaves bacterial 
flagella, a vital TLR5 ligand, thereby reducing immune recognition and the response 
against pathogens possessing flagellum [32, 33]. Secondly, NE cleaves host immune 
receptors. NE-induced cleavage of host-derived antimicrobial peptides and 
complement opsonising peptides/receptors blocks the action of these proteins and 
impairs the host immune response. Soluble IL-6R is susceptible to cleavage and 
inactivation by NE [34, 35]. Elements of the complement immune response such as 
C3bi, CR1 and C5R are cleaved and rendered obsolete by NE [35, 36]. NE can also 
cleave cell surface receptors such as TLR4 and CD11b in the CF airway setting [32, 37]. 
The impact of NE on C-type lectin receptors (CLRs) has not previously been elicited. A 
role for neutrophils and NE impairing the immune response in the airway of CF 
patients and enhancing inflammation is clear. However, how this impacts the ability 
of CF patients to recognise and mount an immune response against A.f. has not been 
described. The ability of A.f. to avoid the immune response and germinate when 
retained in thick mucus is accepted; however, the A.f. immune-evasion mechanisms 
have not been described. Understanding this A.f. evasion before a damaging 
neutrophil response is generated may improve patient’s CF disease.  
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1.1.5: A.f. clinical relevance  
 
A.f. is a very clinically relevant pathogen with a rapidly increasing disease burden 
encompassing immune-compromised and immune-competent patients. Within the 
last two decades the number of patients treated with immune-suppressants has 
dramatically expanded. This correlates to an equally dramatic rise in the prevalence of 
invasive fungal infections, specifically IA. In the 2000’s IA accounted for 60% of invasive 
fungal infections identified during autopsy [38]. A.f. disease has emerged as a leading 
cause of infection-related mortality among immune-compromised individuals with 
mortality rates up to 90% [39]. Figure 1.3 describes the high incidence of A.f. infections 
identified in patients undergoing hematopoietic stem cell transplant, solid organ 
transplant or receiving cancer immune-suppressing chemotherapy treatments   
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Figure 1.3: A.f. incidence and mortality rates in at-risk patient groups. (A) Charts 
describing the incidence of IFI and A.f. infections and their lethality in patient cohorts 
at-risk of developing invasive fungal infections. A) AML patient’s IFI incidence and A.f. 
incidence and lethality. B) HSCT patient’s A.f. incidence and lethality. C) Lung 
transplant patient’s A.f. incidence and lethality. D) CF patients ABPA incidence and A.f. 
sensitisation incidence. Figure data derived from [7, 19, 40-48].   
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The increased prevalence of IA disease in patients with hematologic malignancies is 
attributed to profound immune-suppression and neutropenia brought about by the 
extensive therapeutic use of cytotoxic chemotherapies, radiation therapy, HSCT-
requirement and the use of corticosteroids and cyclosporine. A large study aiming to 
describe the incidence and outcome of invasive fungal infections in patients with 
hematologic malignancies offers some insight into the disease burden associated with 
A.f. infections. A total of 11802 patients diagnosed with acute myeloid leukaemia 
(AML), acute lymphoid leukaemia (ALL), Hodgkins or non-Hodgkins lymphoma, or 
multiple myeloma were recruited. As displayed in figure 1.3 (A), an overall incidence 
of invasive fungal infection of 4.6% was attained across the total patient sample; AML 
patient’s incidence of 12% (373/3021) was the highest. Of the 373 AML patient fungal 
infections, 213 (69%) were Aspergillus spp. of which 80 (37%) were lethal. This study 
concluded IA was the most prevalent invasive fungal infection recorded. Patients with 
AML were twice as likely to become infected with Aspergillus spp. when compared to 
the next most IA-likely hematologic malignancy, ALL. Mortality rates after the 
incidence of IA was confirmed varied between hematologic malignancy groups and 
ranged from 38% to 80% [40]. 
 
Patients receiving allogeneic HSCT are also at high risk of developing an IA infection. 
These patients typically experience chemotherapy-induced neutropenia and are often 
treated post-transplant with corticosteroids reducing the impact of graft versus host 
disease [49-51]. As highlighted in figure 1.3 (B), the incidence of IA in allogeneic HSCT 
patients ranges from 6-10.5% [7, 41]. More recent studies combining allogeneic and 
autologous HSCT have found incidence rates ranging from <1-4% depending on the 
individual hospital and location [42]. Mortality rates following HSCT and confirmed IA 
vary from 53.8% up to 76.3% [7, 40, 42]. These concerning results led to the generation 
of a USA-wide survey completed by the CDC with the objective of monitoring trends 
in the incidence of invasive fungal infections through a nationwide survey of hospitals.  
 
IA has been described as a leading cause of mortality among recipients of solid organ 
transplants [43]. The profound and prolonged immune-suppression required for 
successful solid organ transplant has been described as the main risk factor for 
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developing an A.f. infection post-transplant [44]. Figure 1.3 (C), highlights lung 
transplant patients experience the highest incidence of IA (6-16%) within the total 
solid organ transplant patient cohort examined [45, 52]. IA has also been identified in 
patients undergoing heart (~5-14% IA incidence), liver (~1-8% IA incidence) and kidney 
(~0.7-4% IA incidence) transplants with A.f. infections presenting immediately post-
transplant up to many years after transplant [42, 53-55].  
 
Immune-competent patients with underlying airway disease such as CF also 
experience a significant A.f. disease burden. A.f. has been isolated from 10-57% of 
airway secretions from CF patients and A.f. specific IgG has been detected in 41% of 
CF patients by the age of 4, rising to 98% by age 10 [19]. These seropositivity rates 
were much higher than healthy control patients and even asthma patients [46]. 
Aspergillus sensitisation (AS) and ABPA is highly prevalent in the CF population. Figure 
1.3 (D), displays results from a meta-analysis review combining 64 studies. This study 
quantified the incidence of AS and ABPA within the CF population and described a 
39.1% prevalence of AS and 8.9% prevalence of APBA [47]. A 2013 study assessing the 
prevalence of ABPA specifically within the UK CF population described ABPA incidence 
of 17.7% [48]. Considering the earlier described (1.1.3 & 1.1.4) significant disease 
pathology associated with ABPA, a CF population ABPA prevalence of 8.9-17.7% is 
extremely concerning. Due to the high incidence and unacceptable mortality rates of 
IA across a spectrum of immune competent and immune compromised patients, 
improvements in diagnosis, treatment and identification of at-risk patients are 
required. 
 
 
1.1.6: Therapeutic insufficiencies  
 
Despite the regular introduction of new anti-fungal therapeutics, treatment of IA 
remains challenging. Amphotericin B has extensively and effectively been used to treat 
prophylactically or at first suspicion of A.f. infection; however, this drug causes serious 
side effects including nephrotoxicity, electrolyte disturbances and hypersensitivity 
[56]. Perhaps more concerning is that the patient’s primary disease treatment is often 
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negatively impacted by the use of anti-fungal agents such as Amphotericin B [43, 57]. 
In the early 1990’s the generation of a new anti-fungal class containing azoles was 
produced. Initially, fluconazole treatment was used prophylactically and upon 
suspicion of IA. Many fungal species were originally susceptible to fluconazole 
treatment; however, since the year 2000 a range of resistant fungal strains, including 
resistant A.f. has rendered this therapy almost obsolete. Recently the azole 
Voriconazole has become the treatment of choice against A.f. infections [58]. 
Voriconazole was compared to Amphotericin B in a large multi centre trial aiming to 
identify the most effective therapy in the primary treatment of IA. Patients who 
received Voriconazole had a higher favourable response after 1 week (53% versus 
32%) and a higher 12-week survival rate (71% versus 58%) [57]. Voriconazole also has 
much milder side effects than Amphotericin B; despite this, Voriconazole has a 
significant number of drug-drug interactions and radically alters patient’s primary 
disease treatment [59, 60]. Although Voriconazole is effective against A.f. infections, 
survival rates post-treatment are still unacceptably low and patient’s primary disease 
treatment can rarely continue whilst the therapeutic is administered [57, 60]. Due to 
these challenges a targeted personalised medicine approach whereby high-risk IA 
patients are prophylactically treated should be the aim for future anti-A.f. treatment.  
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Figure 1.4: Stratification of patients according to their risk of developing IA would 
allow a personalised medicine approach to treat primary and anti-fungal disease 
most effectively. Figure developed from [57, 61-63] and consultation with Public 
Health Wales’ microbiology clinical lead Dr Lewis White and Haematology consultants.  
 
 
Many attempts at identifying risk factors associated with an increased likelihood of 
developing A.f. infections have been unsuccessful. Neutropenia and corticosteroid 
treatment remain the only widely accepted risk factors increasing the likelihood of an 
A.f. infection [7-9]. Lymphopenia has been described as a risk factor that may increase 
the likelihood of developing an A.f. infection although this data only arises from 
smaller studies [7, 64]. No significant risk factors associated with patient’s age, gender, 
CMV serology, type of graft versus host disease, and anti-fungal or graft versus host 
prophylaxis treatment have been identified [64-66]. Recently, mutations in Dectin-1 
and DC-SIGN, A.f. positive PCR from patient bronchiolar alveolar lavage (BAL), 
allogeneic stem cell transplantation and infection with a respiratory virus were 
described as significant risk factors when three or more positive factors were present 
[67]. Identifying risk factors associated with an increased likelihood of developing IA 
may aid the implementation of targeted prophylactic anti-fungal therapy in a 
personalised medicine approach as suggested in figure 1.4. 
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1.2: The anti-A.f. immune response 
 
 
1.2.1: A.f. Infection 
 
A.f. is a serious, complicated and potentially lethal human pathogen. The infectious 
life cycle of A.f. begins upon inhalation of RC and their potential deposition in the 
bronchioles or alveolar spaces. From this point onwards, the immune capability of the 
infected individual is key to determining whether disease may ensue as discussed in 
1.1.2 and 1.1.3. Upon infection A.f. must exhibit thermo-tolerant growth utilising 
specific biosynthetic pathways evolved to promote germination and survival in hostile 
environments such as the human airway and lung [68]. Once A.f. RC have infected the 
host lung, multiple factors such as the A.f. cell wall and surface composition, A.f. 
secondary metabolite production, A.f. HY growth rate, HY tissue invasion and A.f.’s 
resistance to host killing mechanisms influence survival and dissemination. However, 
these factors are secondary to the immune competence of the infected host [69].  
 
 
1.2.2: A.f. cell wall and surface 
 
The surface and cell wall of A.f. RC is complex and plays many crucial roles in the 
successful survival, host-infection and growth of A.f. in the host-lung. The outer RC 
surface contains a hydrophobic, immunologically inert protein rodlet layer that 
maintains RC survival in challenging environmental conditions. Once RC have infected 
a host this rodlet layer is shed allowing RC germination thereby unveiling immune 
activating cell wall components, which consequently results in immune recognition. 
A.f. RC lacking a rodlet layer displayed enhanced susceptibility to alveolar macrophage 
killing [70]. A.f. RC also express sialic acid residues on their surface. These residues are 
likely involved in RC dispersal and pulmonary deposition as sialic acid blocks RC 
agglutination. Interestingly, a role for sialic acid binding host-lung fibronectin has also 
been identified. Lung damage often caused by A.f. infection and the ensuing anti-A.f. 
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response results in fibronectin production. A.f. may utilise lung fibronectin to bind RC, 
enhancing infection and disease progression [71, 72]. The cell wall of RC after the 
rodlet layer has been shed is predominately composed of α-(1-3) glucan, β-(1-3) 
glucan, β-(1-6) glucan, chitin and galactomannan [73]. Genetic deletion of these cell 
wall components (when viability is retained) has been demonstrated to generate 
hyper-virulent A.f. strains. Mutated strains possess increased virulence due to their 
evasion of the host immune response as α-glucans and β-glucans act as PAMPs and 
are required for A.f. recognition and the generation of a robust anti-A.f. immune 
response [74-76].  
 
 
1.2.3: Soluble lung components and respiratory epithelia 
 
Immediately after inhalation, A.f. RC encounter the respiratory tract and airway 
epithelial mucosa. A key aspect of the epithelial anti-A.f. defence involves the 
mucociliary escalator. This is comprised of epithelial cell secreted mucus, ions, 
proteins, lipids and fats and contributes to the efficient, pathology-free clearance of 
inhaled pathogens including A.f. [77, 78]. Opsonic PRRs such as collectins are also 
found in this mucus secretion and opsonise inhaled pathogens increasing pathogen-
recognition and bolstering host defence. Other opsonic PRRs such as mannose-binding 
lectin, surfactant protein A and surfactant protein D have been shown in vitro to bind 
and agglutinate A.f. RC leading to their enhanced phagocytosis and killing by alveolar 
macrophages and neutrophils [79, 80]. Mannose binding lectin, surfactant protein A 
and surfactant protein D were also recently identified to play a role in the activation 
of complement [81]. Knocking out these three PRRs in vivo enhanced susceptibility to 
A.f. infection, whilst recombinant Mannose binding lectin, surfactant protein A and 
surfactant protein D have been used to enhance anti-A.f. responses in vivo [80, 82]. 
Epithelial-derived collectins and soluble PRRs are crucial during the early A.f. response 
as they enhance A.f. RC clearance via opsonising phagocytosis and aggregating A.f. RC 
[4].  
Epithelial cells also play a direct role in the anti-A.f. response. A.f. RC have been 
demonstrated to bind and be engulfed by epithelial cells. Engulfed RC are retained and 
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killed in phagolysosomes; however, some evidence suggests A.f. growth and escape 
can occur inside epithelial cells [83, 84]. A.f. can secrete factors that modulate and 
disrupt the airway epithelium, counteracting epithelial anti-A.f. immune responses. 
Culture filtrates from A.f. have been demonstrated to alter epithelial cell function and 
viability by inducing cell shrinkage, actin rearrangement and desquamation [85, 86]. 
Inhibiting local serine and cysteine proteases can abrogate this anti-epithelial activity; 
demonstrating that A.f. secreted proteases induce this effect [86]. Disruption of the 
epithelial barrier and epithelial cell immune functions enhances A.f. pathogenicity 
allowing A.f. to interfere with mucociliary clearance, bind airway epithelia and 
establish infection. 		
1.2.4: Alveolar macrophages 
 
As the primary resident phagocytic cell of the airway and lung, alveolar macrophages 
are a crucial component of the anti-A.f. immune response. Alveolar macrophages act 
as the front-line response against A.f. RC that have inoculated the lung. PRRs located 
on the surface of alveolar macrophages mediate the recognition of A.f.-associated 
PAMPs and actin-dependent phagocytosis of A.f. RC and SC as shown in figure 1.5 [87]. 
Following phagocytosis, A.f. RC and SC are retained in a phagosome that matures and 
acidifies into a phagolysosome concluding with A.f. killing [87]. Alveolar macrophages 
treated with NADPH oxidase inhibitors ex vivo were unable to acidify their 
phagosomes resulting in significantly impaired A.f. phagocytic killing [88]. A.f. can 
resist phagolysosomal killing via the production of the pigment melanin. Melanin’s role 
in ROS scavenging is clear and has been described for many pathogenic fungi. A.f. 
produced melanin greatly increases A.f. virulence and survival by blocking acidification 
of the phagolysosome [89, 90].  
 
A.f. engagement of alveolar macrophage associated PRRs initiates a pro-inflammatory 
response comprising of the production and release of many chemokines and cytokines 
including TNF, IL-1β, IL-6, IL-8, MIP-1α and KC [1, 91-94]. The initiation of a robust pro-
inflammatory response is critical for host defence against A.f.. TLR2, TLR4 and Dectin-
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1 are the best-described PRRs involved in the alveolar macrophage recognition of A.f.. 
TLR2 and TLR4 have been identified to activate macrophages upon stimulation with 
A.f.. TLR2 has been demonstrated to recognise both conidial and HY morphologies 
whilst TLR4 only HY [95]. In vivo TLR2-/- and TLR4-/- mice display higher A.f. fungal 
burdens when compared to WT mice. This fungal burden difference is exacerbated 
when KO mice were used in a neutropenia model suggesting a requirement for the 
expression of these receptors not only on alveolar macrophages but also on 
neutrophils. Crucially, in vivo TLR2-/- and TLR4-/- mice did not exhibit differences in 
survival when compared to WT mice, despite the increased fungal burden observed 
[96, 97].  
 
Dectin-1 is a well-characterised PRR which, unlike TLRs, is fundamental for host 
defence against A.f.. Dectin-1 is constitutively expressed on alveolar macrophages and 
recognises A.f. cell surface expressed β1-3 glucans [98]. When RC germinate and shed 
their immunologically inert rodlet layer, β1-3 glucans located abundantly on the 
surface of RC and SC are engaged by Dectin-1. Dectin-1 engagement activates alveolar 
macrophages resulting in A.f. RC and SC phagocytosis as well as the robust induction 
of a pro-inflammatory cytokine and chemokine response [2, 99]. Immune competent 
individuals who lack functional Dectin-1 expression are at significant risk of developing 
an invasive fungal infection without any immune-suppression [100]. The ability of 
Alveolar macrophages to rapidly recognise and kill regularly inhaled A.f. RC without 
pathology preserves host homeostasis. Perhaps more impressive is the capability of 
alveolar macrophages, when encountering larger quantities of germinated A.f., to 
orchestrate a complex, coordinated and robust anti-A.f. response.   
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1.2.4: Neutrophils 
 
The generation of a successful anti-A.f. immune response relies on the recruitment 
and immune capabilities of neutrophils. This imperative cell requirement is highlighted 
by the fact that neutropenia is the primary risk factor for the development of A.f. 
infections [7, 8]. The importance of neutrophils when combating the larger EG and HY 
morphologies of A.f. is displayed in figure 1.5. These later A.f. morphologies develop 
after RC successfully evade or resist the alveolar macrophage driven early immune 
response and germinate. Alongside alveolar macrophages and epithelial cells, 
neutrophils utilise PRRs such as TLRs and Dectin-1 to mediate A.f. interactions and 
generate appropriate immune responses [97, 101, 102]. An intriguing role for CD11b 
(also known as Complement Receptor 3) binding fungal β1-3 glucans exclusively in 
human neutrophils (not murine) has also been described. This may explain the higher 
than expected incidence of A.f. in leukocyte-adhesion deficiency type-1 syndrome 
patients who lack CD11b expression on neutrophils [103, 104]. In vivo and in vitro 
studies have extensively demonstrated the ability of neutrophils to recognise and bind 
A.f. HY before inducing fungal killing via oxidative and non-oxidative killing 
mechanisms [105, 106]. 
 
Neutrophils use NADPH oxidase-generated ROS to mediate efficient A.f. HY killing. 
Neutrophils isolated from chronic granulomatous disease (CGD - characterised by 
mutations present in NADPH oxidase genes blocking ROS formation) and 
Myeloperoxidase Deficiency (MPO - Myeloperoxidase catalyses the formation of the 
ROS produced hypochlorous acid from hydrogen peroxide) have been used to 
determine the important role of anti-A.f. neutrophil ROS. Neutrophils obtained from 
patients with these diseases lack the ability to kill A.f. HY [105, 107]. The lack of A.f. HY 
neutrophil-derived ROS killing activity present in CGD and MPO patient neutrophils 
could be completely rescued with the addition of hydrogen peroxide or hydrochloric 
acid. This clear link between A.f. HY killing and neutrophil-derived ROS function 
highlights the importance of ROS in the anti-A.f. HY immune response [105, 108].  
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Neutrophils also possess the ability to perturb and kill A.f. using non-oxidative 
responses. Neutrophils upon activation can de-granulate releasing a range of potent 
antimicrobial compounds such as proteases, lactoferrins, defensins, pentraxin-3 and 
lysosymes [109]. Further to this, neutrophils can utilise an elaborate killing mechanism 
forming neutrophil extracellular traps (NETs). This involves neutrophils, as a final dying 
act of defence termed NETosis, unravelling chromatin-coiled nuclear DNA, covering 
this DNA with highly antimicrobial granular proteins and violently forcing this DNA out 
of the cell rupturing the cell membrane [110]. Neutrophils have been demonstrated in 
vitro to rapidly (within 3 hours of A.f.-neutrophil co-incubation) produce NETs against 
A.f. with both conidial and HY morphologies being embedded within the released 
antimicrobial DNA trap. NETosis was also demonstrated to occur and embed A.f. 
conidia and HY within an in vivo A.f. lung infection model [111]. Neutrophils isolated 
from NADPH oxidase deficient mice identified the potential requirement of a 
functional NADPH oxidase for the successful formation of NETs. Again reiterating the 
importance of the oxidative capabilities of neutrophils in the anti-A.f. response [29]. 
 
Recently, neutrophils have been shown to aggregate and surround A.f. before 
saturating the local environment with high concentrations of anti-microbial 
compounds. This resulted in sequestered A.f. being killed. Neutrophil aggregation and 
anti-microbial compound release was shown to be particularly efficient at killing early 
A.f. morphologies. When larger A.f. HY were sequestered, oxidative killing 
mechanisms were required to kill the fungi [112]. 
 
As a result of evolutionary pressure, A.f. has developed defence mechanisms against 
ROS. These mechanisms are relevant during human infection and target neutrophil-
mediated ROS production.  A.f. secreted catalases act as ROS scavengers limiting the 
potential damage and killing impact associated with neutrophil-derived ROS. 
Experiments deleting both A.f. HY catalyses (CAT1 and CAT2) resulted in an increased 
HY susceptibility to hydrogen peroxide. In vivo this translated to reduced A.f. virulence 
suggesting HY catalases protect against neutrophil-derived ROS-mediated killing; 
although, the reduced A.f. virulence was subtle [113]. A.f. HY may possess multiple 
ROS-scavenger mechanisms that provide redundancy to the underwhelming ROS 
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scavenger impact CAT1 and CAT2 models displayed [90, 114]. Despite this, the 
profound immune-suppression and resulting neutropenia common in IA patients likely 
render the subtle action of A.f. ROS scavengers ineffective, as neutrophils are not 
present. A.f. ROS scavengers may play a more fundamental role against neutrophil-
derived ROS in corticosteroid or CF-associated A.f. infections. Neutrophils are a key 
facet of the anti-A.f. response and are almost exclusively required to combat larger 
morphologies of the fungi. Due to this, lacking an efficient anti-A.f. neutrophil 
response is the predominant risk factor for the development of IA.  
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Figure 1.5: Macrophage and Neutrophil driven anti-A.f. immune response and killing 
mechanisms. (Blue) Alveolar macrophage and (Purple) neutrophil anti-A.f. (Green) 
immune response including phagocytosis, cytokine and chemokine production, ROS 
production and release, antimicrobial peptide release and NET formation. Figure 
adapted from [69, 115]. 
 
 
1.2.5: Secondary metabolites 
 
The pathology of A.f. infections is strongly influenced by the fungal production of 
secondary metabolites. These molecules are typically produced during HY formation 
and exert disease progressive effects. A single A.f.-produced secondary metabolite has 
been isolated in vivo and in the serum of IA positive patients. This secondary 
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metabolite is called epipolythiodioxopiperazine toxin, or gliotoxin and conveys an 
immune suppressive impact on the host [116, 117]. Gliotoxin, via the formation of a 
sulphide:thiol exchange donated from gliotoxin’s own internal disulphide bridge, 
disrupts binding and inactivates host immune receptors, proteins and ROS as displayed 
in figure 1.6 [118]. Almost all A.f. clinical isolates (>95%) produce gliotoxin implying 
this molecule is integral for A.f. viability and has been evolutionarily conserved [116]. 
Research into the in vitro effects of gliotoxin have elicited a multitude of immune 
suppressive actions including the inhibition of alveolar macrophage phagocytosis, 
mast cell activation, cytotoxic T-cell responses, the induction of epithelial damage and 
the induction of apoptosis in lymphocytes, alveolar and peripheral macrophages, 
dendritic cells, fibroblasts and neutrophils. Gliotoxin has also been demonstrated to 
block antigen presentation by monocytes and DCs to effector T-cells preventing the 
expansion of antigen-specific T-cells and the formation of an adaptive immune 
response [119-122]. The repertoire of gliotoxin’s immune suppressive actions was 
described using gliZ (gliotoxin transcriptional regulator) and gliP (glioxin nonribosomal 
peptide synthase) mutants. Mutating either gene resulted in abrogated gliotoxin 
production [123, 124]. Interestingly, in a neutrophil depleted in vivo model, gliZ and 
gliP mutant A.f. strains were found to be no more or less virulent than non-mutated 
A.f. [124, 125]. In a corticosteroid-treated in vivo model, significantly reduced A.f. 
virulence was attained with the gliP mutant strain [126]. The reduced gliP mutant-A.f. 
virulence was attributed to a lack of neutrophil apoptosis at the site of HY growth that 
was present in WT A.f. strains [127]. These in vivo models suggest a specific role for 
gliotoxin inducing apoptosis in neutrophils in the locality of A.f. HY thereby suppressing 
the anti-A.f. immune response. Gliotoxin has an immune suppressive impact on a 
range of innate and adaptive immune cell types; however, the mechanisms and 
interactions between gliotoxin and these cell types are not well understood.  
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Figure 1.6: A.f. mechanisms of resisting the host anti-fungal immune response. (Red) 
Identifies A.f. blocking mechanisms against neutrophil (Purple), respiratory epithelia 
(Green) and alveolar macrophage (Blue) anti-fungal actions. Figure adapted from [85, 
86, 89, 90, 113, 128]. 
 
 
1.2.6: The adaptive response 
 
As neutropenia is the primary risk factor for the development of A.f. disease, the 
adaptive immune response has not been extensively investigated as a contributor to 
the anti-A.f. response. T-cells are unlikely to be involved in the front-line lung response 
against inhaled A.f. RC as conidia are so efficiently cleared by lung-resident alveolar 
macrophages without any disease. If RC evade immediate front-line clearance and 
germinate into HY, any anti-fungal impact T-cells may be able to exert over large HY 
structures has not been described; although, the formation of a TH1 anti-A.f. response 
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is thought to be beneficial to the host. A.f. HY secrete multiple antigens that promote 
host-protective TH1 and TH17 immunity as well as host-destructive TH2 immunity. 
Interestingly, A.f. appears to be particularly effective at initiating TH2 immunity and 
allergic inflammation via the secretion of several allergen proteins such as Asp F. These 
proteins promote the generation of an allergic-type response allowing A.f. to evade a 
cytotoxic TH1 response that may enhance A.f. clearance [129].  
 
The adaptive response is initiated as CD14+ inflammatory monocytes recruited to the 
site of A.f. infection in the lung phagocytose A.f. and curtail germination [130]. Upon 
A.f. recognition inflammatory monocytes differentiate into monocyte-derived 
dendritic cells, which migrate and deposit A.f. conidia in local lymph nodes. This 
process culminates in the priming of CD4+ T cells and initiates the adaptive anti-A.f. 
immune response [131]. Successful protection against A.f. in humans and mice is 
benefitted by the generation of an A.f.-specific CD4+ T cell population and subsequent 
TH1 and TH17 response [132, 133].  
 
Research into the recruitment of T-cells and generation of TH1, TH2 and TH17 adaptive 
immune responses during A.f. infection has been undertaken. C57BL/6 mice were 
challenged intranasally with A.f. weekly for one, two, four or eight weeks. Leukocyte 
composition, activation and cytokine production were examined after each repeated 
challenge was complete. As expected, upon first challenge all A.f. was cleared within 
24 hours. The second A.f. challenge resulted in a small neutrophil and regulatory T-cell 
influx. From four repeated challenges onwards, A.f. induced T-cell recruitment and 
activation within the lungs. This culminated in the development of TH1, TH2 and TH17 
adaptive anti-A.f. responses [134]. 
 
Recently an intriguing adaptive immune role for Dectin-1 and TLRs has been identified. 
The initiation of TH1 and TH17 immune responses against A.f. were found to depend 
on TLR/MyD88 signalling and Dectin-1 signalling respectively. Dectin-1 signalling 
following A.f. recognition reduced the expression of IFNγ and IL-12p40 in the lung. This 
in turn reduced T-bet expression in responding CD4+ T-cells and enhanced TH17 
immunity [135]. 
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1.2.6: Requirement of A.f. immune recognition, signalling and response 
 
The anti-A.f. immune response is complex and requires further study. The required 
involvement of alveolar macrophages, neutrophils and airway epithelia is well 
described whilst a role for the adaptive immune system is also emerging. A.f. 
possesses its own unique immune evasion mechanisms producing anti-inflammatory 
secondary metabolites and hiding many of its PAMPs until nutrient uptake and growth 
has begun. The initiation of a successful anti-A.f. response requires the immediate 
recognition of A.f. and rapid signalling cascade to orchestrate an appropriate immune 
response. If recognition and signalling does not occur due to A.f. evasion, a lack of PRR 
expression, function or collaboration, a lack of effector cells or the suppression of 
effector cells, A.f. disease can ensue.  
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1.3: A.f. recognition and C-type lectin receptors 
 
 
1.3.1: PRRs 
 
The innate immune response against pathogens is initiated by PRR-mediated 
recognition of microbial-specific PAMPs. This activates intracellular pathways that 
drive an immune response against the pathogen. PRRs also recognise damage-
associated molecular patterns, these molecules are frequently released from 
damaged or necrotic cells and act as danger signals further promoting inflammation 
[136]. Four families of PRRs: the TLRs, NOD-like receptors, RIG-I like receptors and CLRs 
have been identified to recognise fungal pathogens [137-139].  
 
A controversial anti-fungal role has been described for the best characterised family 
of PRRs, the TLRs. In vivo experiments using MyD88-/- mice, a key adaptor in the TLR 
signalling pathway, demonstrated an increased susceptibility to multiple fungal 
infections including Candida albicans and A.f.; although, these animals also lacked IL-
1R signalling so the fungal susceptibility cannot be directly associated with a lack of 
TLR signalling. In humans, immune-competent individuals lacking MyD88 do not 
experience an increased susceptibility to fungal infections [140]. However, multiple 
TLRs have been implicated in fungal recognition, including TLR1, TLR2, TLR4, TLR6, 
TLR7 and TLR9 [141-143]. The mechanisms underpinning TLR involvement in anti-
fungal immunity are not clear although the impact of some TLRs in the anti-fungal 
response in vivo has been described [144-147]. Interestingly, research suggesting TLRs 
can collaborate with CLRs to enhance anti-fungal immunity has been described.  
 
CLRs have a well characterised role in driving anti-fungal immunity via the recognition 
of highly conserved cell wall carbohydrate structures which act as PAMPs. CLRs bind 
all known human pathogenic fungi and their signalling pathways are essential for the 
generation of successful anti-fungal responses [148]. The recognition of A.f. is 
mediated predominantly by CLRs. 
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The impact of NOD-like receptors and RIG-I like receptors in A.f. disease is not clear; 
however, the role of these receptors during anti-fungal immune responses has been 
researched. NLRs are categorised into two main subsets, NOD1/2 receptors and 
inflammasome-forming receptors [149]. NLR inflammasome-forming receptors are 
important for controlling oral Candida albicans infection and preventing the systemic 
dissemination of this fungus [150]. The impact NOD1/2 convey over anti-fungal 
immunity is not clear. Recently, the role of RIG-I like receptors during anti-fungal 
immune responses has been investigated. IFIHI, a RIG-I like receptor, was induced by 
Candida albicans. IFIHI deficient macrophages generated impaired IFN-β in response 
to Candida albicans challenge [139].  
 
 
1.3.2: CLRs 
 
C-type lectin receptors (CLRs) encompass a large and diverse family of proteins 
exclusively found in the animal kingdom. These proteins have been highly conserved 
in vertebrates suggesting they play a crucial role within these organisms. CLRs are also 
prevalent throughout invertebrates; however, these proteins show considerable 
structural variation between invertebrate species proposing they’re less important in 
this phylum [151]. CLRs are characterised by their possession of a carbohydrate 
recognition domain (CRD); unfortunately, this led to numerous proteins being 
inappropriately described as CLRs. Since then, this domain has been identified in over 
1000 proteins with a diverse range of functions [151]. Many proteins that contain a 
CRD are not involved in carbohydrate recognition. Therefore, it is more appropriate to 
consider the CRD region a characteristic of C-type lectin-like domains to reflect their 
similarity to CRDs without implying their function. Multiple C-type lectin-like domain 
structures have been discovered with subtle variation between Ca2+ binding regions 
and oligomerisation domains. This variation is responsible for CLR’s different ligands 
and functions [152, 153].  
 
Vertebrates possess up to 17 groups of CLRs offering a diverse range of functions and 
responses. Many of these CLRs bind PAMPS and can lead to the mediation of host 
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immune responses. Soluble CLRs such as the collectin family (CLR group III) bind 
pathogens and activate host complement. The prototypic collectin, Mannose-binding 
lectin, binds carbohydrate regions located on bacteria, fungi and viruses and opsonises 
the pathogens for phagocytosis. This response can provide protection from common 
pathogens such as Staphylococcus aureus and Streptococcus pneumonia [151, 154].  
Although these soluble proteins can be described as a CLR PRR they are not cell-
associated and cannot directly impact gene expression through signalling. In contrast, 
many CLRs do function as signalling receptors within the innate immune system 
directly regulating gene expression upon ligand binding and signalling initiation [151]. 
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Figure 1.7: Signalling pathways downstream 
of myeloid CLRs and their transcriptional 
impact. Dectin-1 likely homodimerises and 
recruits Syk to initiate downstream signalling 
through its hemITAM domain. Dectin-2 and 
Mincle recruit FcRγ and Syk to induce 
downstream signalling. Mcl has no known 
signalling motif although can signal through 
Syk. Recent evidence suggests Mcl can 
directly couple with FcRγ or Mcl can couple 
alongside Mincle or another CLR to induce 
signalling. Syk recruitment and signalling 
initiate anti-fungal immune gene expression 
through the CARD9-Bcl10-MALT1 pathway 
and regulation of NFκB, NFAT, MAPK and 
IRF1. Mincle engagement can down regulate 
IRF1 thereby blocking IL-12 expression. Figure 
adapted from [155-158]. 
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Myeloid cells express many trans-membrane CLRs (often belonging to CLR group II, V 
and VI). The activation of these CLRs typically induces intracellular signalling utilising 
one of two distinct signalling pathways. Dectin-1 signals directly through its 
cytoplasmic tyrosine-based activation motif (hemITAM) whilst Dectin-2 and Mincle 
require association with an ITAM domain coupled to FcRγ as displayed in figure 1.7. 
Both the direct and indirect hemITAM/ITAM intracellular signalling pathways require 
the recruitment of spleen tyrosine kinase (Syk) and coordination of CARD9, Bcl10 and 
MALT1 complex. Signalling through this complex leads to the activation of NFκβ, 
MAPK, NFAT and IRF1 eventually culminating in innate immune gene expression and 
cellular immune responses [155, 156]. Individuals with mutated and defective CARD9 
are highly susceptible to fungal infection [159]. CLR signalling pathways lead to the 
induction of a diverse repertoire of innate functional responses against pathogens 
including the phagocytosis of non-opsonised bacteria, fungi and viruses, the formation 
of a robust cytokine and chemokine response driving the pro-inflammatory immune 
response, respiratory burst and inflammasome activation [156]. Lately, a role for CLRs 
in the formation of adaptive immune responses has also been identified. The key roles 
CLRs play driving the multi-faceted innate immune response and coordinating the 
adaptive response highlights the importance of these proteins. CLRs ability to direct 
and orchestrate complex anti-fungal immune responses are fundamental to host 
survival. 
 
 
1.3.6: Dectin-1 
 
Dectin-1 is a member of the group V CLRs and possesses a single extracellular 
carbohydrate-recognition domain connected to an intracellular cytoplasmic tail 
containing a hemITAM domain. Dectin-1 is expressed predominantly on myeloid cells 
such as macrophages, neutrophils and dendritic cells but is also found on some 
lymphocyte populations [160]. The CLR is present in two isoforms, a full-length isoform 
(A) and a shorter isoform (B), which lacks part of the extracellular stalk region. Isoform 
B lacks exon 3 meaning the extracellular CRD of the receptor sits closer to the 
membrane. These two isoforms both recognise ligands with the same affinity at 37oC; 
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although, recognition and signalling through Dectin-1 isoform B led to a greater TNF 
response [161].  
 
Dectin-1 recognises β1-3 glucans from yeast, fungi, plants and bacteria in a calcium-
independent mechanism [162, 163]. Dectin-1 is often found on the cell surface as a 
homodimer. β-glucan recognition and binding to Dectin-1 homodimers induces 
Dectin-1 oligomerisation [163]. Dectin-1-mediated recognition of particulate ligand 
leads to the formation of a phagocytic synapse, while recognition of soluble Dectin-1 
ligand does not induce a robust response [164].  
 
Upon ligand binding Dectin-1 mediates intracellular signalling through its hemITAM, 
which is phosphorylated and recruits Syk. It is proposed this novel signalling pathway 
requires Syk to bind the cytoplasmic tails of two Dectin-1 monomers in close proximity 
[165]. The recruitment and phosphorylation of the SH2 region of Syk is necessary for 
Dectin-1 signalling [165, 166]. Downstream of Syk signalling MAPK, NFκB and NFAT 
transcriptional responses are reliant on the phosphorylation of Protein Kinase C and 
formation of the CARD9-Bcl10-MALT1 complex [156, 167]. As briefly mentioned in 
1.3.3 a syk-independent role for Dectin-1 signalling has been described. This is thought 
to occur exclusively in human dendritic cells and use the signalling molecule Raf-1 to 
induce downstream signalling [157, 168, 169].  
 
Ligand engagement through Dectin-1 has the capability to induce a range of diverse 
cellular responses coordinated by MAPK, NFκβ and NFAT gene transcription 
regulators. Dectin-1 can act as a phagocytic receptor and induce ligand uptake by 
endocytosis. The CLR also plays a key role in the generation of innate immune 
responses via the production of several chemokines and cytokines including TNF, IL-6, 
MIP-1, MIP-2 and KC. Dectin-1 can also induce cellular respiratory burst and activate 
and regulate COX2 and PLA2. These described cellular responses can occur from 
Dectin-1 signalling alone; however, aspects of Dectin-1 signalling that lead to the larger 
formation of an innate response require collaborative signalling likely from TLRs and 
other CLRs [160]. Dectin-1 has also been demonstrated to induce DC maturation and 
direct TH17-cellular responses independently of other TLRs and CLRs. This suggests 
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Dectin-1 signalling can independently direct and modulate adaptive immune 
responses [170]. 
 
The immune role of Dectin-1 has been well described in vitro and in vivo. In vitro 
analysis has identified the vast repertoire of fungal pathogens that Dectin-1 can 
recognise, mediate fungal uptake and killing of, and generate a robust chemokine and 
cytokine response against. The cell walls of many fungi contain large quantities of 
carbohydrate sugars, particularly β1-3 glucans allowing for Dectin-1 recognition [160].  
 
The role of the receptor in vivo has been investigated for some time; however, the 
requirement of Dectin-1 during anti-fungal immune responses remains controversial. 
Experiments blocking Dectin-1 during an intra-tracheal A.f. infection generated 
significantly reduced levels of lung inflammation and significantly higher fungal burden 
than WT animals [2]. A similar enhanced susceptibility and increased fungal burden 
was identified in Dectin-1 KO mice. Upon A.f. infection, Dectin-1 KO animals had 
succumbed to infection within 5 days whereas 80% of WT mice survived past day 5. 
This was mainly thought to be due to a lack of A.f. recognition by macrophages, 
reduced neutrophil recruitment and subsequently impaired anti-A.f. immune 
response [100]. Dectin-1 KO mice possess enhanced susceptibility to Candida albicans; 
this was associated with inflammatory defects and a limited reduction in fungal killing 
[171]. Mice lacking the downstream signalling component CARD9 were also more 
susceptible to A.f. and Candida albicans infection [167]. These data suggest an 
important role for Dectin-1 in driving the innate cytokine and chemokine responses 
and controlling fungal killing and fungal burden.  
 
Contradicting these studies, a different Dectin-1 KO strain displayed the same 
susceptibility as WT controls and no significant difference in chemokine or cytokine 
response upon challenge with Candida albicans. A small discrepancy in macrophage 
respiratory burst was observed in this Dectin-1 KO model although this had a minor 
impact on pathogen clearance and fungal burden [172]. This model suggests a lesser 
role for Dectin-1, or Dectin-1 redundancy in vivo. The reasons for the differences 
observed between these two Dectin-1 KO strains were, until recently, unknown. The 
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requirement for Dectin-1 during Candida albicans infection was found to be fungal 
strain dependent. Specifically, variation between Candida albican’s cell wall chitin 
composition significantly influenced Dectin-1 recognition [173]. 
 
An interesting pathologic role has recently been described for Dectin-1 in an allergic-
type A.f. disease model. In this chronic exposure setting Dectin-1 was demonstrated 
to induce the expression of multiple pro-allergy and pro-inflammatory mediators that 
exacerbated underlying airway disease potentially via the Dectin-1-dependent 
production of IL-22. Removing Dectin-1 and blocking IL-22 in the model reduced 
pathology associated with chronic A.f. exposure and restored lung function [174].  
 
Dectin-1’s impact during the anti-A.f. immune response is complicated. The CLR’s 
signalling capabilities are likely dependent on the cell type the receptor is expressed 
on and morphological state of A.f. encountered. The ability of Dectin-1 to collaborate 
with TLRs during A.f. challenge has been described; a similar mechanism has not been 
identified for CLR collaboration. The important role of Dectin-1 during anti-fungal 
immune responses suggests any CLR-enhancing collaboration could be a very 
attractive therapeutic target. 
 
 
1.3.6: Dectin-2 
 
Dectin-2 is a member of the group II CLRs and is a type II transmembrane receptor 
possessing a highly conserved, single extracellular C-type lectin-like domain (CTLD) 
[175]. The receptor is expressed on tissue-resident macrophages, neutrophils and DCs 
[176]. Recent evidence suggests Dectin-2 is also expressed at a low level on peripheral 
blood monocytes although its expression on these cells can be greatly up regulated by 
fungal and other inflammatory stimuli [176, 177]. In the lung Dectin-2 mRNA 
expression is restricted to alveolar macrophages and is significantly up regulated 
during A.f. infection suggesting a role for this receptor in the anti-A.f. immune 
response [178]. Cell surface expression of Dectin-2 on alveolar macrophages has not 
been confirmed. 
	 43	
 
Dectin-2 possesses a short cytoplasmic tail that signals indirectly via FcRγ association. 
Receptor signalling is mediated through Syk and the CARD9-Bcl10-MALT1 complex 
leading to the induction and formation of an immune response [179]. Dectin-2 
signalling results in the production of an extensive range of pro and anti-inflammatory 
cytokines and chemokines such as TNF, IL-1β, IL-10, IL-6 and IL-12 [156, 180]. 
Activation of Dectin-2 also induces respiratory burst and inflammasome activation 
[181]. Dectin-2 has been shown to utilise the MAPK pathway and drive a TH17 
regulatory response via the induction of IL-23 and IL-1β [182].  
 
Dectin-2 predominantly recognises larger, hyphal morphologies of fungi. Binding 
occurs through its carbohydrate recognition domain containing a cation-dependent 
mannose-binding EPN motif, which binds high mannose structures. Limited evidence 
suggests the receptor may recognise conidial morphologies of fungi but with weak 
affinity [183]. Dectin-2 is proficient in recognising a range of pathogens including A.f., 
Candida albicans, Mycobacterium tuberculosis, and house dust mite allergens [179, 
183, 184]. Dectin-2 has been directly implicated in anti-A.f. immunity. In this role the 
recognition of A.f. HY and formation of a cytokine and chemokine response was 
dependent on the presence of Dectin-2, and not Dectin-1 [185].  
 
A clear role for Dectin-2 has been described in Candida albicans infection. During 
infection Dectin-2 was essential for host protective immune responses and the 
receptor was shown to drive inflammatory cytokine and chemokine responses and 
direct an adaptive TH1 and TH17 response against Candida albicans. Mice lacking 
Dectin-2 were significantly more susceptible to infection possessing increased fungal 
burden and decreased survival compared to WT mice [180, 186]. The impact Dectin-2 
has on the immune response during the complex stages of A.f. infection has yet to be 
clearly described. 
 
 
1.3.7: Mincle 
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Like Dectin-2, Mincle is a member of the group II CLRs and is a type II transmembrane 
receptor possessing a highly conserved, single extracellular CTLD [175]. The name 
Mincle stands for Macrophage-inducible C-type lectin and the receptor was identified 
by its strong induction after inflammatory stimuli on macrophages. Since the initial 
discovery of Mincle on macrophages, the receptor has been shown to be present on 
monocytes, neutrophils, DCs and some B-cell subsets [136]. Mincle, like Dectin-2, 
couples to FcRγ to induce intracellular signalling through Syk and the CARD9-Bcl10-
MALT1 complex resulting in the production of many cytokines and chemokines such 
as TNF, IL-6, MIP2 and KC and inducing cellular respiratory burst [136]. These immune 
responses represent a solo role for Mincle pathogen-recognition through to cellular 
response and are generated independently of MyD88.  
 
A role for Mincle synergistically collaborating with TLRs and generating an enhanced 
inflammatory cytokine and chemokine response has been described, most recently 
during Fonsecaea perdrosoi infection [187]. Infections caused by this pathogen are 
thought to result from an insufficient host pro-inflammatory response induced by the 
pathogen. Exogenously administering TLR ligands resolved disease by inducing a 
synergistic Mincle:TLR collaboration enhancing the pro-inflammatory cytokine 
response [187]. This data describes the improvement Mincle:TLR collaboration 
provides the pro-inflammatory host immune response. 
 
Mincle recognises several different types of carbohydrates through its single CTLD. 
Mincle has a particularly strong binding affinity for α-mannose, a carbohydrate 
typically found on fungal cell walls [188]. Mycobacterial molecules such as trehalose 
dimycolate and cellular necrosis markers such as spliceosome-associated protein 130 
have also been identified as Mincle ligands suggesting a role for the CLR in bacterial 
immunity and host-homeostasis [136, 189]. Although, the spliceosome-associated 
protein 130 binding site on Mincle was not located within the CRD [136]. The evidence 
that Mincle acts as a fungal PRR results from experiments utilising cell wall 
components of Candida albicans. Mincle was able to recognise cell wall components 
from this fungus and subsequently induce a robust inflammatory cytokine response 
and enhance Candida albicans phagocytosis [190]. This data describes a role for Mincle 
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in driving the anti-fungal protective immune response. Mincle’s involvement in A.f. 
infections has not been thoroughly explored. Recently, the receptor’s up regulation 
upon A.f. infection has been described in a rat A.f. keratitis model. Mincle up 
regulation was significantly associated with the changing expression of TNF, IL-1β, IL-
10 and MIP-1α; although, this research only states “Mincle may play a role in the early 
innate immune response against A.f.” [191].  
 
Mincle’s impact in vivo is controversial. A protective role for Mincle has been identified 
with experiments using Mycobacterium tuberculosis strains Erdman or BCG. Knocking 
out Mincle in these models resulted in modified inflammatory responses and 
increased bacterial loads in Mincle KO mice. Conversely, Mincle KO mice infected with 
Mycobacterium tuberculosis H37Rv produced a normal inflammatory response and 
disease burden was not increased [192, 193]. 
 
An intriguing role has been described for Mincle in vitro. A human Helicobacter pylori 
infection model identified a pathogen immune evasion aspect to Mincle engagement. 
This model involved in vitro cultured human macrophages being stimulated with 
Helicobacter pylori. The pathogen was found to drive an anti-inflammatory response 
by up regulating Mincle expression independently of host-cell contact. The proposed 
mechanism involves up-regulated Mincle interacting with the Lewis antigens of 
Helicobacter pylori resulting in an anti-inflammatory response; therefore, aiding the 
survival of Helicobacter pylori due to the evasion of an appropriate pro-inflammatory 
immune response. A robust pro-inflammatory response could be restored upon siRNA 
knockdown of Mincle in the stimulated macrophages [194].  
 
Recently a similar Mincle-engagement evasion role for fungal pathogens has been 
identified. The fungal pathogen Fonsecaea monophora (responsible for the chronic 
skin infection chromoblastomycosis) when engaged by Dectin-1 activates the 
transcription factor IRF1 and results in the downstream production of pro-
inflammatory cytokines such as IL-12 and orchestration of protective anti-fungal 
immune responses. However, Fonsecaea monophora can evade this Dectin-1 driven 
pro-inflammatory response by engaging Mincle. The engagement of Mincle induces 
	 46	
the E3 ubiquitin ligase Mdm2-dependent degradation pathway that culminates in the 
loss of IRF1 and lack of pro-inflammatory cytokine production. Therefore the 
engagement of Mincle by Fonsecaea monophora results in the evasion of an 
appropriate anti-fungal immune response and pathogen survival [157].   
  
There is still much to understand about Mincle’s action. The CLR’s ability to 
synergistically collaborate with other PRRs such as TLRs, its ability to recognise 
bacterial and fungal pathogens driving proinflammatory and protective immune 
response as well as the CLRs role recognising self-necrotic tissue have begun to be 
unravelled. Mincle’s more recently described implications in pathogen immune 
evasion via the receptors ability to control immune responses and modulate anti-
inflammatory responses highlight an intriguing aspect to Mincle engagement.  
 
 
1.3.8: Mcl 
 
Mcl is the most recently described CLR within the group II family of CLRs. Mcl is a type 
II transmembrane receptor with a single extracellular CTLD. This CLR is expressed on 
macrophages, neutrophils, monocytes and some DC subsets. Mcl’s ability to couple 
and signal through FcRγ is controversial. Research has suggested Mcl does not 
associate with FcRγ but can initiate intracellular signalling through the Syk and CARD9-
Bcl10-MALT1 complex pathway. This signalling leads to the induction of phagocytosis, 
respiratory burst and production of pro-inflammatory cytokines [158, 195]. 
Interestingly, Mcl requiring Mincle coupling before FcRγ could be recruited has also 
been described [196]. Conversely, challenging Mcl-deficient mice with trehalose 
dimycolate has elicited a direct role for Mcl coupling with FcRγ. Trehalose dimycolate 
(TDM), is a glycolipid molecule found in the cell wall of bacteria such as Mycobacterium 
tuberculosis. TDM-induced acquired immune responses such as experimental 
autoimmune encephalomyelitis were almost completely dependent on Mcl, not 
Mincle. This research also found Mcl was crucial for driving Mincle induction upon 
TDM challenge [158]. Mcl’s ability to directly couple to FcRγ is unclear; the receptor 
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may directly couple to FcRγ or require heterodimerisation with other CLRs such as 
Mincle to induce signalling through FcRγ.  
 
Mcl possesses no known signalling motifs in its cytoplasmic region and no charged 
amino acid residues in its transmembrane domain drawing much investigation into 
how the CLR signals using Syk. The CTLD of Mcl does not contain an EPN motif or similar 
conserved amino acid region associated with carbohydrate recognition. Therefore, it 
is hypothesised Mcl cannot recognise unconjugated sugars but may bind glycolipids. 
Glycolipid recognition is thought to occur as the receptor possesses a shallow 
hydrophobic region located in its extracellular CTLD. The ability of Mcl to recognise 
glycolipids explains the receptors affinity to bind trehalose dimycolate [195, 197]. 
 
The ability of Mcl to signal using Syk may rely on the receptor collaborating with other 
CLRs. The intracellular retention of Mcl has been demonstrated to greatly increase 
Mincle surface expression suggesting the two CLRs may be linked. Analysing the 
expression of Mincle and Mcl on peritoneal macrophages after IL-4 or LPS stimulation 
identified a tight co-linear expression relationship for the two receptors. 
Immunoprecipitation experiments co-transfecting 293T cells with combinations of 
Mcl, Mincle and FcRγ revealed a complex of these three molecules was present. This 
data suggests that Mcl ligand recognition and Syk signalling is Mincle-dependent [198]. 
A similar collaborative role for Mcl and Dectin-2 has been explored. Mcl and Dectin-2 
were co-expressed in RAW264.7 cells before these cells were challenged with Candida 
albicans HY. Cells expressing both receptors produced an enhanced response linked 
with their increased NFκB activation. No Mcl collaborations with other Dectin-2-CLR 
family members mimicked this synergistic response. A series of antibody blocking 
experiments elicited the function of Mcl and Dectin-2 to form hetero, or homodimers; 
although, the signalling and response implications of this were not explored beyond 
the increased NFκB expression [199].  
A role for Mcl during fungal infection is still unknown; however, the CLR has been 
demonstrated upon recognition of trehalose dimycolate to drive anti-mycobacterial 
immunity [158]. In vivo experiments challenging Mcl KO mice with Mycobacterium 
tuberculosis resulted in exacerbated pulmonary inflammation, higher mycobacterial 
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burdens and increased mortality when compared to WT mice [200]. It is thought Mcl 
plays a similar role in human Mycobacterium tuberculosis infection. An Mcl 
polymorphism in humans is significantly associated with an increased susceptibility to 
pulmonary mycobacterium infections such as Mycobacterium tuberculosis [200]. 
Recently an in vivo anti-fungal role for Mcl has begun to be explored. Mcl KO mice, 
when infected with a low dose of Candida albicans displayed increased mortality 
compared to WT mice. Around 60% of Mcl KO mice succumbed to infection within 2 
weeks whereas no mortality was present in WT mice, this was likely the result of a 
significantly reduced cytokine and chemokine response present in Mcl KO mice. 
Contrary to this, when a higher dose of Candida albicans was used to infect WT and 
Mcl KO mice, no difference in survival or cytokine and chemokine response was 
attained [199].  
 
The anti-fungal capability of Mcl is complicated, as the receptor likely requires 
collaboration with other CLRs to signal and potentially even recognise ligands. The 
impact Mcl has on the Candida albicans response does suggest this CLR is important 
in anti-fungal immunity. Due to this receptor’s likely ability to collaborate with other 
CLRs either by physically interacting with or up regulating their expression, this 
receptor may be an interesting therapeutic target to enhance CLR expression and/or 
synergistically improve anti-fungal responses. 
 
 
1.3.3: CLRs and phagocytosis 
 
CLRs coordinate immune responses with multiple anti-fungal immune response 
outcomes. The alveolar macrophage and neutrophil phagocytic uptake and 
destruction of fungal pathogens within the phagolysosome is one of the most 
important mechanisms of host anti-fungal defence. CLRs are exclusively required for 
fungal uptake and phagocytosis. TLRs play a role as their signalling can regulate 
phagosomal maturation; however, TLRs themselves are not directly required for 
phagocytic uptake [201]. A complex role for TLR involvement in the alveolar 
macrophage and neutrophil uptake of A.f. conidia has been described. Alveolar 
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macrophages require MyD88-independent involvement of TLR2 in A.f. phagocytosis. 
While neutrophils require MyD88-dependent involvement of TLR4 in A.f. 
phagocytosis. The mechanistic role of TLR2 and TLR4 during uptake of A.f. is not fully 
understood [202]. 
 
The recognition and phagocytosis of fungal pathogens is dependent on a range of host 
and fungal components. The variable mechanisms of host-fungal phagocytosis is 
directed by the host-cell type the CLR is expressed on, the composition of the fungal 
cell wall, the opsonisation of the fungi and the morphological form of the fungi. For 
example, the phagocytic mechanism Dectin-1 uses to engulf fungal pathogen varies 
depending on the host-cell type Dectin-1 is expressed on. Dectin-1, unlike most 
myeloid cell resident phagocytic CLRs, possesses a distinct hemITAM domain on its 
cytoplasmic tail. Upon ligand binding and CLR activation this motif promotes the syk-
dependent phagocytic internalisation of the CLR:fungi complex leading to the 
formation of early endosomes [203]. Following this, an additional intracellular tri-
acidic motif directs this early endosome to the lysosome. These motifs instruct 
pathogen phagocytosis and the required signalling cascade necessary for the pathogen 
to be trafficked to lysosomes and killed [204].  
 
Dectin-1’s cell-specific phagocytosis response has been demonstrated using zymosan. 
The murine dendritic cell-expressed Dectin-1 phagocytosis of zymosan requires the 
tyrosine-kinase Syk pathway and culminates in actin polymerisation, membrane 
extension and zymosan phagocytosis. Syk signalling generates the production of ROS 
within the endocytosed vesicle [165, 205]. The murine macrophage-expressed Dectin-
1 phagocytosis of zymosan was demonstrated to also require actin polymerisation and 
membrane extension phagocytosis but occurred independently of Syk. Although, ROS 
production within the endocytosed vesicle was still Syk-dependent [206]. The 
mechanisms by which Dectin-1 and other non-soluble CLRs mediate phagocytosis is 
not clearly known and varies depending on a range of host and fungal factors [207]. 
 
After the CLR-directed phagocytosis of a fungal pathogen has taken place, the 
internalised vesicle containing the CLR:fungi complex matures through the endosomal 
	 50	
pathway and culminates in the formation of a phagolyosome. This compartment 
contains potent anti-microbial peptides that lead to fungal killing. CLRs, whilst 
trafficked through the phagosome maturation pathway, can be recycled and re-
positioned back to the cell surface [205]. The role CLRs and TLRs convey over the 
kinetics of phagosomal maturation is complex and not well described. Some evidence 
suggests TLRs and CLRs influence phagosomal maturation perhaps linked with their 
ability to communicate with autophagy pathways [208]. The activation of the group V 
secretory phospholipase A2 (a key enzyme involved in the regulation of inflammation 
and endosome pathway control) by CLRs may lead to phagosome maturation and 
fungal killing [209].  
 
The mediation of phagocytosis and phagosome maturation by CLRs is key not only for 
pathogen clearance but also for the generation of antigenic fragments driving adaptive 
immunity. Antibody mediated targeting to CLRs such as DC-SIGN (which possesses a 
tri-acidic internalisation motif) has been shown to deliver antigen to lysosomal 
compartments of antigen-presenting cells and generates a peptide complex with MHC 
for T-cell presentation [210, 211]. CLRs ability to couple PAMP recognition with the 
downstream induction of innate immune responses, including A.f. phagocytosis is vital 
for the generation of appropriate anti-fungal immune responses. 
 
 
1.3.4: CLRs and non-phagocytic fungal killing 
 
CLRs also possess many non-phagocytic anti-fungal immune response capabilities. The 
receptors through their ability to induce pro-inflammatory gene expression play a 
critical role in orchestrating the anti-fungal immune response. Signalling cascades 
initiated by CLR-fungi interaction drive the release of a range of pro-inflammatory 
cytokines and chemokines such as TNF, IL-1β, IL-6, IL-12, MIP1α, MIP2 and KC. The 
release of these pro-inflammatory mediators leads to the mobilisation of the innate 
immune system against fungal pathogens. Consequently, the innate response via 
antigen-presenting cells generates and presents antigen, mobilising the adaptive 
immune response. Antigen presenting cells induce naïve CD4+ T cells to differentiate 
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into TH1, TH2 or TH17 effector cells. CLR-associated cytokines and chemokines co-
ordinate and control the complex and multi-faceted anti-fungal response. 
 
A successful host immune response against fungal pathogens requires CLR induced 
gene expression resulting in the release of cytokines and chemokines. Lacking TNF or 
IL-6 significantly enhances in vivo susceptibility to fungal infection by impairing 
macrophage and neutrophil function and fungal killing [212, 213]. The necessity of a 
TNF response against fungal pathogens has been highlighted in humans that possess 
a TNF mutation that increases the production of this cytokine far beyond normal 
quantities. These individuals are particularly resistant to A.f. infection [214]. CLRs can 
also induce many oxidative and non-oxidative fungal killing mechanisms in a variety of 
immune cell types. These responses are largely influenced by the cytokine and 
chemokine controlled state of cellular activation, which as previously mentioned is 
itself primarily controlled by CLRs.  
 
The respiratory burst is a crucial anti-fungal killing mechanism triggered by CLRs. The 
NADPH oxidase complex containing NOX2 assembles at the cell membrane and upon 
activation transfers electrons from cytoplasmic NADPH to O2 generating superoxide 
molecules. Superoxides through the Haber-Weiss reaction produce H2O2 and hydroxyl 
radicals that act as potent fungicidal oxidants [215]. Dectin-1 and Fcγ are capable of 
directly activating the respiratory burst via the syk-dependent signalling through their 
ITAM domain [206]. CLR activation has also been described to induce the release of 
many antimicrobial peptides. These molecules such as α-defensins are small cationic 
proteins that interfere with the fungal cell wall and lead to fungal killing; however, 
their exact mechanism of cell wall interference and disruption is unknown [216]. CLRs 
expressed on many innate immune cells and epithelial cells secrete antimicrobial 
peptides following activation and intracellular signalling. The extensive repertoire of 
CLR-associated anti-fungal responses regularly leads to the efficient clearance of 
fungal pathogens and, when required, can orchestrate and mediate complex anti-
fungal immune responses.  
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1.3.5: PRR collaboration  
 
Fungal pathogens are often morphologically complex organisms and their recognition 
by the immune system involves multiple PRRs that produce a coordinated response 
[217]. Receptor collaboration ensures redundancy and reduces the risk of immune 
evasion by the pathogen despite the pathogen’s genetic diversity. Several TLRs have 
been demonstrated to recognise fungal pathogens and the requirement of CLRs when 
combating fungal pathogens is clear. Many examples of TLR and CLR anti-fungal 
receptor collaboration have been described. Due to the challenging nature of fungal 
pathogens, it is highly likely that multiple receptors recognising multiple PAMPs are 
required to initiate a successful immune response against the pathogen.  
 
The first TLR CLR collaboration was described when macrophages and DCs were 
stimulated with β-glucan particulates. An enhanced TNF, IL-10 and IL-23 response was 
achieved when both TLR2 and Dectin-1 were engaged. This synergistic response relied 
upon the Dectin-1 collaboration with MyD88-coupled TLR2 [218]. The mechanisms of 
TLR CLR collaboration are not well understood; they’re thought to involve the physical 
interaction of receptors upon ligand binding and subsequent modification of 
intracellular signalling cascades [219].  
 
Recent work using the fungal pathogen Fonsesaea pedrosoi has provided further 
evidence highlighting the requirement of TLR CLR collaboration. Fonsesaea pedrosoi is 
recognised by CLRs such as Mincle whilst no recognition was identified with TLRs. 
Interestingly, CLR-exclusive Fonsesaea pedrosoi recognition produced what was found 
to be a deficient inflammatory response against the pathogen. The in vivo engagement 
of TLRs by the exogenous administration of TLR ligands produced TLR CLR 
collaboration, enhanced the inflammatory response and led to Fonsesaea pedrosoi 
clearance. The successful initiation of an appropriate inflammatory response able to 
resolve the infection was dependent on the activation of both the Syk/CARD9-Bcl10-
MALT1 signalling pathway and the MyD88 signalling pathway [187].  
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The requirement for a collaborative response is not limited to Fonsesaea pedrosoi; 
treatment with heat-killed E. coli enhances the clearance of chronic P. carinii infections 
in vivo [220]. These limited results suggest collaborative PRR signalling is necessary for 
the generation of an appropriate immune response against the pathogen. Although 
TLR:CLR immune enhancing collaboration has begun to be investigated, CLR:CLR 
collaboration has not been extensively explored. Recently, a CLR:CLR collaboration 
was identified between Dectin-1 and Dectin-2 during Trichophyton rubrum infection. 
Although some IL-1β, TNF, IL-10 and IL-6 was produced when Dectin-1 KO and Dectin-
2 KO BMDCs were stimulated with the fungal pathogen, knocking out both CLRs almost 
completely abrogated cytokine production. In vivo Dectin-1 Dectin-2 DKO mice 
possessed the highest fungal burden when compared to single KO and WT controls. 
This data suggests collaboration between Dectin-1 and Dectin-2 is required for the 
successful control of Trichophyton rubrum [221]. 
 
Pathogenic fungi possess multiple life cycles and complex infectious mechanisms. 
Hosts likely require extensive CLR collaboration throughout the fungi’s life cycle stages 
and disease progression to generate appropriate immune responses. Understanding 
CLR receptor collaboration may allow the development of immune-modulating 
therapeutics that enhance the anti-A.f. immune response. Similar to the exogenous 
administration of TLR ligands improving Mincle-TLR collaboration and response 
against Fonsesaea pedrosoi, the therapeutic engagement of CLRs may enhance 
collaboration synergistically improving the anti-fungal response.  
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1.4: Hypothesis 
 
 
The hypothesis tested in this thesis is that CLRs are important during Aspergillus 
fumigatus infection. CLRs mediate A.f. recognition and orchestrate complex immune 
responses. CLR collaboration is required to successfully clear A.f. disease.  
 
 
 
1.5: Aims 
 
 
I. Identify the role of Dectin-1 in immune-compromised cystic fibrosis patients 
at risk of A.f. disease 
 
II. Use in vivo CLR KO and CLR DKO models to determine the role of CLRs during 
immune-competent A.f. disease 
 
III. Identify CLR-associated risk factors that stratify immune-suppressed patients 
according to A.f. disease susceptibility  
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Chapter 2 
 	
Methods 
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2.1: Notes 
 
 
2.1.1: Reagents  
 
All reagents including cell specific media, experiment specific buffers, PCR primers, 
qPCR probes, antibodies and ELISA KITS are detailed in chapter 7 appendix. All 
sequences of CLR genes are detailed in chapter 7 appendix. 
 
 
2.1.2: Animals used in this research 
 
All in vivo animal work was conducted in accordance with UK Home Office and Cardiff 
University guidelines and regulations. Experiments were completed under Cardiff 
University’s Home Office establishment license, Professor Phil Taylor’s Home Office 
project license (P05D6A456, formerly 30/2938) and my Home Office personal license 
(Mice A & B). Mice were housed and maintained in Cardiff University’s Joint Biological 
Services Unit.  
 
 
2.1.3: Patient samples used in this research 
 
The clinical research project was undertaken with sponsorship from Cardiff University 
and ethical approval from Health and Care Research Wales (NISCHRC CRC 1351-14). 
REC reference 14/WA/1119 and IRAS project ID 151136. I completed the NISCHRC CRC 
‘Good Clinical Practice’ course before undertaking this clinical research study. Samples 
were collected from medical staff on the hematology ward (B4) at the University of 
Wales teaching hospital, Heath Park. Samples were link-anonymised by Dr Lewis 
White, the microbiology lead for hematology.  
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2.1.4: DNA sequencing 	
Sequencing reactions were completed using a Lightrun Sanger sequencing service 
from GATC Biotech. The sequencing of purified PCR product required 5μl of 20-
100ng/μl DNA to be premixed with 5μl 0.5μM gene-specific primer. The sequencing of 
purified Plasmid DNA required 5μl of 80-100ng/μl DNA to be premixed with 5μl 0.5μM 
gene-specific primer. 
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2.2: Cell culture 
 
 
2.2.1: Cell counting 
 
Cells were counted using a bright line haemocytometer (Neubaur) with a depth of 
0.1mm and small square area of 0.0025mm2. The total cells in the four large squares 
(made up of 16 smaller squares) were counted and the number divided by 4 to gain 
the average cell count per 0.001mm3. This cell number was multiplied by 104 to provide 
the cell count per 1cm3, or per 1ml of cell solution. 
 	
2.2.2: Bone marrow derived macrophages (BMDMs) 
 
Mice were sacrificed by exposure to CO2 and cervical dislocation. Mice femurs were 
harvested, cleaned and cut either side of the knee joint. Bone marrow was flushed 
from the femur with 10ml PBS (Life Technologies) in a syringe and collected. Bone 
marrow in PBS was centrifuged at 350g for 5 minutes, PBS was aspirated and 5ml fresh 
PBS added. This wash cycle was repeated three times. Cells were counted and re-
suspended at 2x105/ml in BMDM media. Occasionally bone marrow was obtained 
from stocks stored in liquid nitrogen. Bone marrow was retrieved from liquid nitrogen 
storage and rapidly warmed to 37oC before the immediate addition of 10ml BMDM 
media. Cells were centrifuged at 350g for 5 minutes and the BMDM media aspirated. 
Cells were counted and re-suspended at 2x105/ml in BMDM media. 
 
On day 0, 7x106 bone marrow cells in 35ml BMDM media were added to each 145mm2 
culture dish. M-CSF (Peprotech) was added to each culture dish at a final concentration 
of 10ng/ml. The plates were then incubated at 37oC 5% CO2. On day 3, 15ml BMDM 
media was added to each BMDM culture dish and the concentration of M-CSF brought 
up to 10ng/ml. On day 6 or 7 BMDMs were fully developed from bone marrow cells. 
BMDMs were harvested with the removal of BMDM media and addition of 4mg/ml 
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lidocaine (Sigma) in 5ml PBS or 5ml trypsin (Life Technologies) incubated for 5 minutes 
at 37oC 5% CO2. After incubation the addition of 7ml BMDM media neutralised 
lidocaine or trypsin. BMDMs were collected and centrifuged at 350g for 5 minutes. 
BMDM media and lidocaine or trypsin was aspirated before BMDMs were counted 
with a haemocytometer, plated out as each experiment required and rested overnight 
at 37oC 5% CO2 before use. 
 
 
2.2.3: Alveolar macrophages 
 
Mice were anaesthetised with 140mg/kg intra-peritoneal Euthatal (Vet Tech) and 
sacrificed by exsanguination. Alveolar macrophages were extracted by bronchiolar 
alveolar lavage. A 0.8mm3 tube was inserted into the trachea, taking care not to go 
past the carina and only access one lung. A total of 10ml PBS supplemented with 
0.01mM EDTA (Fisher Scientific) was flushed through the lungs in 0.5ml increments. 
Each increment of PBS supplemented with 0.01mM EDTA was left to dwell in the lungs 
for 10 seconds before being removed and collected. Two 10ml syringes and a stopcock 
were used to inject and retrieve PBS supplemented with 0.01mM EDTA so each 0.5ml 
increment only passed through the lungs once. The recovered alveolar macrophage 
containing lavage fluid was immediately stored at 4oC. Lavage fluid was pooled per 
genotype and centrifuged at 350g for 5 minutes at 4oC. PBS supplemented with 0.1mM 
EDTA was aspirated before cells were re-suspended in 1ml Alveolar macrophage 
media and counted by haemocytometer. Cells were plated at 1x106/ml in a 96 well 
plate and rested for 2-4 hours at 37oC 5% CO2 before use in experiments.  
 
 
2.2.4: BIOgel elicited cells 
 
Mice were intra-peritoneally injected with 0.5ml 2% BIOgel (Bio-Rad). 14-16 hours 
later mice were sacrificed by exposure to CO2 and cervical dislocation before 
peritoneal lavage was performed. 5ml ice cold PBS supplemented with 0.01mM EDTA 
was injected into the peritoneal cavity and manually washed around for 60 seconds 
	 60	
before being extracted. Recovered lavage fluid was immediately stored at 4oC. When 
ready for processing recovered lavage fluid was run through a 100μM filter and the 
pass-through was centrifuged at 350g for 5 minutes at 4oC. PBS supplemented with 
0.01mM EDTA was aspirated and recovered cells suspended in Neutrophil/Monocyte 
media, NE assay buffer or PBS and counted by haemocytometer. Cells were plated out 
at 1x106/ml in a 96 well plate and immediately used for experiments. 
  
 
2.2.5: NIH-3T3 cells 
 
Cells were typically cultured from NIH-3T3 parental stocks stored in liquid nitrogen. 
Parental NIH-3T3 cells were removed from liquid nitrogen and rapidly warmed to 37oC 
before the immediate addition of 10ml 3T3 media. Cells were centrifuged at 350g for 
5 minutes, 3T3 media aspirated and 10ml fresh 3T3 media added. NIH-3T3 cells were 
added to a T25 tissue culture flask to be grown and passaged.  
 
NIH-3T3 cells were maintained in 3T3 media and incubated at 37oC 5% CO2, Geneticin 
(G418) was added at a concentration of 0.6mg/ml if selection was required. Cells were 
passaged when necessary by incubation with 5ml trypsin for 5 minutes at 37oC 5% CO2. 
After trypsin incubation the addition of 7ml 3T3 media neutralised trypsin. NIH-3T3 
cells were collected and centrifuged at 350g for 5 minutes. 3T3 media and tryspin was 
aspirated before cells were re-suspended in 1ml 3T3 media. From this 1ml, 100μl was 
removed and used to start a new culture flask. NIH-3T3 cells were progressed through 
T25 flasks before larger T75 or T175 flasks were used for cell culture.  
 
For experimental use, cells were harvested via incubation with 5 ml PBS supplemented 
with 10mM EDTA and 4mg/ml lidocaine at 37oC 5% CO2. After lidocaine incubation the 
addition of 7ml 3T3 media neutralised lidocaine. NIH-3T3 cells were collected and 
centrifuged at 350g for 5 minutes. 3T3 media and lidocaine was aspirated before cells 
were counted with a haemocytometer and used in experiments. 
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2.2.6: Culture and preparation of A.f. conidia 
 
A.f. isolate 13073 (stored in endofree dH2O at -80oC) was cultured on potato dextrose 
agar for 7 days at 37oC. Conidia were harvested by vigorous washing with 40ml PBS 
supplemented with 0.1% Tween 20 and passed through a 40μm filter to remove 
hyphal fragments. The pass-through suspension was centrifuged at 350g for 5 minutes 
and the A.f. pellet re-suspended in 25ml PBS. Conidia were counted by 
haemocytometer. A final culture concentration of ~1x108 conidia/ml was typically 
attained and stored at 4oC. Cultures maintained efficacy for 6-8 weeks and were 
discarded after this time. To confirm normal, expected A.f. culture growth 1x105 
resting conidia were incubated with RPMI 1640 (GE Healthcare) supplemented with 
0.2mg/ml Polymixin B (Sigma) at 37oC 5% CO2. Successful development of hyphal 
fragments at 24 hours indicated a healthy culture; this was confirmed using a light 
microscope. 
 
A.f. has four morphologies; incubating resting conidia in RPMI 1640 supplemented 
with 0.2mg/ml Polymixin B for specific periods of time attained the different 
morphologies. Typically, 3x106 A.f. resting conidia were incubated in 1ml RPMI 1640 
supplemented with 0.2mg/ml Polymixin B at 37oC 5% CO2. Swollen conidia developed 
at 6 hours, early germlings developed at 10 hours and hyphae developed at 24 hours. 
Germination of resting conidia into latter A.f. morphologies was confirmed using a 
light microscope. 
 
 
2.2.7: Preparation of heat-killed A.f. 
 
A.f. swollen conidia were used to produce heat-killed A.f. required for experiments. 
A.f. resting conidia were grown into swollen conidia, 10mls of 3x106 A.f. resting 
conidia/ml of RPMI 1640 supplemented with 0.2mg/ml Polymixin B were grown in a 
tissue flask for 6 hours at 37oC 5% CO2. A.f. swollen conidia in solution were transferred 
to a 50ml falcon, which was then submerged in boiling water for 20 minutes. Heat-
killing was confirmed by incubating 100μl of boiled A.f. swollen conidia solution on a 
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potato dextrose agar plate for 37oC for 48 hours. No visible A.f. growth (small white 
colonies) confirmed successful heat killing. 
 
 
2.2.8: Freezing and reviving cells 
 
Cells to be frozen were centrifuged at 350g for 5 minutes and any media aspirated. 
Cells were re-suspended in FCS supplemented with 10% DMSO before being aliquoted 
into 1ml cryogenic vials. A ‘Mr Frosty” (Thermo Scientific) was used to prepare cell 
aliquots for liquid nitrogen storage, this isopropanol filled contained buffered interior 
container temperature reduction to 1oC per minute. Cells in cryogenic vials were 
stored in a ‘Mr Frosty’ for a minimum of two hours at -80oC. Cryogenic vials were then 
transferred to liquid nitrogen for long-term storage.  
 
Once removed from liquid nitrogen, cells in cryogenic vials were rapidly thawed in a 
37oC water bath. When fully thawed the 1ml cell aliquot was added to 10ml of cell-
specific complete media and centrifuged at 350g for 5 minutes. All media was 
aspirated and cells re-suspended in their specific complete media. Cells were then 
counted before being plated out or added to tissue culture flasks and incubated at 
37oC 5% CO2. Cells were typically rested overnight before being ready for use in 
experiments. 
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2.3: Generation of cell lines 
 
 
2.3.1: Infusion primer design 
 
Primers were designed and ordered (Sigma) with a target gene specific sequence and 
15 base pair vector-overhang specific sequence included. These primers were used to 
amplify target genes for expression vectors by PCR. Designed primers were used with 
the In-fusion cloning kit (Clontech) to generate new vectors. 
 
2.3.2: Restriction endonuclease vector digestion 
 
Plasmid vectors were cut using restriction endonuclease enzymes in the presence of 
their appropriate accompanying buffer (New England Biolabs). Digestion reactions 
were incubated at 37oC for 1 hour before restriction endonuclease enzymes were 
inactivated at 65oC for 15 minutes. Digested vector product was separated from any 
undigested vector by gel electrophoresis. Digested vector was cut out of the gel and 
purified using a gel-excision purification kit (Qiagen). 
 
 
2.3.3: Infusion reaction  
 
The infusion reaction involved mixing gel-purified, restriction endonuclease digested 
vector (100ng) with gel-purified target gene insert (50ng) and 2μl 5X In-Fusion HD 
enzyme premix. The reaction was incubated at 50oC for 15 minutes before being 
immediately used for cell transformation or stored at -20oC. 
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2.3.4: Transformation  
 
Stellar competent cells (Clontech) were used for all transformation reactions. A Stellar 
competent cell 50μl aliquot was thawed on ice for 15 minutes and gently mixed. 2.5μl 
of completed reaction mixture from the previous Infusion reaction was added to a 
50μl aliquot of Stellar competent cells and the mixture incubated at 4oC. After 30 
minutes cells were heat-shocked at 42oC for 45 seconds before being placed on ice for 
2 minutes to cool. 447.5μl SOC media (Sigma) was pre-warmed to 37oC and added to 
the cells. The mixture was incubated at 37oC 200 rpm for one hour. After an hour 
incubation, 1μl cell solution, 50μl cell solution and 100μl cell solution were spread on 
LB agar plates containing 100μg/ml ampicillin (Sigma) or carbenocillin (Fisher 
Scientific) and incubated at 37oC overnight. These antibiotics were appropriate for 
both PFB-Neo and Pmx-IP plasmid vectors used.  
 
 
2.3.5: Plasmid DNA extraction 
 
Once the LB plate overnight incubation was complete individual isolated bacteria 
colonies were picked and grown in 5ml LB broth containing 50μg/ml ampicillin or 
carbenocillin at 37oC 250rpm overnight. After incubation, 0.5ml of this culture was 
removed and added to 0.5ml sterile glycerol in a cryogenic vial. Each vial was 
cryogenically frozen as previously described in 2.2.8. Plasmid vector DNA was 
extracted from the remaining 4.5ml culture using a plasmid mini-prep kit (Invitrogen). 
Extracted plasmid DNA was quantified using a nanodrop (Thermo Scientific) and sent 
for sequencing with target gene insert primers. The correct insertion, orientation and 
nucleotide sequence of target gene in plasmid was confirmed. 
 
Bacterial colonies containing plasmid with the correct target gene insert were grown 
up from glycerol stocks in 100ml LB broth containing 50μg/ml ampicillin or 
carbenocillin at 37oC 250rpm overnight. After incubation, plasmid DNA was extracted 
from the bacterial culture using a plasmid midi-prep kit (Invitrogen). Extracted plasmid 
DNA was quantified using a nanodrop before being used to transfect cells. 
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2.3.6: Retroviral infection 
 
Ecopack 2.293 cells (Clontech) were used to generate viral particles containing 
extracted plasmid DNA. 2.5 x 105 Ecopack cells in 2ml Ecopack media were added to 
each well on a 6 well plate and incubated for 6 hours at 37oC 5% CO2. After incubation, 
Ecopack cells were transfected. The following reaction was completed for each 
plasmid construct added to each well of Ecopack cells. 200μl RPMI 1640 was mixed 
with 9μl Fugene (Promega) for 5 minutes at RT before 1.5μg extracted plasmid DNA 
was added. The mixture was incubated for 30 minutes at RT and then added to each 
well containing Ecopack cells. Transfected Ecopack cells were incubated at 37oC 5% 
CO2 for 24 hours before Ecopack media was replaced.  
 
48 Hours after transfection the supernatant from each Ecopack well was collected and 
filtered through a 0.45μm filter. 5μg/ml polybrene (Sigma) was added to the collected 
Ecopack supernatant. This filtrate was used to infect parental NIH-3T3 cells that had 
been cultured as described in 2.2.5. 1x105 Parental NIH-3T3 cells in 3ml 3T3 media 
were added to each well on a 6 well plate and incubated at 37oC 5% CO2 for 48 hours. 
After incubation, media was removed from NIH-3T3 cells and replaced with the 
supernatant from Ecopack cells. The 6-well plate containing NIH-3T3 cells and Ecopack 
supernatant was centrifuged at 1025g for 90 minutes at RT. Once this was complete 
cells were incubated overnight at 37oC 5% CO2. 
 
 
2.3.7: Transfected cell selection 
 
Infected NIH-3T3 cells media was aspirated and cells removed from the 6 well plate 
via the addition of 1 ml PBS supplemented with 10mM EDTA and 4mg/ml lidocaine for 
5 minutes at 37oC 5% CO2. After lidocaine incubation the addition of 2ml 3T3 media 
neutralised lidocaine. NIH-3T3 cells were collected and centrifuged at 350g for 5 
minutes. 3T3 media and lidocaine was aspirated before 10ml 3T3 media was added 
	 66	
and cells placed in a T25 tissue culture flask at 37oC 5% CO2. G418 (Life Technologies) 
was used to select NIH-3T3 successfully infected with plasmid. 600μg/ml of G418 was 
added to each T25 tissue culture flask. Cells were maintained as described in 2.2.5. 
Once cells had been passaged a minimum of 5 times, expression of transfected plasmid 
was confirmed by flow cytometry before cells expressing target genes were used in 
experiments.  
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2.4: In vitro assays 
 
 
2.4.1: Flow cytometry 
 
Flow cytometry was performed on a minimum of 2x104 and maximum of 5x105 cells 
per individual sample. Cells to be analysed by flow cytometry were added to wells on 
a 96 well plate and centrifuged at 350g for 5 minutes at 4oC. Cells were washed twice 
with 150μl FACS buffer. All aspirations were completed carefully to avoid dislodging 
cells from each well. Cell non-specific binding was blocked with the addition of 4mg/ml 
rat 2.4G2 (Life Technologies) in FACS Buffer supplemented with 5% rabbit serum 
(Sigma) for 15 minutes at 4oC.  
 
If purified antibodies were used, these were added on top of block and each well made 
up to 50μl with FACS buffer. Cells were incubated at 4oC for 30 minutes before being 
thoroughly washed three times with 150μl FACS buffer. Anti-Biotin secondary 
antibodies were added to required wells in 50μl FACS buffer for 20 minutes at 4oC. 
Cells were again thoroughly washed three times with FACS buffer. After this, all other 
conjugated-antibodies were added to the required wells and cells incubated for 30 
minutes at 4oC. Cells were washed for a final three times with FACS buffer before 
samples were immediately analysed by flow cytometry or fixed with ¼ cytofix (BD) and 
analysed by flow cytometry within 5 days.  
 
If purified antibodies were not required, conjugated-antibodies were added on top of 
block and each well made up to 50μl with FACS buffer. After 30 minutes incubation at 
4oC cells were washed three times with FACS buffer before cells were immediately 
analysed by flow cytometry or fixed with ¼ cytofix and analysed by flow cytometry 
within 5 days.  
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Flow cytometry samples were run through a benchtop flow cytometer (Beckman 
Coulter) using SUMMIT (Cryomation) software. Flow cytometry sample data was 
analysed with FlowJo (BD, formerly FlowJo LLC) software.  
 
 
2.4.2: ELISA 
 
Two ELISA kits were used to quantify protein concentrations. ELISA DuoSet (R&D) and 
ELISA KIT (Thermo Scientific, formerly ebioscience) have slightly different 
experimental methods. Each method will be described in this section and each kit will 
be referred to as R&D ELISA or ebioscience ELISA respectively.  
 
Half-well 96-well plates were coated with 50μl capture antibody. For R&D ELISA this 
involved diluting capture antibody in PBS supplemented with 1% BSA. For ebioscience 
ELISA 250X capture antibody was diluted in PBS supplemented with 10% capture 
coating solution. Capture-coated ELISA plates were incubated overnight at 4oC. After 
incubation plates were washed three times. Each wash step was completed using a 
Bio-Plex Washstation (BIO-RAD), plates were washed with PBS supplemented with 
0.05% Tween 20 (Sigma). ELISA plates were then blocked with reagent diluent for 1 
hour at RT. R&D reagent diluent was typically PBS supplemented with 1% BSA, 
specifically for human IFNγ reagent diluent was PBS supplemented with 1% BSA and 
10% goat serum. Reagent diluent concentrate was provided with ebioscience ELISA 
kits and was diluted with dH2O.  
 
Blocked plates were washed three times and carefully dried by gentle tapping on 
absorbent paper. Standards were prepared for each ELISA plate. R&D standards were 
provided lyophilised and were re-suspended following individual kit specifications 
with R&D reagent diluent before being stored at -80oC. For each ELISA experiment the 
kit recommended top-standard was produced in reagent diluent before six serial 
dilutions were performed producing the seven required standards. Standards from 
ebioscience ELISA kits were either already made-up or lyophilised. If required, 
standards were made up in reagent diluent. For each ELISA experiment the kit 
	 69	
recommended top-standard was produced in reagent diluent before six serial dilutions 
were performed producing the seven required standards. 50μl of each standard 
sample was then added to the required wells on the blocked 96-well plate; following 
this, experimental samples were added. If necessary, samples were diluted in each 
kit’s appropriate reagent diluent; 50μl sample was required per well. A reagent diluent 
only control was added to each plate to act as blank. This allowed the removal of 
optical imperfections when reading absorbance through the plate. Plates containing 
standard and sample were incubated overnight at 4oC. 
 
After overnight incubation, standards and samples were removed from the plate and 
the plate washed three times as previously described. If samples were infectious the 
aspiration of the plate and first wash were manually completed in appropriate safety 
category conditions. A Plate washer was used to wash plates a further three times. 
Gentle tapping onto absorbent paper carefully dried plates before detection antibody 
was added. R&D ELISA detection antibody was diluted according to kit instructions in 
reagent diluent, 50μl was added to each well. Detection antibody from ebioscience 
was provided at 250X and diluted in reagent diluent before 50μl was added to each 
well. Plates with detection antibody added were incubated at RT for a minimum of 2 
hours or overnight at 4oC. 
 
Once detection antibody incubation was complete, plates were washed three times. 
Plates were gently dried and HRP-streptavidin antibody added. This was provided 250X 
for ebioscience and diluted in reagent diluent. Either 40X or 200X HRP-streptavidin 
was provided with R&D ELISA and diluted in reagent diluent. 50μl HRP-streptavidin 
was added to each well and the plate was incubated at RT away from direct light. For 
R&D ELISA 1 hour incubation was required, for ebioscience ELISA 30 minute incubation 
was required. After HRP-streptavidin incubation, plates were washed five times before 
being dried. TMB substrate was then added to each well. TMB substrate reagent kit 
(BD) was used with R&D ELISA kits; ebioscience ELISA provided their own TMB 
substrate. 50μl TMB substrate was added to each well, the reaction was stopped with 
H2SO4 when standards colour change was appropriate to generate a standard curve.  
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ELISA plates light absorbance was read at λ 450nm – 570nm using a Multiscan 
Spectrum (Thermo Scientific). Standard curve absorbance values, minus blank value 
were used to generate a standard curve. The standard curve allowed the 
determination of experimental sample protein concentrations. 
  
 
2.4.3: NE treatment  
 
NE, purified from human neutrophils (Athens research technology) was used in NE-
induced cleavage assays. For typical cleavage assays 1x106 cells/ml were re-suspended 
in NE Assay buffer. Macrophages or NIH-3T3 cells were rested by incubation at 37oC 
5% CO2 overnight prior to re-suspension in NE assay buffer. BIOgel elicited neutrophils 
or monocytes were used immediately. 50μl cells in assay buffer (5x104 cells) were 
added to a 96-well plate. 50µl NE diluted to the required concentration in NE assay 
buffer was added on top of the cells in each well.  
 
NE was inactivated using two methods; firstly, heat inactivation was completed by 
incubation at 95oC for 10 minutes. Secondly, inhibition inactivation was completed by 
incubation at 37oC with AAT (or other small molecule inhibitor) for 10 minutes before 
addition to cells. These were also added on top of cells.  
 
 
2.4.4: NE-induced receptor cleavage 
 
The impact NE had on cell’s receptor expression was often examined. After incubation 
with NE, cells were centrifuged at 350g for 5 minutes and washed with NE assay buffer. 
Cells were analysed by flow cytometry.  
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2.4.5: NE-induced functional response deficiency 
 
The impact NE has on cell’s ability to produce TNF was examined. After incubation with 
NE, cells were stimulated with zymosan (Sigma), Pam(3)CSK(4) (Invivogen) or A.f. SC 
on top of NE treatment for up to 4 hours at 37oC 5% CO2. After incubation cells were 
centrifuged at 350g for 5 minutes and supernatant aspirated and stored. ELISA was 
used to determine TNF concentration in cell supernatant. 
 
 
2.4.6: NE-induced recognition deficiency 
 
Typically, FITC-labeled zymosan was used in recognition assays. Fluorophore-labelled 
A.f. was also generated and used in recognition assays. A.f. RC were grown into SC as 
described in 2.2.6 before being stained with a fluorophore. 
 
Cell’s ability to recognise ligands after NE treatment was examined. After incubation 
with NE, cells were stimulated with flurophore-labeled ligand such as FITC-labeled 
zymosan on top of cells and NE treatment for up to 4 hours at 37oC 5% CO2. After 
incubation cells were centrifuged at 350g for 5 minutes and washed three times with 
NE assay buffer. Cells ability to recognise ligands was analysed by flow cytometry. 
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2.5: In vivo assays 
 
 
2.5.1: Animals used  
 
BALB/C male and female mice were bought from Charles River Services. C57BL/6 male 
and female mice were either bred from in-house colonies or bought from Charles River 
Services. C57BL/6 Dectin-1-/-, C57BL/6 Mincle-/-, C57BL/6 Dectin-1-/- Mincle-/- and 
C57BL/6 Dectin-2-/- Mincle-/- were bred from in-house colonies. All in vivo experiments 
were age and sex matched, unless otherwise stated.  
 
 
2.5.2: In vivo A.f. infection 
 
A.f. challenge experiments were completed in mice aged 8-12 weeks. Male and female 
mice underwent the same infection process; each experiment describes whether 
males or females were used.  
 
Prior to A.f. infection, mice were weighed and caged. Males were not co-housed, only 
littermate males were caged together. Females were co-housed placing one mouse of 
each genotype per cage. Males used in microbiome-controlled experiments were 
housed only with littermates; bedding was swapped around experiment cages every 
48 hours for a minimum of 14 days before A.f. infection experiments.  
 
In vivo A.f. challenge was completed using A.f. RC prepared in PBS at concentrations 
clearly stated in each experiment. The A.f. solution was thoroughly mixed before being 
used to inoculate each mouse as the solution settled rapidly. The following inoculation 
protocol was completed per mouse. 
 
Individually, mice were lightly anesthetised with 5% Isoflurane (Vet Tech) and oxygen 
from a tube controlled by an anaesthetic rig. A mouse was positioned to inhale 
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isoflurane for 15 seconds whilst the A.f. solution was mixed and 50μl drawn into a 
pipette. Quickly, the mouse was removed from the anaesthetic-delivering tube and 
the mouse’s front teeth exposed by gently pulling back on the jaw. The exposed front 
teeth were used to hang the mouse onto a thin wire held in place on a stand. The 
mouse was secured to the stand with tape placed over its tail. Tweezers were used to 
gently pull the tongue out of the mouth whilst a pipette containing 50μl A.f. solution 
was inserted and ejected into the trachea of the mouse. Care was taken not to go too 
far down the trachea past the carina, ensuring both lungs were inoculated with A.f. 
solution.  
 
Immediately after A.f. inoculation, whilst the mouse’s tongue was held out of the 
mouth, the nose was plugged with a finger for 15 seconds (1 second per 5μl ejected + 
5 seconds). When inoculation was successful the mouse was heard gulping the A.f. 
solution into their lungs and not swallowing the solution. Mice came round rapidly 
from the anaesthetic effects and so after A.f. inoculation was complete mice were 
placed gently in a recovery cage (layered towel without wood-chip). Once the animal 
had fully regained consciousness and recovered it was placed back in its holding cage. 
Mice were weighed once and examined and scored twice daily according to Home 
Office guidelines, the scoring sheet used can be found in 7.6. 
 
 
2.5.3: Lung extraction 
 
Mice were anaesthetised with 140mg/kg intra-peritoneal Euthatal and sacrificed by 
exsanguination. This method preserved the integrity of lung tissue and reduced 
bleeding within the cardio-respiratory cavity. Left and right lung were extracted. For 
fungal burden analysis, left-lung was stored in 1ml PBS at 4oC or 1ml RNAlater (Thermo 
Scientific) at 4oC, this is made clear for each experiment. For cytokine and chemokine 
analysis, right-lung was stored in 1ml PBS at 4oC. Both lungs were processed 
immediately.  
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2.5.4: Lung homogenisation for fungal burden analysis 
 
Fungal burden was determined from left lungs using two different protocols. The 
protocol used for each experiment is clearly stated in results.  
 
2.5.4i: Method A 
 
Left-lung stored in 1 ml PBS was manually homogenised for 30 seconds using a tissue 
homogeniser. RNA was extracted from 0.1ml of homogenised lung using the 
MasterPure yeast RNA extraction kit (Illumina).  
 
2.5.4ii: Method B 
 
Left-lung stored in 1ml RNAlater was manually cut using scissors into 1mm3 sections 
before being placed into a bead-beater eppendorf (BioSpec). This eppendorf was 
topped up with 1ml PBS and 0.5mm3 glass beads (BioSpec). The lung tissue was 
homogenised at 4200rpm (middle speed setting for this machine) for four 30-second 
periods using a Mini-beadbeater 1 (BioSpec). To avoid heat damage to samples, 
between each homogenisation round eppendorfs were stored at 4oC for 5 minutes. 
After bead beating was complete, RNA was extracted from 0.1ml homogenate using 
the MasterPure yeast RNA extraction kit. 
 
 
2.5.5: Lung fungal RNA extraction 
 
Fungal RNA was extracted from 100μl of left lung homogenate using the MasterPure 
yeast RNA extraction kit. 
 
The following was completed per lung sample. 100μl of lung homogenate was 
centrifuged at 17000g for 60 seconds and supernatant aspirated. Contaminating 
protein, DNA nucleases and RNA nucleases were digested by incubation with 50μg 
Proteinase K diluted in 300μl extraction reagent at 70oC for 15 minutes. After 
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digestion, samples were cooled to 4oC before 175μl MPC protein precipitation reagent 
was added to each sample. Samples were centrifuged at 4oC, 17000g for 10 minutes 
to remove precipitated debris and contaminants. Supernatant was transferred to a 
new eppendorf and 500μl isopropanol added to precipitate RNA out of the sample 
solution. Each sample was thoroughly inverted 40 times to allow complete RNA 
precipitation. Samples were centrifuged at 4oC, 17000g for 10 minutes to pellet 
precipitated RNA, supernatant and isopropanol were carefully aspirated without 
disrupting the RNA pellet.  
 
Contaminating DNA was removed with DNAse I treatment at 37oC for 30 minutes. 
After DNAse I treatment, 200μl tissue and cell lysis solution was added and the solution 
incubated at 4oC for 10 minutes to remove any final cell or protein traces. Finally, 200μl 
MPC protein precipitation reagent was added at 4oC for a further 10 minutes. Any 
remaining precipitated contaminants or debris were removed from solution by 
centrifugation at 4oC, 17000g for 10 minutes. Supernatant was transferred to a new 
eppendorf and 500μl Isopropanol added. The sample was thoroughly inverted 40 
times before precipitated RNA was pelleted by centrifugation at 4oC, 17000g for 10 
minutes. Isopropanol was carefully aspirated from the RNA pellet before two washes 
with 70% EtOH were completed. All EtOH was apirated from the RNA pellet and the 
eppendorf left open to dry. The RNA pellet was re-suspended in 35μl TE buffer and 
stored at -80oC. 
 
 
2.5.6: Fungal RNA standard curve 
 
A standard curve of fungal RNA was generated; fungal RNA was extracted from 
concentrations of A.f. conidia. This was required to determine experimental sample 
fungal burden. A.f. RC concentrations of 109, 108, 107, 106, 105, 104, 103 and 102 were 
produced in 1ml PBS. Fungal RNA was extracted from each 1ml A.f. RC sample using 
the same lung homogenisation method (manual homogenisation or bead-beating) 
that was used for each in vivo experiment.  
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For experiments where lung samples were tissue homogenised, the A.f. standard 
curve was produced by tissue homogenising each 1ml A.f. concentration in PBS and 
extracting RNA from 100μl homogenate using the MasterPure yeast RNA extraction 
kit. For experiments where lung samples were subject to bead beating, the A.f. 
standard curve was produced following the same bead beating protocols as described 
above. After bead beating fungal RNA was extracted from 100μl homogenate using 
the MasterPure yeast RNA extraction kit.  
 
Appropriately produced standard curves were run alongside every experiment. Each 
standard curve was stored at -80oC and used for a maximum of 8-weeks before efficacy 
was lost.  
 
 
2.5.7: Generation of fungal cDNA 
 
A.f. fungal burden was determined by the qPCR quantification of the 18S rRNA subunit 
of A.f. Therefore, cDNA was generated from lung extracted fungal RNA samples and 
standard curve fungal RNA samples. From each lung extracted fungal RNA sample or 
standard curve fungal RNA sample, 2μl RNA in TE solution was used to produce cDNA 
using the Quantitect Reverse Transcription Kit (Qiagen). The quantity of kit reagents is 
described in table 2.1. 
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Reagents Quantity required 
RT 20X Mastermix 1μl 
RT 5X Buffer 4μl 
RT Primer mix 1μl 
dH2O 12μl 
Fungal RNA 2μl 
Reaction total volume 20μl 
 
 
Table 2.1: Quantitect Reverse Transcription (Qiagen) reaction mixture. Table 
describing the quantities of Quantitect Reverse Transcription (Qiagen) reagents used 
when generating cDNA from extracted fungal RNA. 
 
 
The cDNA reaction was incubated at 42oC for 30 minutes, followed by 95oC for 3 
minutes. Generated cDNA was purified using the PCR purification Kit (Qiagen) and 
used immediately to determine lung fungal burden by qPCR or stored at -80oC. 
 
 
2.5.8: Determination of fungal burden by qPCR 
 
The quantification of A.f. in lung extracted fungal RNA samples and standard curve 
fungal RNA samples was determined by the qPCR quantification of the single copy 18S 
rRNA gene of A.f.. 5μl of experimental sample or standard curve sample cDNA was 
used in each qPCR reaction to determine the copy number of the 18S rRNA gene of 
A.f.. Each standard curve or experimental sample was assayed in technical duplicate. 
Taqman reagents were used for the qPCR assay as described in table 2.2. A 42-cycle 
comparative Ct Taqman protocol was selected on a Quant Studio 12K Flex Real-Time 
PCR system (Thermo Scientific). 
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Reagents Quantity required 
Taqman 60X qPCR Probe  0.33μl 
Taqman 2X Mastermix 10μl 
dH2O 4.7μl 
Fungal cDNA 5μl 
Reaction total volume 20μl 
 
 
Table 2.2: Taqman qPCR reaction mixture. Table describing the quantities of Taqman 
qPCR used when quantifying the 18S rRNA gene of A.f. in cDNA generated from 
extracted fungal RNA. 
 
 
After the qPCR was completed, a graph was created plotting Ct value against the 
standard curve sample A.f. concentrations. This allowed experimental sample’s Ct to 
be compared to this standard curve graph; therefore, the quantity of A.f. each 
experimental sample Ct value corresponds to was determined. 
 
 
2.5.9: Extracted lung cytokine and chemokine analysis 
 
Whole right lung was extracted and stored in PBS at 4oC. Right lung was manually 
homogenised for 30 seconds using a tissue homogeniser. After homogenisation, right 
lung sample in PBS was centrifuged at 17000g for 3 minutes and the supernatant 
removed and stored at -80oC. ELISA was used to quantify cytokine and chemokines 
present in the homogenised lung sample supernatant. 
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2.6: Patient study 
 
 
2.6.1: Sample collection 
 
From each patient, 17.5ml whole blood was collected into EDTA tubes and 2ml whole 
blood was collected into PAXgene blood RNA tubes (Preanalytix). Upon receipt of the 
patient sample, 17.5ml whole blood was removed from the EDTA tubes and mixed 
with an equal volume of sterile PBS before being immediately processed or stored for 
a maximum of 24 hours at 4oC. Whole blood in PAXgene blood RNA tubes were 
sequentially cooled for long term storage and processing in batches. PAXgene blood 
RNA tubes were incubated at RT for 48 hours (away from direct light), +4oC for 48 
hours, -20oC for 48 hours and finally -80oC for a maximum of 6 months. PAXgene blood 
RNA samples were processed in batches of 6-8. 
 
 
2.6.2: Isolation of RNA from whole blood 
 
2ml whole blood was collected into a PAXgene RNA tube and stored at -80oC. Samples 
were equilibrated at RT for a minimum of 2 hours before completing RNA extraction. 
PAXgene tubes containing 2ml whole blood and the PAXgene RNA stabilising solution 
were centrifuged at 3000g for 10 minutes, supernatant was aspirated and the pellet 
re-suspended in 4ml dH2O. Samples were again centrifuged at 3000g for 10 minutes, 
supernatant aspirated and pellet re-suspended in 350μl re-suspension buffer. Protein 
was digested from each sample with the addition of 40μl Proteinase K in 300μl binding 
buffer. Incubation at 55oC for 10 minutes with 800rpm shaking ensured complete 
protein digestion. Increasing the temperature to 65oC for 10 minutes then inactivated 
proteinase K. 
 
Protein digested sample was added to a PAXgene shredder spin column and 
centrifuged at 17000g for 3 minutes. Cellular protein and debris did not pass through 
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the column. 350μl of 100% ethanol was added to the column flow-through sample to 
optimise RNA binding conditions. This sample solution was then added to a PAXgene 
RNA spin column and centrifuged at 17000g for 3 minutes. RNA was bound to the 
column whilst DNA, impurities and cellular debris were removed through a series of 
washes. 
 
Contaminated DNA was removed from the column with DNAse I solution treatment. 
10μl DNAse I in 70μl DNA digestion buffer was added to each column and incubated 
at RT for 15 minutes. The column membrane was thoroughly washed with wash buffer 
and centrifuged at 17000g to remove any remaining debris and contaminants.  
 
RNA was eluted from the column with the addition of 40μl elution buffer. This was 
carefully added to the column membrane and incubated for 5 minutes at RT before 
the column was centrifuged at 17000g for 5 minutes. Eluted RNA was heat-denatured 
by incubation at 65oC for 10 minutes. A nanodrop was used to quantify extracted RNA. 
Typically, ≥3μg RNA per 40μl sample was obtained. RNA was extracted with high 
purity, A260/A280 values were consistently measured between 1.8 and 2.2. RNA was 
stored at -80oC. 
 
The integrity of extracted RNA was determined for the first 8 patient samples. This 
confirmed the kit and protocols used were successfully extracting and isolating high 
quality RNA. 100ng of extracted RNA from each of the first 8 patient samples was run 
on a 1% agarose gel at 100V for 30 minutes alongside a 100bp ladder (Promega). 
Clearly visible and correctly sized 28S and 18S rRNA bands indicated successful RNA 
extraction and high RNA integrity. 
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2.6.3: Generation of patient cDNA 
 
Patient extracted RNA was used to generate cDNA. In batches of 8, 600ng of patient 
extracted RNA was used to produce 600ng of cDNA using a RT-PCR kit (Life 
Technologies). Assay reagents used are described in table 2.3 below.  
 
 
Reagents Quantity required 
RT 10X Taqman Buffer 2.5μl 
RT 25mM MgCl2 5.5μl 
RT dNTPs 5μl 
RT Hexamers 0.625μl 
RT Oligos 0.625μl 
RT RNAse inhibitor 0.5μl 
RT Multi-Scribe reverse 
transcriptase 
0.625μl 
Patient RNA 600ng RNA, make up  
to 9.6μl with dH2O dH2O 
Reaction total volume 25μl 
 
 
Table 2.3: Reverse Transcription Kit (Life Technologies) reaction mixture. Table 
describing the quantities of Reverse Transcription Kit (Life Technologies) reagents used 
when generating cDNA from extracted patient RNA. 
 
 
This reaction was incubated at 25oC for 10 minutes, 48oC for 30 minutes and 95oC for 
5 minutes. Generated cDNA was purified using a PCR purification Kit. For the first 8 
patient samples, the successful generation of cDNA from extracted RNA was 
examined. 100ng of cDNA from each of the first patient 8 samples was run on a 1% 
agarose gel at 100V for 30 minutes alongside a 100bp ladder. The absence of clear 28S 
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and 18S rRNA bands and presence of a smear of cDNA confirmed successful cDNA 
generation. 
 
 
2.6.4: Patient CLR sequencing 
 
Patient cDNA was used to identify the presence of any mutations within patient’s CLR 
gene sequences. 50ng cDNA was used in each PCR reaction to amplify Dectin-1, Dectin-
2, Mcl and Mincle DNA. The reaction mixture for each PCR reaction is described below 
in table 2.4, Platinum High Fidelity PCR Supermix (Invitrogen) was used. 
 
 
Reagents Quantity required 
Gene specific Forward 
Primer 10mM 
1μl 
Gene specific Reverse  
Primer 10mM 
1μl 
Platinum High Fidelity PCR 
Supermix 
21μl 
Patient cDNA 2μl 
Reaction total volume 25μl 
 
 
Table 2.4: PCR reaction mixture using Platinum High Fidelity PCR Supermix 
(Invitrogen). Table describing the quantities of PCR reagents used when generating 
CLR DNA from patient cDNA. 
 
 
Each PCR reaction was incubated at 95oC for 2 minutes before 30 cycles of 95oC for 30 
seconds, 56oC for 30 seconds and 68oC for 1 minute were completed. After the PCR 
reaction, samples were purified using a PCR purification Kit and stored at 4oC for up to 
48 hours or -20oC for 6 months. For the first 8 patients, the successful amplification of 
CLR gene DNA was examined. 5μl of purified CLR gene PCR product was run on a 1% 
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agarose gel at 100V for 30 minutes alongside a 100bp ladder. A Band for each PCR 
amplified CLR gene around 600bp confirmed successful PCR amplification. Two bands 
were attained for patient Dectin-1 amplification samples around 100bp difference in 
size. These two bands were separately excised from the gel and the DNA purified using 
a Gel Purification Kit (Qiagen). Both patient Dectin-1 samples were sent for sequencing 
alongside the other amplified patient CLR DNA. Each CLR sequence was examined 
using four primers, one forward and reverse at each end of the gene and one forward 
and reverse in the middle of the gene, this provided thorough sequencing coverage.  
 
 
2.6.5: Patient CLR expression 
 
The expression of patient’s CLRs at RNA transcript level was determined. A qPCR 
reaction was completed using patient’s cDNA with qPCR probes specific for each CLR 
gene. 25ng patient cDNA was used for each CLR reaction and HPRT was used as a 
patient control.  
 
The qPCR reaction was completed using Taqman PCR Mastermix (Thermo Scientific) 
and CLR gene-specific qPCR probes (Thermo Scientific), details in 7.4. The reaction 
mixture for each qPCR reaction is displayed below in table 2.5. The qPCR experiment 
was run for 40 cycles under standard qPCR Taqman incubation durations and 
temperatures. A Quant Studio 12K Flex Real-Time PCR system (Thermo Scientific) 
completed the qPCR reaction.  
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Reagents Quantity required 
2X Taqman PCR Mastermix 10μl 
20X CLR probe 1μl 
cDNA 25ng cDNA, make up  
to 9μl with dH2O dH2O 
Reaction total volume 20μl 
 
 
Table 2.5: Taqman qPCR reaction mixture. Table describing the quantities of Taqman 
qPCR used when quantifying the patient CLR genes from cDNA generated from 
extracted blood RNA. 
 
 
Every patient’s experimental CLR samples were normalised against their HPRT control. 
The expression of each patient’s CLRs was determined against a control patient’s CLR 
expression using ΔΔCt analysis. This allowed the comparison of all patient’s CLR 
expression at RNA transcript level. 
 
 
2.6.6: Extraction of patient PBMCs from whole blood 
 
17.5ml whole blood was collected into EDTA collection tubes. Upon receipt of the 
sample, whole blood was removed from the EDTA tubes and mixed with 17.5ml PBS 
in a 50ml falcon tube. FicollPLUS (Sigma) was warmed to RT and thoroughly mixed 
before 17.5ml was added to two 50ml Falcon tubes. 17.5ml Whole blood PBS solution 
was layered on top of FicollPLUS in each Falcon tube. Whole blood PBS solution was 
added very slowly being careful not to disturb the liquid separation between the 
FicollPLUS and whole blood PBS solution. Once layering was complete, falcon tubes 
were centrifuged at 400g for 30 minutes with the centrifuge brake turned off. 
 
After centrifugation, PBMCs (a thin white layer of cells below the plasma fraction) 
were collected using a Pasteur pipette and pooled. Collected PBMCs were washed 
once with PBSMg+Ca+ (Life Technologies) and washed three times with RPMI 1640. 
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Between each wash PBMC solution was centrifuged at 350g for 5 minutes and 
supernatant aspirated and discarded. During the final RPMI 1640 wash, cells were 
counted using a haemocytometer and re-suspended at 2x107 PBMCs/ml in PBMC 
media.  
 
For flow cytometry analysis experiments, 100μl per well of 2x107 PBMCs/ml were 
plated out on a 96-well plate. For stimulation and ELISA analysis experiments, 100μl 
per well of 5x106 PBMCs/ml were plated out on a 96-well plate.  
 
 
2.6.7: Patient PBMC stimulation 
 
Patient PBMCs were plated out on a 96-well plate at the required concentration and 
rested for 4 hours by incubation at 37oC 5% CO2. A.f. SC were grown following the 
protocol described in 2.2.6, a culture of live A.f. SC and a quantity of heat-killed A.f. SC 
were produced. Once PBMCs had been rested and A.f. SC and HKSC were prepared, 
the PBMCs were stimulated according to figure 2.1. All stimulation reactions were 
incubated at 37oC 5% CO2 for the duration of the experiment. 
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A Initial experiments 
24 Hours 
 
 7 Days 
 
Media   Media   
LPS   LPS   
Curdlan   Curdlan   
Live A.f. SC   Live A.f. SC   
HK A.f. SC   HK A.f. SC   
 
B Later experiments 
24 Hours 
 
Media      
LPS      
Curdlan      
Live A.f. SC      
HK A.f. SC      
 
 
Figure 2.1: Protocol for patient PBMC stimulation. 100μl per well of 5x106 PBMCs/ml 
were plated out on a 96-well plate, rested and stimulated. PBMCs were stimulated 
with 100μl 1μg/ml LPS, 100μl 2μg/ml Curdlan, 100μl of 5x106 A.f. SC/ml and 100μl of 
5x106 HK A.f. SC/ml. 100μl PBMC media was added as an un-stimulated control. 
Stimulation experiments were completed for 24 hours and 7 days or 24 hours only 
before 96-well plates were centrifuged at 350g for 5 minutes and the supernatant 
collected. A Initially stimulation experiments were completed for 24 hours and 7 days 
with three replicates for each condition. After ELISA examination of these samples, the 
longer 7-day stimulation was stopped. B The 24-hour stimulation was continued and 
the sample replicates increased to six. This was the protocol layout used for the 
majority of samples. 
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Once stimulations were complete, 96-well plates were centrifuged at 350g for 5 
minutes and the supernatant removed and immediately used or stored at -80oC. ELISA 
was used to determine quantity of cytokines and chemokines in PBMC stimulation 
supernatant. 	
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Chapter 3 		
Neutrophil Elastase cleavage of Dectin-1 Isoform A enhances 
susceptibility to A.f. infection 
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3.1: Aims 
 
 
I. Determine whether Neutrophil Elastase can cleave Dectin-1 on immune cells 
 
II. Identify the NE cleavage location within Dectin-1 
 
III. Determine any functional consequence resulting from Dectin-1 NE-induced 
cleavage 
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3.2: Introduction 
 
 
A.f. is a well-described invasive pathogen causing serious disease in immune-
compromised individuals. Before the use of modern immune-suppressing 
therapeutics A.f. infections were rare and usually resulted from the repeated 
inhalation of high quantities of A.f. conidia. Even then, conidia were rapidly cleared 
and only mild allergic-type disease would present [4]. Complications arose if pre-
existing immune-privileged lung cavities were present allowing A.f. growth; however, 
this growth would be limited within the immune-privileged cavity [1]. More recently, 
A.f. has been recognised as an important pathogen in immune-competent patients 
with pre-existing airway disease such as cystic fibrosis (CF). A.f. infections in these 
patients can cause allergic-hypersensitivity and invasive disease resulting in further 
deterioration of the underlying airway disease [222]. Patients are often caught in a 
cycle of recurrent A.f. infection exacerbating their underlying airway disease, reducing 
the local-airway immune response, and further inhibiting A.f. clearance. 
 
It is estimated worldwide that ~10 million patients with pre-existing airway disease are 
impacted by A.f. infections. A.f. has been identified in 10-57% of airway secretions 
from CF patients and anti-A.f. IgG has been detected in 41% of CF patients at age 4, 
rising to 98% of patients by age 10 [19]. This incidence is much higher than that 
detected in asthmatic and healthy patient cohorts [46]. Furthermore, allergic 
bronchopulmonary Aspergillosis (ABPA), a serious A.f. allergic-type disease 
culminating in airway narrowing and obstruction affects 17.7% of the adult CF 
population. A.f.-induced bronchitis affects 30% of CF patients [48]. Research is 
required to understand why patients with pre-existing lung disease such as CF but 
otherwise healthy immune systems are highly susceptible to A.f. infection. 
 
The anti-A.f. immune response is complicated and poorly understood. As previously 
mentioned, TLRs and CLRs form a crucial component of the anti-A.f. response [1, 137]. 
The role these receptors exhibit has typically been studied in invasive disease and 
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immune-suppressed in vivo models. Although many of the deductions from these 
studies are relevant to the overall anti-A.f. immune response, the anti-A.f. response in 
the setting of underlying airway disease has not been extensively investigated. In this 
setting the response may differ greatly from invasive, immune-suppression induced 
disease. The CLR Dectin-1 has previously been thoroughly discussed. The vital role this 
receptor plays in the anti-A.f. immune response is well described and the increased 
susceptibility of Dectin-1 KO mice to A.f. infection highlights this crucial role [100]. 
Whilst defects in CLRs such as Dectin-1 increase susceptibility to A.f. infection, little is 
known about their functional status in patients with pre-existing airway disease such 
as CF. These patients possess a very complex airway inflammatory and structural 
setting. The presence, expression and function of CLRs in this setting may be markedly 
different when compared to healthy individuals [223]. Understanding the behavior of 
CLRs in the CF airway is of critical importance when aiming to identify why CF patients 
possess increased susceptibility to A.f. infection. 
 
CF is a genetic disorder affecting the cystic fibrosis transmembrane conductance 
regulator (CFTR). A mutated CFTR gene reduces Cl- transport subsequently reducing 
hydration of the epithelial surface. This culminates in reduced action of the 
mucociliary escalator and deposition of thick mucus in the airway [20, 23]. The long-
term presence of thick mucus dramatically alters airway homeostasis and results in 
regular airway infection [26]. Bacteria and fungi are not rapidly cleared from the 
airway and a chronic inflammatory state is produced. Recruited immune cells are 
retained in thick mucus further contributing to the inflammatory setting [25, 26]. 
Eventually the chronic inflammatory environment generated in the airway of CF 
patients leads to fibrosis of the airway epithelia and lung. Fibrosis results in narrowing 
of the airway and reduced lung function. Declining lung function in CF patients is 
associated with profound neutrophilic inflammation and the presence of high 
quantities of poorly regulated, neutrophil-derived serine proteases such as neutrophil 
elastase (NE) [27, 224]. These proteases form an important part of the anti-microbial 
immune response but when poorly regulated can cause local tissue damage and 
reduce the capabilities of the local immune response [225, 226]. A poorly regulated 
neutrophil-driven chronic protease response is widely recognised as a contributor to 
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CF airway pathology [27]. Many facets of the immune response such as complement 
receptors and signalling, soluble IL-6R and TLRs are susceptible to functional 
inactivation by serine proteases in the CF airway [32, 34, 35]. Here we investigate the 
possibility that high quantities of NE present in the CF airway contribute to a reduced 
anti-A.f. response by disrupting Dectin-1’s ability to recognise and clear A.f.. Reduced 
A.f. clearance may enhance the local inflammatory setting and exacerbate the 
underlying CF airway disease. 
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3.3: Results  
 
 
3.3.1: Does Neutrophil Elastase cleave Dectin-1? 
 
As neutrophil-derived serine proteases have been shown to cleave various immune 
receptors and Dectin-1 is susceptible to trypsin cleavage, I wanted to determine 
whether NE cleaves Dectin-1 [227]. NIH-3T3 cells expressing human Dectin-1 were 
incubated with NE or bronchiolar alveolar lavage fluid (BALF) from CF patients. The 
ability of NE or CF BALF to reduce Dectin-1 expression was examined along with 
correlation analysis of CF BALF neutrophil infiltration, CF BALF NE activity and loss of 
Dectin-1 expression on NIH-3T3 cells. 
 
The experiments and results displayed in this chapter were undertaken for my thesis 
after an initial series of experiments, shown in figure 3.1, were completed and 
analysed by Dr Eamon McGreal.  
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Figure 3.1: Cystic Fibrosis patient’s bronchiolar alveolar lavage fluid induces cleavage 
of Dectin-1. (A) NIH-3T3 cells expressing human HA-tagged Dectin-1 Isoform A were 
exposed to 0.5μM NE or 50μl CF BALF in the presence or absence of AAT (a small 
molecule NE inhibitor) for 30 minutes at 37oC 5% CO2. Cells were stained with anti-HA 
and analysed by flow cytometry. Graph displays mean +/- s.d.. Student’s t-test was 
used to determine statistical significance. (B-C) NIH-3T3 cells expressing human HA-
tagged Dectin-1 Isoform A were exposed to CF BALF for 30 minutes at 37oC 5% CO2. 
Cells were stained with anti-HA and analysed by flow. (B) NE activity in CF BALF 
samples was measured. Correlation analysis between NE activity and % Dectin-1 loss 
was performed. (C) Neutrophil numbers in CF BALF were counted and correlation 
analysis between neutrophil numbers in CF BALF and % Dectin-1 loss performed. (A, B 
& C) Data are cumulative results of 7 independent experiments. (B & C) Each symbol 
represents data from a single patient.  
A	
B	
C	
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Eamon incubated NIH-3T3 cells expressing Dectin-1 with NE and he demonstrated that 
NE cleaves Dectin-1 (figure 3.1). The loss of Dectin-1 expression in this experiment can 
be attributed to NE activity as alpha-antitrypsin (AAT) an NE inhibitor, prevents Dectin-
1 loss. This identified cleaving capability of NE is also present when NIH-3T3 cells 
expressing Dectin-1 are incubated with CF BALF. This suggests that CF patient BALF has 
the capability to cleave Dectin-1, likely due to its high neutrophil infiltration and high 
NE activity. Although these overexpression experiments were completed in vitro, an 
interesting role for NE cleaving Dectin-1 in the airway of CF patients potentially 
impairing the anti-fungal immune response required further investigation. 
 
The experiments displayed in figure 3.1 were completed using NIH-3T3 cells expressing 
hDectin-1 Isoform A. hDectin-1 Isoform B is also highly prevalent on many immune 
cells relevant to the anti-fungal immune response [228]. hDectin-1 Isoform B is 
functionally similar to hDectin-1 Isoform A but lacks the stalk region of the receptor, 
meaning isoform B sits closer to the membrane and does not contain a glycosylation 
region [229, 230]. The ability of NE to cleave hDectin-1 Isoform B must also be 
examined. Therefore, NIH-3T3 cells expressing hDectin-1 isoform B were incubated 
with NE alongside NIH-3T3 cells expressing hDectin-1 Isoform A. 
  
	 96	
 
 
 
Figure 3.2: NE cleaves hDectin-1 Isoform A but not hDectin-1 Isoform B. NIH-3T3 cells 
expressing human Dectin-1 isoform A (A) or B (B) were exposed to 1μM NE for 15 
minutes at 37oC 5% CO2. Cells were stained with anti-hDectin-1 (an antibody that 
recognises both isoforms of the receptor) and the expression of hDectin-1 Isoform A 
or B was analysed by flow cytometry. Data displayed are representative of 4 
independent experiments.  
 
 
Interestingly, figure 3.2 shows that NE specifically cleaves hDectin-1 Isoform A but not 
hDectin-1 Isoform B. This suggests that NE requires the isoform A-exclusive 
extracellular stalk region of hDectin-1 in order to cleave the receptor.  
 
The experiments displayed in figure 3.1 and 3.2 identify a role for NE cleaving hDectin-
1 isoform A on NIH-3T3 cells. It was next important to determine whether the Dectin-
1 cleaving action of NE is present on immune cell types resident or recruited to the CF 
airway that naturally express Dectin-1. Both hDectin-1 Isoform A and B are structurally 
and functionally similar to their mouse homologues [161, 231]. Therefore, mouse cells 
would be appropriate to examine NE’s ability to cleave Dectin-1 on primary cells. 
However, before primary mouse cells could be used, the ability of NE to cleave 
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mDectin-1 Isoform A was confirmed by incubating NIH-3T3 cells expressing mDectin-
1 isoform A with NE. 
 
 
 
 
 
Figure 3.3: NE cleaves mDectin-1 Isoform A. NIH-3T3 cells expressing murine Dectin-
1 isoform A (A) were exposed to 1μM NE for 15 minutes at 37oC 5% CO2. Cells were 
stained with anti-mDectin-1 and the expression of mDectin-1 Isoform A analysed by 
flow cytometry. Data displayed are representative of 3 independent experiments.  
 
 
The NE-induced cleavage of hDectin-1 isoform A is conserved for mDectin-1 Isoform 
A. Figure 3.3 permits the use of mDectin-1 isoform A as a model for the human 
receptor. Having demonstrated that NE cleaves mDectin-1 isoform A, I next examined 
the ability of NE to cleave mDectin-1 Isoform A on primary myeloid immune cells. 
Dectin-1 is expressed on many immune cells types; those relevant to the CF airway 
include macrophages, neutrophils and monocytes [227, 231-233]. 
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In order to retain as much similarity to the human CF airway as possible, all future 
experiments (unless otherwise mentioned) were performed in primary cells isolated 
from BALB/c mice. BALB/c mice express mDectin-1 isoform A and B in a ~1:1 ratio. 
Humans highly express both Dectin-1 isoform A and B. Therefore, BALB/c mice 
represent a more relevant model than, for example, C57 BL6 mice that express ~97% 
isoform B and ~3% isoform A [161]. 
 
I first examined the ability of NE to cleave Dectin-1 expressed on cultured BMDMs; 
therefore, BMDMs were incubated with NE in the presence or absence of the NE 
inhibitor, AAT.   
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Figure 3.4: NE cleaves mDectin-1 Isoform A on BALB/c derived BMDMs. (A, B & C) 
Bone marrow derived from BALB/c mice was used to culture BMDMs. Cultured 
BMDMs were exposed to 1μM NE or 3μM NE with and without the NE inhibitor AAT 
present for 15 minutes at 37oC 5% CO2. Cells were stained with anti-mDectin-1 and the 
expression of mDectin-1 analysed by flow cytometry. Representative flow plot displays 
(A) the total overlay of BMDM cells exposed to 1μM NE, 3μM NE, 3μM NE AAT and 
AAT alone, (B) 1μM NE treatment, (C) 3μM NE treatment. Data displayed are 
representative of 3 independent experiments. 
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Figure 3.4 demonstrates the susceptibility of BMDM-expressed Dectin-1 to NE 
cleavage. Having identified that mDectin-1 on macrophages was cleaved by NE, it was 
next important to determine whether NE cleaves Dectin-1 on neutrophils. Neutrophils 
represent the majority immune cell present in the CF airway and a cell type responsible 
for much CF pathology [25]. Low activation state neutrophils were obtained via intra-
peritoneal BIOgel injection. In order to determine whether NE cleaves Dectin-1 on 
neutrophils, total BIOgel recovered cells were incubated with NE or NE and inhibitor. 
Following NE treatment, total BIOgel-recovered cells were stained with antibodies 
allowing the identification of specific cell populations within the total BIOgel-
recovered population by flow cytometry.  
 
 
 
 
 
Figure 3.5: NE cleaves Ly6G on BIOgel recovered cells. BIOgel recovered cells were 
stained with anti-Ly6G and anti-CD11b before being analysed by flow cytometry to 
identify neutrophils and monocytes within the recovered total cell population. (A) 
Without NE treatment, clear separation of neutrophils and monocytes by anti-Ly6G 
staining is achieved. (B) After 15 minute exposure to 1μM NE at 37oC 5% CO2 the clear 
Ly6G+ population had reduced Ly6G expression. As displayed in gating percentages the 
neutrophil and monocyte populations were still distinguishable and were gated on as 
such for future experiments. Data displayed are representative of 4 independent 
experiments.   
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Figure 3.5 identifies an intriguing and novel role for NE cleaving Ly6G on BIOgel-
recovered cells. Although this made the identification of BIOgel-recovered cells more 
challenging post-NE treatment, neutrophils and monocytes could still be identified and 
gated on. Figure 3.5 demonstrates the flow cytometry gating required to identify 
neutrophils and monocytes in total BIOgel-recovered cells. This gating allowed the NE 
cleaving capability for Dectin-1 to be determined on both these monocyte and 
neutrophil populations.  
 
In order to examine the ability of NE to cleave Dectin-1 expressed on neutrophils and 
monocytes, total BIOgel-recovered cells were incubated with NE or NE and inhibitor 
before cells were stained with antibodies allowing their cell type identification and 
Dectin-1 expression.  
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Figure 3.6: NE cleaves mDectin-1 Isoform A on BALB/c BIOgel derived neutrophils. 
(A, B & C) BIOgel derived neutrophils from BALB/c mice were isolated as previously 
identified in figure 5.5. Neutrophils were exposed to 1μM NE or 3μM NE with and 
without the NE inhibitor AAT present for 15 minutes at 37oC 5% CO2. Cells were stained 
with anti-mDectin-1 and the expression of mDectin-1 analysed by flow cytometry. 
Representative flow plot displays (A) the total overlay of neutrophils exposed to 1μM 
NE, 3μM NE, 3μM NE AAT and AAT alone, (B) 1μM NE treatment, (C) 3μM NE 
treatment. Data displayed are representative of 3 independent experiments.   
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Figure 3.7: NE cleaves mDectin-1 Isoform A on BALB/c BIOgel derived monocytes. (A, 
B & C) BIOgel derived monocytes from BALB/c mice were isolated as previously 
identified in figure 5.5. Monocytes were exposed to 1μM NE or 3μM NE with and 
without the NE inhibitor AAT present for 15 minutes at 37oC 5% CO2. Cells were stained 
with anti-mDectin-1 and the expression of mDectin-1 analysed by flow cytometry. 
Representative flow plot displays (A) the total overlay of monocytes exposed to 1μM 
NE, 3μM NE, 3μM NE AAT and AAT alone, (B) 1μM NE treatment, (C) 3μM NE 
treatment. Data displayed are representative of 3 independent experiments. 
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I have demonstrated the NE-specific cleavage of mDectin-1 occurred on BALB/c 
derived macrophages (figure 3.4), neutrophils (figure 3.6) and monocytes (figure 3.7). 
These myeloid cell types are readily recruited to the CF airway and contribute to the 
local inflammatory setting as well as playing a key role in the host immune response 
against pathogens in the CF airway [25, 232, 233]. Loss of Dectin-1 Isoform A 
expression from these cells likely reduces their ability to recognise and respond to 
pathogens such as A.f.. 
 
Here we have identified that NE cleaves hDectin-1 Isoform A not Isoform B. I have also 
demonstrated that NE cleaves the structurally and functionally similar mDectin-1 
Isoform A on myeloid immune cells relevant to the CF airway and A.f. disease. These 
immune cells are required for the generation of an appropriate immune response 
against pathogens.  
 
 
3.3.2: Which Dectin-1 amino acid is required for NE-induced cleavage to occur? 
 
As previously described in figure 3.2, NE cleaves Dectin-1 Isoform A and not Isoform 
B. This suggests NE cleaves Dectin-1 at a location within the stalk region of Dectin-1. 
This region is exclusively found in Isoform A, the longest Dectin-1 isoform. Dectin-1 
Isoform B is identical to Isoform A aside from the lack of stalk region. [229]. The 
nucleotide sequence of hDectin-1 stalk region was identified and the corresponding 
protein sequence was examined using two protease databases that predict the 
cleavage site residues of known enzymes [163]. The stalk region protein sequence was 
analysed for NE cleavage sites by brenda-enzymes.org and merops.sanger.ac.uk 
databases. Both databases returned the same predicted NE cleavage sites within the 
protein stalk region of hDectin-1. 
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Figure 3.8: NE was predicted to cleave hDectin-1 at four amino acid residue sites located within the CLR’s stalk-region. These residues 
were mutated to glycine. (A) Potential NE cleave sites were identified using the protease databases brenda-enzymes.org and 
merops.sanger.ac.uk. hDectin-1 stalk-region protein sequence was submitted and NE selected as the enzyme. Residues highlighted in 
green represent amino acids and their corresponding nucleotide sequence that were predicted cleave sites of NE. Nucleotides highlighted 
in red represent nucleotides that were mutated to guanine resulting in a corresponding amino acid substitution to glycine. 
MEYHPDLENLDEDGYTQLHFDSQSNTRIAVVSEKGSCAASPPWRLIAVILGILCLVILVIA 
VVLGTM AIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT GVLSSPC 
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As displayed in figure 3.8 the four residues identified as potential NE cleavage sites 
located in hDectin-1 Isoform A stalk region were mutated so the corresponding amino 
acid was altered to glycine. Glycine was chosen, as it is the simplest amino acid with 
no side chain. Altering each NE-cleave predicted residue to a glycine does not 
introduce any new charges across the molecule and although Dectin-1 function may 
be impacted, tertiary structure and assembly should not change [234]. Unfortunately, 
the 329 mutant could not be generated.  
 
Each hDectin-1 Isoform A mutant retroviral construct was used to infect NIH-3T3 cells. 
Wild-type hDectin-1 Isoform A and empty vector controls were also used to infect 3T3 
cells. These cell lines were used to determine at which amino acid residue NE cleaves 
hDectin-1 Isoform A. Each cell line was incubated with NE and the expression of 
Dectin-1 determined.  
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Figure 3.9: Mutating predicted hDectin-1 NE cleave sites to glycine residues increased the NE-induced loss of hDectin-1 when compared 
to WT. (A) Previously identified NE cleave sites located in hDectin-1 were mutated from their WT amino acid residue to glycine and 
inserted (in parallel with empty vector and WT hDectin-1) into NIH-3T3 cell lines. These cells were exposed to 1μm NE for 15 minutes at 
37oC 5% CO2 before being stained with anti-hDectin-1 and analysed by flow cytometry. (B) Geometic mean of untreated and NE-treated 
cells anti-hDectin-1 PE was calculated for each EV, WT and mutant hDectin-1 and used to determine NE-induced geometric mean shift. 
Graph displays mean +/- s.e.m.. (A) Displays one experiment, data representative of 4 independent experiments. (B) Geometric mean 
from 3 independent experiments averaged and used to determine NE-induced geometric mean shift. 
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The results displayed in figure 3.9 were not expected, (B) indicates that Dectin-1 
expression of each mutant after NE treatment was lower than the WT Dectin-1 
expression after NE treatment. This suggests mutating the predicted NE cleave site 
residues increased Dectin-1 susceptibility to NE treatment. Mutating a WT Dectin-1 
amino acid to glycine may have straightened the tertiary structure of Dectin-1 and 
increased the ability of NE to access and cleave Dectin-1 Isoform A [235]. Further 
experiments mutating cleave sites to a different amino acid or mutating multiple 
cleave sites in tandem may lead to the identification of NE’s multiple cleave site 
residues present in the stalk region of Dectin-1 Isoform A.  
 
 
3.3.3: Is there a functional consequence resulting from the NE-induced cleavage of 
Dectin-1?  
 
In order to ascertain whether the NE-induced loss of Dectin-1 impacts the functional 
immune response against A.f., BMDMs from BALB/c mice were cultured, incubated 
with NE or NE + AAT under various media and treatment conditions before stimulation 
with Curdlan or A.f. SC.  TNF production was determined. The Dectin-1 blocking 
antibody 2A11 was included in experiments to highlight the Dectin-1 specific effect on 
TNF responses.  
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Figure 3.10: BMDM cells must be constantly treated with NE in the absence of serum-containing media to retain Dectin-1 expression 
loss. The small molecule inhibitor of NE, AAT results in TNF release. (A - D) BALB/c derived BMDMs were treated for 1 hour at 37oC 5% 
CO2 with 0.5μM, 1μM NE, 1μM NE AAT or 4μg/ml 2A11 antibody. BMDMs were then simulated for 3 hours at 37oC 5% CO2 with 25μg 
curdlan in serum-containing media or serum-lacking assay buffer in the presence of continued NE treatment or with the NE treatment 
removed. (Ai - Di) After stimulation BMDMs were stained with anti-F4/80, anti-CD11b and anti-mDectin-1. Dectin-1 expression for each 
media or treatment condition was determined by flow cytometry. (Aii - Dii) After stimulation ELISA determined TNF concentration for 
each media or treatment condition. Results displayed are representative of (Ai - Di) 3 and (Aii – Dii) 2 independent experiments. 
No
 tre
atm
en
t
0.5
uM
 N
E
1u
M 
NE
1u
M 
NE
 AA
T
AA
T
2A
11
Iso
typ
e
0
200
400
600
800
No
 tre
atm
en
t
0.5
uM
 N
E
1u
M 
NE
1u
M 
NE
 AA
T
AA
T
2A
11
Iso
typ
e
0
200
400
600
800
No
 tre
atm
en
t
0.5
uM
 N
E
1u
M 
NE
1u
M 
NE
 AA
T
AA
T
2A
11
Iso
typ
e
0
200
400
600
800
LPS NE+ media -
No
 tre
atm
en
t
0.5
uM
 N
E
1u
M 
NE
0.5
uM
 N
E A
AT
1u
M 
NE
 AA
T
AA
T
2A
11 IS
O
0
500
1000
1500
2000
TN
F 
pg
/m
l
No
 tre
atm
en
t
0.5
uM
 N
E
1u
M 
NE
1u
M 
NE
 AA
T
AA
T
2A
11
Iso
typ
e
0
200
400
600
800
%
	o
f	m
ax
	
100	
Dectin-1	
0	
%
	o
f	m
ax
	
100	
0	
%
	o
f	m
ax
	
100	
0	
Dectin-1	 Dectin-1	
No
 tre
atm
en
t
0.5
uM
 N
E
1u
M 
NE
1u
M 
NE
 AA
T
AA
T
2A
11
Iso
typ
e
0
200
400
600
800
TN
F	
pg
/m
l	
No
 tre
atm
en
t
0.5
uM
 N
E
1u
M 
NE
1u
M 
NE
 AA
T
AA
T
2A
11
Iso
typ
e
0
200
400
600
800
TN
F	
pg
/m
l	
No
 tre
atm
en
t
0.5
uM
 N
E
1u
M 
NE
1u
M 
NE
 AA
T
AA
T
2A
11
Iso
typ
e
0
200
400
600
800
TN
F	
pg
/m
l	
Media	+	|	NE	retained	 Media	-	|	NE	removed	 Media	-	|	NE	retained	
A	i	
A	ii	
Untreated	
0.5μM	NE	
1μM	NE	
NE	+	AAT	
TN
F	
pg
/m
l	
Media	-	|	NE	retained	
Curdlan	Stimulation	Unstimulated	
%
	o
f	m
ax
	
100	
Dectin-1	
0	
B	i	
B	ii	
C	i	
C	ii	
D	i	
D	ii	
110	
The results displayed in figure 3.10 highlight the challenges encountered when aiming 
to isolate a functional response deficiency specifically resulting from the NE-induced 
cleavage of Dectin-1. Alongside results shown, experiments were also completed using 
A.f. SC as a stimulant instead of curdlan. No TNF response was detected when using 
live A.f. SC. A.f. may not provide a fast or robust enough stimulus to lead to the release 
of TNF after 3 hours. Live A.f. may also kill the cells resulting in no TNF release. 
 
Figure 3.10 (Bi) identifies the requirement for completing the 3-hour stimulation 
without using serum-containing media. These experimental conditions recovered the 
expression of Dectin-1 and blocked the cleaving impact of NE. Figure 3.10 (Ai, Ci & Di) 
stimulations were completed in serum-free buffer and the NE-induced cleavage of 
Dectin-1 was present. Figure 3.10 (Ci) displays the limited impact removing NE after 
the initial 1-hour treatment has on maintaining Dectin-1 expression loss. Dectin-1 
expression was reduced; although, when NE was removed, expression recovered. 
Figure 3.10 (Di) proposes the most effective way of maintaining the NE-induced loss 
of Dectin-1 requires NE-treating cells for 1 hour before stimulating with curdlan in 
serum-free buffer on top of existing NE treatment. Unfortunately, although the loss of 
Dectin-1 was maintained through this method, BMDMs likely die or lack nourishment 
as these cells only produced ~50% the curdlan TNF response that cells in serum-
containing media produced.  
 
Figure 3.10 (Aii – Dii) highlights the difficulties encountered when trying to block NE’s 
cleaving impact on cells whilst measuring TNF responses. AAT appears to stimulate 
cells and result in TNF release independently of Dectin-1. This blocked the association 
of the NE-induced cleavage of Dectin-1 resulting in a reduced TNF response. 
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Taking the above-mentioned points from figure 3.10, a refined approach was used 
attempting to elicit the functional impact the NE-induced cleavage of Dectin-1 may 
have. Therefore, BMDMs were treated with NE for the entirety of the stimulation 
experiment and no serum-containing media was added to the cells. BMDMs were 
stimulated with curdlan or curdlan and Pam(3)CSK(4). This TLR2 ligand was used to 
greatly enhance the TNF response [236]. Multiple small molecule NE inhibitors were 
trialed, along with heat-killed NE, to allow the NE-cleavage of Dectin-1 to be directly 
associated with a TNF response deficiency.  
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Figure 3.11: NE-induced cleavage of Dectin-1 cannot be directly associated with an impaired TNF response. (A, B & C) BMDM cells 
derived from BALB/c mice were treated for 1 hour at 37oC 5% CO2 with 0.5μM or 1μM NE, 1μM NE PMSF or 4μg/ml 2A11 antibody. 
BMDMs were then stimulated with (B) 25μg Curdlan or (C) 25μg Curdlan + 10ng PAM (3) CSK (4) in serum lacking assay buffer in the 
presence of continued NE treatment for 3 hours at 37oC 5% CO2. After stimulation supernatant was collected and TNF concentration of 
each stimulation condition determined by ELISA. Results displayed are representative of 2 independent experiments. 
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The results displayed in figure 3.11 further highlight the challenges encountered when 
aiming to attribute the NE-induced loss of Dectin-1 to a reduced functional TNF 
response.  
 
Figure 3.11 identifies un-stimulated BMDMs consistently released a large quantity of 
TNF against small-molecule NE inhibitors such as PMSF. A range of different small-
molecule NE inhibitors and heat-killed NE also elicited TNF responses (data not 
shown). Therefore, the NE-induced loss of Dectin-1 and subsequent reduced TNF 
response could not be directly associated. A much larger TNF release was achieved 
when stimulating BMDMs with Curdlan and the TLR2 ligand Pam(3)CSK(4). This co-
stimulation was attempted to enhance the subtle TNF response differences identified 
in figure 3.10 between NE-treated and NE-inhibited or untreated samples. Although 
this has been achieved and an NE dose-response reduction in TNF release was 
attained, the PMSF inhibition of NE has still resulted in a large TNF response.  
 
Due to the challenges faced attempting to treat BMDMs with NE and elicit a functional 
response deficit by stimulating cells through Dectin-1 and quantifying TNF production, 
a different approach was required. Identifying whether the NE-cleavage of Dectin-1 
compromises the ability of cells to recognise zymosan or A.f. SC may provide a 
functional response outcome directly linked to the NE-cleavage of Dectin-1.  
 
Neutrophils from C57BL/6 WT and Dectin-1 KO mice were obtained from intra-
peritoneal BIOgel. These cells were used to determine zymosan and A.f. SC recognition 
and elicit the maximal impact losing Dectin-1 had on the recognition of these two 
Dectin-1 ligands. Zymosan is derived from fungal cell walls and is well recognised as a 
Dectin-1 ligand and appropriate sterile model for fungal recognition and phagocytosis 
[237].   
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Figure 3.12: Dectin-1 KO neutrophils possess impaired zymosan recognition but 
retain high binding affinity for A.f. SC. (A & B) 2.5μg FITC-zymosan or 1x106 PE-A.f. SC 
was incubated with BIOgel-obtained cells. Cells were stained with anti-Ly6G, anti-
CD11b and anti-Dectin-1. Flow cytometry was used to identify Ly6G+ and CD11b+ 
neutrophils; Zymosan or A.f. SC binding was determined on these cells. (A) FITC-
labeled zymosan or far-red labelled A.f. SC was incubated with BIOgel-obtained cells 
from 5-60 minutes at 37oC 5% CO2. Zymosan or A.f. SC binding by neutrophils was 
determined at each time point by flow cytometry. Graph displays mean +/- s.e.m.. (B) 
Zymosan or A.f. SC were incubated with BIOgel-derived cells for 15 minutes at 37oC 
5% CO2 before binding by neutrophils was determined by flow cytometry. (A) Mean 
data displayed from two independent experiments. (B) Data displayed representative 
of two independent experiments.  
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Figure 3.12 (A) suggests the Dectin-1 recognition of zymosan and A.f. SC occurs rapidly. 
Zymosan recognition peaks at 15 minutes. The quantity of zymosan used (2.5μg) 
resulted in ~50% binding at 15 minutes. This binding percentage is optimal for the 
identification of NE-induced binding deficiencies. The cells are not saturated with 
zymosan but sufficient binding is present for a NE-induced binding reduction to be 
discernable.  
 
The binding efficiencies identified at 15 minutes in figure 3.12 (A) were used at this 
time point for the experiments displayed in figure 3.12 (B). These data suggest 
neutrophils can recognise A.f. SC completely independently of Dectin-1; however, 
zymosan recognition relies heavily on Dectin-1. The redundant role of Dectin-1 in the 
recognition of A.f. SC meant future experiments were carried out using zymosan. 
Neutrophils are difficult to maintain in a low activation state for use in recognition 
experiments; therefore, this experiment was completed in BMDMs in order to 
ascertain a similar zymosan recognition trend between WT and Dectin-1 KO was 
present in this cell type.  
 
The zymosan used in the experiments displayed in figure 3.12 was a purchased FITC-
labeled zymosan (Thermofisher). This FITC-labeled zymosan was very bright. The cell 
population lacking zymosan recognition could not be contained in the same flow 
cytometry gate as the positive zymosan-recognition population. Therefore, zymosan 
(Sigma) was conjugated with a FITC-fluorophore generating a less bright FITC-labeled 
zymosan ligand that could be used in future recognition experiments. This homemade 
FITC-labeled zymosan allowed the determination of cells that have and have not 
recognised zymosan to be viewed in the same flow-cytometry gate.  
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Figure 3.13: Dectin-1 KO BMDMs possess significantly impaired zymosan 
recognition. (A) 2.5μg FITC-labeled zymosan was incubated with C57BL/6 WT or 
Dectin-1 KO derived BMDMs for 15 minutes at 37oC 5% CO2. Cells were stained with 
anti-F4/80, anti-CD11b and anti-mDectin-1. Flow cytometry was used to identify 
CD11b+ and F4/80+ macrophages; zymosan recognition was determined on these cells. 
(B) Dectin-1 expression on WT or Dectin-1 KO BMDMs was determined by flow 
cytometry. (C) Data as displayed in (A) was used to elicit zymosan binding of WT and 
Dectin-1 KO BMDMs. WT zymosan binding was set at 100% per independent 
experiment and corresponding Dectin-1 KO zymosan recognition result calculated 
against each experiments WT recognition result. Graph displays mean +/- s.e.m.. (A & 
B) Data displayed are representative of three independent experiments. (C) Data 
shown are the mean collated from three independent experiments. Student’s t-test 
was used to determine statistical significance, **p<0.005. 
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Figure 3.13 shows that Dectin-1 expression on BMDMs is required in order for cells to 
recognise zymosan. This experiment confirms the Dectin-1 dependency trend 
identified in neutrophils (figure 3.12) is conserved in BMDMs. The experimental 
protocol could now be used to identify whether NE-treatment reduces zymosan 
recognition. These experiments were completed using C57BL/6 WT and C57BL/6 
Dectin-1 KO BMDMs. In order to elicit the impact the NE-induced cleavage of Dectin-
1 has on the ability of BMDMs to recognise zymosan, BALB/c -derived BMDMs were 
treated with NE before being incubated with FITC-labeled zymosan.  
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Figure 3.14: NE cleavage of mDectin-1 on BALB/c 
derived BMDMs significantly impairs zymosan 
recognition. (A) BALB/c derived BMDMs were 
treated with 0.5μM NE, 1μM NE or 1μM HK NE 
for 1 hour at 37oC 5% CO2 before 2.5μg FITC-
zymosan was incubated with the cells for 15 
minutes. Cells were stained with anti-CD11b, 
anti-F4/80 and anti-mDectin-1. Flow cytometry 
was used to identify CD11b+ F4/80+ 
macrophages; zymosan recognition was 
determined on these cells. (B) Untreated BMDM 
zymosan binding was set at 100% per 
independent experiment and corresponding 
treated BMDM zymosan recognition result 
calculated against each experiment’s untreated 
recognition result. Graph displays mean +/- 
s.e.m.. (A) Data displayed are representative of 
three independent experiments. (B) Data shown 
are mean collated from three independent 
experiments. A one-way analysis of variance   
with Bonferroni’s post-test was used to 
determine statistical significance. ** p<0.005. 
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Figure 3.14 describes the significant reduction in BMDM’s ability to recognise zymosan 
following the NE- induced cleavage of Dectin-1. These results allow the NE-induced 
loss of Dectin-1 expression to be associated with a reduced ability to recognise fungal 
ligands. Here, for the first time a potential role describing the NE cleavage of Dectin-1 
reducing airway anti-fungal immune response is described. 
 
The isoform-specific Dectin-1 cleavage impact of NE was examined. Zymosan 
recognition by NIH-3T3 cells expressing either hDectin-1 isoform A or hDectin-1 
isoform B was determined after NE-treatment. This experiment also identified 
whether the significant reduction in zymosan recognition after NE-treatment 
described in mDectin-1 (figure 3.14) was conserved in hDectin-1.  
 
The expression of hDectin-1 Isoform A and Isoform B on NIH-3T3 cells was not 
identical; therefore, optimal zymosan dose was determined to attain ~25-50% 
recognition for both isoforms. This allowed the same zymosan dose to be used for 
both isoforms (as untreated zymosan recognition was set at 100%) and for the impact 
of NE reducing zymosan recognition to be discernable.  
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Figure 3.15: hDectin-1 isoform A and isoform B possess enough zymosan recognition 
affinity that 4μg zymosan provides ~25-50% binding, the optimal requirement for 
determining the impact NE cleavage has on hDectin-1 in recognition assays. (A) NIH-
3T3 cells expressing either hDectin-1 Isoform A or Isoform B were incubated with 
varying concentrations of FITC-labeled zymosan for 15 minutes at 37oC 5% CO2 before 
zymosan recognition was determined using flow cytometry. The expression of 
hDectin-1 Isoform A and Isoform B was not identical on each cell line, see figure 3.2 
for hDectin-1 Isoform expression on each cell line. Data shown are from one pilot 
experiment. 
 
 
A dose of 4μg zymosan provided ~25-50% recognition in both hDectin-1 Isoform A and 
Isoform B. NIH-3T3 cells expressing either hDectin-1 Isoform A or Isoform B were 
treated with NE before being incubated with 4μg FITC-labeled zymosan. NE’s impact 
on zymosan recognition for each hDectin-1 isoform was determined by flow 
cytometry. 
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Figure 3.16: NE cleavage of hDectin-1 Isoform 
A significantly impairs zymosan recognition. 
(A) NIH-3T3 cells expressing either hDectin-1 
Isoform A or Isoform B were exposed to 
0.5μM NE, 1μM NE or 1μM HK NE for 1 hour 
at 37oC 5% CO2 before 4μg FITC-labeled 
zymosan was incubated with the cells for 15 
minutes. Zymosan recognition was 
determined by flow cytometry. (B) Untreated 
zymosan binding was set at 100% per 
independent experiment and corresponding 
treated zymosan recognition result calculated 
against each experiment’s untreated 
recognition result. Graph displays mean +/- 
s.e.m.. (A) Data displayed are representative 
of three independent experiments. (B) Data 
shown are mean collated from three 
independent experiments. A one-way analysis 
of variance with Bonferroni’s post-test was 
used to determine statistical significance. ** 
p<0.005, *** p<0.0005. 
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Figure 3.16 highlights a significant, isoform-specific role for NE-cleaving hDectin-1 
Isoform A and reducing zymosan recognition. No reduction in zymosan recognition 
was attained when hDectin-1 Isoform B cells were treated with NE. This experiment 
confirmed the significant trend seen in figure 3.13 and 3.14 using mDectin-1 was 
conserved in hDectin-1. The greater loss of zymosan binding identified in NIH-3T3 cells 
(figure 3.16) when compared to BALB/c BMDMs (figure 3.14) is likely due to the 
exclusive expression of isoform A in the NIH-3T3 cell line but equal expression of 
Isoform A and B in BALB/c BMDMs.  
 
Finally, although a significant zymosan recognition deficiency has been associated with 
NE treatment, no impact of NE has been identified to directly impair A.f. recognition 
or the anti-A.f. immune response. An A.f. specific recognition deficiency could not be 
described, as immune cells possess A.f. recognition redundancy through a range of 
CLRs and TLRs; therefore, experiments were undertaken to identify an anti-A.f. 
cytokine response deficiency resulting from NE-treatment. The recognition of A.f. may 
not exclusively require Dectin-1; however, the generation of a robust immune 
response against A.f. does require the A.f. engagement of Dectin-1 [2, 99].  
 
The data and experiments displayed in figure 3.17 were completed and analysed by Dr 
Selinda Orr. The protocol used for this experiment was formulated from preliminary 
experiments I had previously completed, some of which are displayed in figure 3.10 
and figure 3.11. In order to identify a functional cytokine impact resulting from the NE-
induced cleavage of Dectin-1, purified monocytes (enriched from BIOgel-elicited cells) 
were treated with NE or HK NE before being stimulated with A.f. SC or zymosan. TNF 
was quantified for each stimulant and treatment condition. 
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Figure 3.17: NE-treated monocytes produce significantly impaired TNF responses 
against zymosan and A.f. SC. (A & B) BIOgel-elicited cells were washed with MACS 
buffer (PBS 0.5% BSA 2mM EDTA) and stained with anti-Ly6G-Biotin before cells were 
incubated with anti-Biotin microbeads. Inflammatory monocytes were enriched by 
MACS separation according to manufacturer’s protocol. 2-4x105 Cells were suspended 
in serum-free assay buffer and treated with 4μM NE or 4μM HK NE for 1 hour at 37oC 
5% CO2. Cells were stimulated on top of existing NE or HK NE treatment for 4 hours at 
37oC 5% CO2 with (A) 2.5μg zymosan or (B) 0.6-1.2x105 A.f. SC in a ratio of 3:1 with 
cells. ELISA was used to determine TNF concentration from each treatment and 
stimulant condition. Graph displays mean +/- s.e.m.. (A) Data shown are mean collated 
from three independent experiments. (B) Data shown are mean collated from five 
independent experiments. (A & B) A one-way analysis of variance with Bonferroni’s 
post-test was used to determine statistical significance. ** p<0.005, *** p<0.0005.  
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The data displayed in figure 3.17 describes the significant impairment of monocytes 
anti-A.f. TNF response after treatment with NE. These data associate the NE-induced 
loss of Dectin-1 on immune cell types recruited to the CF airway with the increased 
susceptibility to A.f. infection CF patient’s experience.  
 
Figure 3.17 suggests the mechanism by which CF patients, already with high neutrophil 
infiltration and high NE airway activity, generate impaired anti-A.f. responses. An NE-
induced loss of Dectin-1 expression results in reduced A.f. recognition and signalling 
likely culminating in reduced A.f. clearance. Recurrent, chronic and poorly challenged 
A.f. infections may enhance airway inflammation and exacerbate underlying airway 
disease. 
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3.4: Discussion 
 
 
CF affects ~1 in every 2500 births in the UK causing progressive airway disease due to 
recurrent, poorly challenged chronic infections. Recurrent bacterial and fungal 
infections lead to the generation of a chronic inflammatory setting in the airway. CF 
patient’s increased susceptibility to chronic infections such as A.f. is not well 
understood. Immune cells recruited to combat pathogens become immobilised in 
mucus not appropriately trafficked by the defective mucociliary escalator and 
contribute to chronic inflammation [26, 222]. Neutrophils are the predominant cell 
recruited and retained in the CF airway. A high airway infiltration of neutrophils is 
directly associated with worsening disease progression and declining lung function 
[27, 224]. Once recruited and trapped in the airway, neutrophils exacerbate airway 
pathology by releasing serine proteases into the local tissue environment. Serine 
proteases are an important facet of neutrophil’s anti-microbial response; however, 
when poorly regulated, proteases damage local tissue and further disrupt the 
mucociliary escalator. Neutrophil-derived serine proteases also interfere with many 
integral components of the immune response, weakening the already CF-dampened 
immune response to pathogens in CF lungs. Currently, neutrophil-derived serine 
proteases have been described to inactivate elements of the complement system, 
cleave TLRs and cleave soluble IL-6R rendering these host defence mechanisms 
obsolete in the CF airway [27, 226].  
 
Similar to NE-induced cleavage of TLRs and IL-6R, the research in this chapter 
demonstrates the susceptibility of Dectin-1 Isoform A to NE-induced cleavage and 
investigates the functional consequences this may convey. Cleavage of Dectin-1 
Isoform A in the CF airway would likely impair A.f. recognition and inhibit A.f. immune 
challenge. This may permit the persistence of A.f. infection in the CF airway further 
enhancing inflammation. Persistent A.f. infection and increased inflammation would 
only worsen CF patient morbidity and mortality. Understanding the immune 
debilitating action of neutrophil-derived serine proteases such as NE may enhance the 
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already commenced development of therapeutics that block their action. Blocking the 
ability of serine proteases to cleave components of the host immune system may 
increase the effectiveness of the local immune response. This would hopefully 
contribute to the clearance of chronic infections, resolution of inflammation and 
improvement of underlying CF disease. 
 
 
3.4.1: Does neutrophil elastase cleave Dectin-1? 
 
Here, a novel role for NE-induced cleavage of the CLR Dectin-1 has been 
demonstrated. I demonstrate that NE cleaves Dectin-1 in an isoform specific manner, 
only cleaving Isoform A that contains the stalk-region. We have also shown that BALF 
from CF patients induces Dectin-1 cleavage. The percentage loss of Dectin-1 
expression in vitro correlates with increased NE activity and greater neutrophil 
numbers in the BALF. This suggests that the cleavage of Dectin-1 may occur in the CF 
airway where high neutrophil infiltration and NE activity are commonplace. Crucially, 
this research adds the first CLR, Dectin-1, to the growing repertoire of human immune 
components including IL-6R, complement receptors and TLRs, susceptible to cleavage 
and inactivation by the neutrophil serine protease NE [32, 34, 35].  
 
The role of Dectin-1 during invasive A.f. infections has been well investigated; the role 
this CLR conveys in the CF airway, especially when cleaved by NE, has not been 
explored. Dectin-1 is vital for anti-fungal responses to A.f. and multiple other fungal 
species. A.f. utilises an immunologically inert rodlet layer present on resting conidia to 
mask cell wall components such as β-glucans and α-mannans that act as PAMPs. Upon 
A.f. germination this rodlet layer is shed allowing host immune PRRs to recognise A.f. 
cell wall components and induce an immune response. Dectin-1 is required for the 
recognition of A.f. β-glucans and generation of an anti-A.f. immune response [99, 171]. 
 
The isoform specific susceptibility of Dectin-1 to NE-induced cleavage is intriguing. The 
important role Dectin-1 plays during the A.f. immune response is clear. Lacking this 
receptor impairs the anti-A.f. response and significantly enhances susceptibility to A.f. 
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infection. The importance of the individual isoforms of Dectin-1 has not yet been 
studied in depth; although, location-specific expression of isoforms A and B on 
different myeloid cell subsets is starting to be unraveled. While both isoforms were 
thought to be functionally similar, recent evidence suggests distinct inflammatory 
responses result from the engagement of each isoform [161, 228]. This requires 
further study in different myeloid cell populations. The resistance Dectin-1 Isoform B 
possesses against NE-induced cleavage suggests this isoform may play a vital role in 
anti-fungal immunity in the CF airway, specifically during periods of intense neutrophil 
inflammation producing high concentrations of NE. 
 
I have demonstrated that the NE-induced cleavage of Dectin-1 Isoform A takes place 
on cell types relevant to the CF airway and recruited during A.f. infection. 
Macrophages act as the front-line immune response against A.f. and possess a range 
of anti-fungal capabilities including A.f. phagocytosis and anti-A.f. cytokine and 
chemokine production [69]. Crucial for macrophage fungal-immunity is their 
expression of Dectin-1. Possessing this CLR is necessary for the orchestration of 
appropriate anti-A.f. immune responses [2]. The NE-induced cleavage of Dectin-1 
Isoform A on macrophages likely reduces the ability of these cells to recognise early 
A.f. morphologies and generate robust immune responses that clear A.f.. The already 
impaired immune capabilities of CF patient macrophages are well known [238]. Here, 
the newly identified role for NE in cleaving Dectin-1 Isoform A and further curtailing 
the immune capabilities of macrophages, may enhance fungal disease and 
inflammation, exacerbating underlying disease pathology.  
 
Neutrophils are the best-described contributors to inflammation in the CF airway, 
mainly due to their release of serine proteases such as NE. Serine proteases have 
potent anti-microbial properties but when poorly regulated, as is often the case in CF 
patients, they can be very damaging to local tissue and immune responses. A high 
infiltration of neutrophils in the CF airway is associated with regular bacterial and 
fungal infection, a highly inflammatory setting and declining lung function [27, 224]. 
The role of Dectin-1 expressed on neutrophils during the anti-A.f. immune response 
has not been thoroughly investigated; although, the anti-fungal capabilities of 
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neutrophil-expressed Dectin-1 has been identified. Experiments blocking Dectin-1 on 
human neutrophils resulted in the reduced phagocytosis of zymosan and Candida 
albicans and also blocked ROS production [102]. It is likely that neutrophils have a 
similar impact against A.f., phagocytosing conidia and producing ROS against hyphae. 
More recently, Dectin-1 deficiency has been shown to disrupt NETosis, a crucial A.f. 
hyphae-killing mechanism [29, 239]. The demonstrated NE-induced cleavage of 
Dectin-1 expressed on neutrophils would suggest these cells lose some capability to 
recognise fungal pathogens such as A.f. and to respond with phagocytosis, ROS 
production or NETosis.  
 
In addition, the NE-induced cleavage of Dectin-1 is conserved in inflammatory 
monocytes/macrophages. Monocytes have a complicated role during the anti-A.f. 
immune response dependent on their maturation stage and expression of CD16. 
CD14+CD16-monocytes were particularly effective at phagocytosing A.f. conidia but 
generated little cytokine response. CD14+CD16+ monocytes were poor at perturbing 
A.f. germination and phagocytosing conidia but generated robust cytokine responses. 
Although monocyte’s role varies and probably depends on multiple factors, many of 
which are not understood, the ability of monocytes to block A.f. growth is widely 
accepted [130]. Monocyte-expressed Dectin-1 is required to control the fungal 
pathogen Paracoccidioides brasiliensis; however, the impact monocytes have against 
A.f. exclusively through Dectin-1 is not clear [240]. The pro-inflammatory role of 
monocytes in the CF airway is interesting. Monocytes have been shown, when 
recruited to the CF airway during inflammation, to become locked in a tolerant state 
unable to act upon bacterial or fungal challenge [241]. This tolerant state was thought 
to be the result of deficient cytokine signalling; however, a role for NE cleaving crucial 
PRRs such as Dectin-1, may contribute to the lack of monocyte mediated anti-fungal 
immune responses in CF lungs. 
 
Here, I clearly demonstrate the capability of NE to induce Dectin-1 Isoform A cleavage 
on macrophages, neutrophils and monocytes. These cell types are readily recruited to 
the CF airway and are key components of anti-fungal immunity. The requirement of 
Dectin-1 expression on these cells when mounting anti-A.f. immune responses is 
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partially described. The lack of Dectin-1-A.f. engagement on these cells would likely 
impair the anti-A.f. immune response allowing pathogen persistence, enhancing 
chronic inflammation and worsening underlying CF disease. 
 
 
3.4.2: Which Dectin-1 amino acid is required for NE-induced cleavage to occur? 
 
Unfortunately, the research undertaken aiming to identify the Dectin-1 amino acid 
residue required for NE cleavage was unsuccessful. Having identified the isoform-
specific cleavage action of NE, two enzyme databases were used to predict cleave 
locations within the Dectin-1 Isoform A specific stalk region. These databases compiled 
enzyme activity data from over 137 000 literature references and are regularly used 
to predict how a range of enzymes may cut sequences [242]. This database request 
provided four likely NE-cleavage sites located within the Dectin-1 Isoform A stalk 
region. All these residues were either alanine or valine, consistent with the NE-cleave 
sites identified in other proteins [243]. For my experiments, these residues were 
mutated to glycine which shouldn’t have altered Dectin-1’s tertiary structure; 
although, it may have impacted protein function [234]. However, as the mutation of 
predicted cleavage sites to glycine increased the NE-induced cleavage of Dectin-1, I 
predict that inserted glycine residues have straightened the tertiary structure of 
Dectin-1 thus increasing the accessibility of the stalk region and enhancing NE 
cleavage. A similar mechanism of glycine straightening protein tertiary structures has 
been previously identified [235].  
 
The NE cleavage location of many immune components susceptible to NE inactivation 
has not been identified. NE’s cleavage of complement C3bi, CR1 and C5aR, epithelial 
cadherins, IL-6R and TLR4 do not have described cleavage sites [32, 34-36, 244]. Here, 
although I was unsuccessful at abrogating NE activity by mutating single potential NE 
cleavage sites, it is likely that NE cleavage can occur at all four predicted residues. The 
fact that NE cannot cleave Dectin-1 Isoform B, at least places the NE-cleavage required 
amino acid residues within the Isoform A exclusive stalk region. Further experiments 
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mutating multiple predicted cleavage sites in tandem, or mutating to a different amino 
acid residue may lead to the abrogation of NE-induced cleavage of Dectin-1 Isoform A.  
 
 
3.4.3: Is there a functional consequence resulting from the NE-induced cleavage of 
Dectin-1? 
 
As previously mentioned, Dectin-1 is crucial for the recognition and generation of 
successful anti-A.f. immune responses. Lacking Dectin-1, or Dectin-1 signalling 
components significantly enhances susceptibility to A.f. infection [69, 171]. We have 
extensively demonstrated human and mouse Dectin-1 Isoform A’s susceptibility to NE-
induced cleavage in cell types resident or recruited to the CF airway during A.f. 
infections. Here I explore the functional consequences lacking Dectin-1 A.f. 
recognition conveys over the anti-A.f. immune response. 
 
Initially experiments were undertaken to identify the importance of Decitn-1 
expression on myeloid immune cells for A.f. recognition. I show that neutrophils 
possess high Dectin-1 redundancy when recognising A.f., this has been previously 
identified [99, 245]. Crucially, although many immune cells possess Dectin-1 
redundancy when recognising A.f., the generation of robust inflammatory responses 
are dependent on Dectin-1 engagement [2]. 
 
In order to investigate a functional consequence resulting from the reduced 
expression of Dectin-1, zymosan was used for Dectin-1 recognition experiments. 
Zymosan is routinely used as a sterile model of fungal infection. As a pure β-(1-3) 
glucan extracted from fungal cell walls, the immunogenic-carbohydrate is recognised 
almost entirely by Dectin-1 [171, 205, 246]. The experiments completed using 
zymosan to identify the dependency of myeloid cells on Dectin-1 to recognise β-(1-3) 
glucans aligns with previous work suggesting this recognition is Dectin-1 dependent 
[2, 100, 205]. Here, I demonstrate myeloid cells reduced capacity to recognise 
common fungal cell wall components such as β-(1-3) glucan after NE-induced cleavage 
of Dectin-1. 
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Finally, we also demonstrate that the NE-induced cleavage of Dectin-1, along with 
reducing zymoson recognition, functionally impairs the immune response against A.f. 
and zymosan. Monocytes treated with NE before being stimulated with live A.f. or 
zymosan generated reduced TNF responses. This concurs with research suggesting 
Dectin-1 KO monocytes exhibit impaired TNF responses [161]. Our results add to the 
increasing repertoire of research already describing the immune-impairing impact of 
NE, including the functional inactivation of complement components and soluble IL-
6R. 
 
However, our results differ from a recently described role for NE, whereby NE induces 
TLR4 cleavage and subsequently promotes cytokine production. This result variation 
may be due to different experimental protocols being used. The study linking TLR4 NE-
cleavage with an increased cytokine response removed NE treatment before 
stimulating cells [32]. In contrast, we stimulated cells in the presence of NE and 
identified a reduced TNF response. Interestingly, our data highlights the rapid recovery 
of Dectin-1 expression when serum-containing media is added to cells and/or when 
NE treatment is removed. It may be the case that Dectin-1 recovered beyond 100% of 
basal expression in the TLR4 experiments in which NE increased cytokine responses. 
The CF airway setting exposes immune cells to consistent, high levels of NE. Therefore, 
our experiments completed in the constant presence of NE are likely more similar to 
the physiological setting. It is worth mentioning that the reduced TNF response 
resulting from Dectin-1 NE treatment cannot be completely attributed to Dectin-1. 
Other CLRs and immune components susceptible to NE-induced cleavage likely 
contribute to the reduced TNF response.  
 
The NE-induced cleavage of Dectin-1 and ensuing lack of A.f. recognition and response 
may have far reaching consequences for the host’s overall anti-fungal response 
capabilities. CLRs and TLRs are not only involved in fungal killing and inflammatory cell 
recruitment, but also provide a link to the adaptive immune response [245, 247]. 
Recent evidence implicating the importance of adaptive immune responses against 
fungal pathogens such as A.f. has emerged [115, 248]. Successful clearance of A.f., 
especially during chronic infections, was associated with the formation of robust TH1 
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and TH17 responses [249]. Dectin-1 and TLRs promote TH1 and TH17 responses through 
their ability to modulate cytokines such as IL-12 and IFNγ. Specifically a robust Dectin-
1 IL-12 response reduces T-Bet expression in A.f. specific CD4+ T cells and facilitates 
TH17 differentiation [135].  
 
A.f. appears to be particularly effective at initiating TH2 immune responses via the 
release of allergen proteins exclusively recognised by CD4+ TH2-cells or IgE. The fungal 
engagement of these immune components likely aids TH1 response evasion promoting 
pathogen survival [129]. Our research is specifically relevant here as monocytes and 
monocyte derived cells link the innate and adaptive immune systems. Recruited 
monocytes phagocytose A.f. using CLRs such as Dectin-1 before migrating to lymph 
nodes and priming CD4+ T-cells [131]. Monocyte A.f. recognition, phagocytosis, 
migration and antigen presentation culminates in a host-protective TH1 response. I 
have demonstrated Dectin-1 expressed on monocytes is susceptible to NE-induced 
cleavage. As Dectin-1 is the principal A.f. phagocytic receptor, NE may block monocyte 
A.f. phagocytosis and antigen presentation abrogating the generation of an anti-A.f. 
TH1 response.  
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3.5: Conclusions 
 
 
The CF airway is a very complicated setting with various immunological and structural 
abnormalities. A dysfunctional mucociliary escalator resulting from a faulty CFTR 
protein leads to the accumulation and reduced clearance of thick mucus. Subsequently 
recurrent and chronic bacterial and fungal infections ensue and large influxes of 
immune cells, specifically neutrophils are recruited to combat pathogens. A highly 
inflammatory setting is generated as pathogens and immune cells are retained in thick 
mucus. Here, neutrophils release serine proteases as a defence mechanism; however, 
this release is poorly regulated due to the local environment and lack of neutrophil 
clearance. Released serine proteases such as NE drastically impact the local setting 
and damage pathogens and host tissues as well as impairing the immune response. 
Here we describe a role for the NE-induced cleavage of Dectin-1 in the CF airway 
reducing the ability of resident and recruited immune cells such as macrophages, 
neutrophils and monocytes to recognise and respond to pathogens such as A.f.. 
Reduced pathogen recognition and an impaired immune response would result in the 
insufficient killing and clearance of the pathogen. Overall this would lead to increase 
inflammation in the CF airway driving further tissue damage, fibrosis and culminating 
in diminished lung function.  
 
Therapeutically blocking the action of serine proteases in the CF airway may halt the 
damaging impact NE has on Dectin-1. Retaining immune cells ability to recognise 
pathogens would permit the more successful killing and clearance of pathogens. This 
may curtail the chronic inflammation resulting from recurrent and ineffectively 
challenged airway infections such as A.f..  
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Chapter 4 
 	
Understanding the collective roles of Dectin-1, Dectin-2 and Mincle in 
anti-Aspergillus fumigatus immunity 		
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4.1: Aims 
 
 
i.Identify the role of Dectin-1, Dectin-2 and Mincle in anti-A.f. immunity  
 
ii.Determine any redundancy/collaboration between these CLRs  
 
iii.Identify whether CLR collaboration enhances the anti-A.f. immune response  
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4.2: Introduction 
 
 
Invasive Aspergillosis is a major cause of infection-related mortality in severely 
immune-compromised patients. The disease often caused by A.f. is becoming an 
increasingly serious, worldwide healthcare problem. The anti-A.f. immune response is 
complex and not well understood. A.f. RC are protected from environmental stress by 
an inert outer protein rodlet layer, this provides very little immune stimulation upon 
conidial inhalation. As conidia begin to germinate multiple carbohydrate molecules are 
revealed and act as PAMPs. Immune recognition and response is driven by the 
exposure of PAMPS to PRRs [2, 99]. The best-described PRR involved in A.f. recognition 
is the CLR Dectin-1. This CLR is crucial in the early anti-A.f. immune response and leads 
to the phagocytosis of inhaled conidia and recruitment of non-resident immune cells 
such as neutrophils via the release of cytokines and chemokines [2]. Dectin-1 has been 
thoroughly investigated and a clear anti-fungal and anti-A.f. role for this CLR has been 
identified. I am particularly interested in the CLRs Dectin-1, Dectin-2 and Mincle. I 
hypothesise that these CLRs are crucial in the recognition, initiation and driving of the 
complex anti-A.f. immune response. 
 
Alveolar macrophages act as the first responders in the anti-A.f. immune response. 
These resident phagocytic cells of the respiratory tract and lung express many PRRs 
[1]. Alveolar macrophages deficient in Dectin-1 possess a significantly reduced ability 
to generate appropriate pro-inflammatory responses against A.f.. When alveolar 
macrophages were stimulated with early morphologies of A.f. a robust TNF, MIP-1, 
MIP-2 and IL-1β response was attained [92-94]. When the same experiments were 
completed with Dectin-1 blockade a significant reduction in the pro-inflammatory 
response occurred highlighting the key role Dectin-1 plays in early A.f. recognition on 
alveolar macrophages [2, 98]. The presence of, and a role for, Dectin-2 and Mincle on 
alveolar macrophages have yet to be fully described. Mincle expression on lung-
resident alveolar macrophages was described after infection with Mycobacterium 
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bovis bacillus Calmette-Guérin [192]. Suggesting the CLR is at least inducible on 
alveolar macrophages. 
 
Although alveolar macrophages are the resident lung immune cell and first responder 
against A.f., it is important to determine the role CLRs play in the whole organism’s 
anti-A.f. response and not just in ex vivo cells. In vivo A.f. challenge experiments have 
previously described the enhanced susceptibility of Dectin-1 KO mice when challenged 
with A.f.. Significantly reduced cytokine and chemokine profiles at 24 hours, increased 
fungal burden at 24 and 48 hours, and reduced survival at 5 days highlight the 
requirement of Dectin-1 expression when challenged with A.f. [100]. Interestingly, a 
collaborative role for Dectin-1 and Dectin-2 during Trichophyton rubrum infection has 
recently been identified. Mice lacking Dectin-1 and Dectin-2 produced significantly 
impaired anti-fungal cytokine and chemokine responses when compared to WT or 
Single CLR KO mice. This resulted in a significantly increased fungal burden [221]. A 
collaborative role for Dectin-1 with other CLRs during A.f. infection has not been 
described. The impact of Dectin-2 and Mincle engagement individually and 
collaboratively on the in vivo anti-A.f. immune response also requires investigation. 
 
Limited data suggests the expression of Dectin-2 is up regulated during fungal 
challenge and the receptor has been demonstrated to recognise predominantly larger 
morphologies of A.f. [179, 183]. Dectin-2 is thought to possess a range of possible 
responses when encountering A.f.. The receptor can induce cytokines and chemokines 
such as TNF, IL-6 and Mip-1, producing a pro-inflammatory anti-fungal response. 
Dectin-2 signalling through the MAPK pathway drives the generation of a TH17 
regulatory response via the induction of IL-1β and IL-23. Dectin-2 can also activate the 
inflammasome resulting in respiratory burst [181, 182]. Dectin-2’s impact during the 
anti-A.f. response has not been extensively investigated. An in vivo role for this 
receptor within the CLR-mediated anti-A.f. response has not been described.  
 
The role Mincle plays within the anti-A.f. response is complicated and poorly defined. 
Mincle associates with FcγR upon Candida albicans stimulation leading to the 
production of pro-inflammatory cytokines and chemokines [190]. A role for Mincle 
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synergistically collaborating with TLRs whilst binding α-mannan has been described. 
This collaboration enhanced bacterial challenge response [187]. A similar role for 
Mincle collaborating with other CLRs is unknown. A controversial role for Mincle has 
been described in vivo during Heliobactor pylori infection. Mincle was up regulated 
and engaged by H. pylori, which consequently skewed the immune response in an anti-
inflammatory direction and increased disease burden [194]. The impact A.f. 
engagement has on Mincle and the subsequent Mincle-driven and anti-A.f. response 
is unknown. 
 
Understanding the role CLRs play within the anti-A.f. immune response will provide 
valuable insights into the complex challenge the immune system faces when 
coordinating appropriate responses to A.f..  This challenge is often made more difficult 
with the complex immune-suppression therapies susceptible patients are often 
receiving. Determining which CLRs are involved in the early and later immune 
response, their expression profile and their role in the collaborative response may 
identify crucial cellular and receptor requirements to successfully challenge A.f.. 
Ultimately, describing the role of CLRs in orchestrating the immune response, and 
identifying any collaboration or redundancy within the system could lead to the 
generation of new therapeutics with the potential to enhance the anti-A.f. response 
in patients struggling to control disease.  
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4.3: Results 
 
 
4.3.1: What role do CLRs play in the alveolar macrophage anti-A.f. response? 
 
Alveolar macrophages are a crucial facet of the anti-A.f. immune response required 
for the host’s control of the pathogen. The ability of alveolar macrophages to challenge 
A.f. is likely dependent on CLR-mediated responses. Here I examine the impact CLRs 
convey over alveolar macrophages anti-A.f. cytokine and chemokine response. The 
requirement of Dectin-1 on alveolar macrophages has been well described [2, 99, 250]. 
This permitted our Dectin-1 KO model results to be aligned with published research 
before all other CLR KO and CLR DKO models were examined.  
 
Alveolar macrophages were extracted by performing BAL on naïve mice. In order to 
determine whether alveolar macrophages needed to be enriched from BAL, the purity 
of alveolar macrophages within recovered BAL was examined. Total recovered BAL 
cells were stained with alveolar macrophage markers and analysed by flow cytometry.  
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Figure 4.1: BAL recovered cells are ~90-95% alveolar macrophage. BAL was 
performed on C57BL/6 mice; BAL-recovered cells were stained with anti-CD11c and 
anti-F4/80 and analysed by flow cytometry. A) Cells were separated by SS Lin: SS and 
FS Lin: FS, dead cells and debris were gated out and live cells were carried through to 
a new gate. B) Alveolar macrophages were identified by CD11c+ and F4/80+ expression. 
Similar flow cytometry profiles were observed for all WT, CLR KO and CLR DKO BAL-
recovered cells. Data displayed are representative of 4 independent experiments each 
with at least 5 mice per WT, CLR KO or CLR DKO genotype. 
 
 
BAL-recovered cells consist predominantly of alveolar macrophages; therefore, in all 
following experiments BAL-recovered cells were used as a pure alveolar macrophage 
population.  
 
To identify the impact CLRs convey over the alveolar macrophage anti-A.f. response 
the expression of CLRs on each CLR knock out (KO) or CLR double knock out (DKO) 
model was confirmed. BAL was performed on WT mice and mice from each CLR KO or 
CLR DKO model. Total BAL-recovered cells were stained with anti-CD11c and anti-
F4/80 to identify alveolar macrophages. Antibodies against each CLR were used to 
elicit the expression of CLRs on each CLR KO or CLR DKO model; this was determined 
by flow cytometry. 
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Figure 4.2: All CLR KO models express their expected CLRs. BAL was performed on C57BL/6, CLR KO and CLR DKO mice. In order to 
determine Mincle and Dectin-2 expression, BAL-recovered cells were stimulated with 2μg/ml LPS for 4 hours at 37oC 5% CO2 prior to 
antibody staining. BAL-recovered cells were stained with anti-CD11c, anti-F4/80 and anti-CLR before being analysed by flow cytometry. 
CLR expression was determined on alveolar macrophages that were gated on as described in figure 4.1. A) Dectin-1 expression on WT, 
CLR KO and CLR DKO mice B) Mincle expression on WT, CLR KO and CLR DKO mice C) Dectin-2 expression on WT, CLR KO and CLR DKO 
mice. CLR Isotype antibody staining is displayed as red-dotted histograms. Data displayed are representative of 3 independent 
experiments.  
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The WT, CLR KO and CLR DKO in vivo models used for experiments possess the 
expected CLR expression profiles. This permits the use of alveolar macrophages from 
these in vivo models to elicit the impact CLRs have on the alveolar macrophage anti-
A.f. response. BAL was performed on WT mice and mice from each CLR KO or CLR DKO 
model. Obtained alveolar macrophages were stimulated with live A.f. and ELISA used 
to quantify cytokine and chemokine response.  
 
A.f. possess an immunologically inert protein rodlet layer that is shed within 4-6 hours 
of germination. This rodlet layer masks PAMPS and helps A.f. resist immune 
recognition during early infection. Consequently, alveolar macrophages respond 
particularly well to germinated, SC and EG A.f. morphologies [2, 98]. 24 hours post-
germination A.f. has developed HY structures that are much larger than alveolar 
macrophages rendering their immune response capabilities mostly obsolete. Due to 
this A.f. morphology-specific recognition and response, alveolar macrophages were 
stimulated for 24 hours with live A.f. RC allowing the immune cells to experience, 
recognise and respond to the full life cycle of A.f..  
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Figure 4.3: Dectin-1 KO and MD1 DKO alveolar macrophages produce a significantly impaired anti-A.f. chemokine and cytokine 
response. BAL-recovered cells from WT, CLR KO and CLR DKO mice were stimulated with A) 2μg/ml LPS or B) 1x105 A.f. RC for 24 hours 
at 37oC 5% CO2. After stimulation, ELISA was used to identify cytokine and chemokine quantities in supernatant. Graph displays mean +/- 
s.e.m.. WT data displayed are collated from 7 experiments, Dectin-1 KO and Mincle KO data displayed are collated from 4 experiments 
and MD1 DKO and MD2 DKO data displayed collated from 3 experiments. A one-way analysis of variance with Bonferonni’s post-test was 
used to determine statistical significance. *p<0.05, **p<0.005. 
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Figure 4.3 indicates all CLR KO alveolar macrophages have the ability to produce TNF, 
KC, MIP-1 and MIP-2 upon LPS stimulation. No significant difference between WT, CLR 
KO or CLR DKO’s LPS response was attained. Alveolar macrophages extracted from 
Dectin-1 KO and MD1 DKO mice produced a significantly impaired anti-A.f. TNF and 
MIP-1 response when compared to WT and Mincle extracted alveolar macrophages. 
The quantity of cytokines and chemokines produced from Dectin-1 and MD1 DKO 
alveolar macrophages is similar. This suggests Dectin-1 expression is required for 
alveolar macrophages to generate robust anti-A.f. cytokine and chemokine responses. 
 
Figure 4.3 confirms the previously described Dectin-1-KO phenotype was preserved in 
the Dectin-1 KO alveolar macrophage model used for these experiments [2, 99, 250]. 
This provides validity to the impact described herein that other CLR KO and CLR DKOs 
have on alveolar macrophage’s ability to respond to A.f..  
 
It was next important to determine how each CLR KO impacts the whole organism’s 
ability to generate an appropriate anti-A.f. response and control fungal burden. 
 
 
4.3.2: Optimising the in vivo A.f. challenge model 
 
An in vivo A.f. infection protocol was established and optimised for use in our facility. 
The protocol used as a starting point was taken from a well-described model of A.f. in 
vivo challenge [100]. These experiments identified the most accurate and least 
variable method of quantifying A.f. fungal burden following in vivo A.f. challenge. This 
method required the extraction of fungal genetic material from lung homogenate and 
A.f. 18S rRNA quantification using qPCR. Fungal burden was calculated by comparing 
experimental samples against a standard curve. This protocol was confirmed as the 
most sensitive method of quantifying fungal burden after comparing multiple 
techniques against actual fungal burden identified by histological analyses [251]. The 
histological determination of fungal burden is costly and time consuming rendering 
this technique unusable for large sample numbers.  
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The above-mentioned protocol for quantifying A.f. fungal burden in vivo requires two 
main components; firstly, the generation of an accurate A.f. standard curve; and 
secondly, the sensitive extraction of fungal genetic material from lung tissue. Typically 
for A.f. in vivo challenge experiments, the extraction of fungal RNA from known 
concentrations of A.f. RC is used to generate an A.f. standard curve. Extracted fungal 
RNA is used to produce cDNA, which is analysed by qPCR alongside experimental 
samples [100, 174, 252]. The clinical method of diagnosing an A.f. infection from BAL 
also involves the extraction of fungal genetic material; however, fungal DNA is 
extracted and used for qPCR quantification [253]. In order to determine most sensitive 
method of generating an A.f. standard curve, the extraction of fungal RNA and fungal 
DNA was compared. 
 
The extraction of fungal genetic material from an infected-lung requires lung tissue 
and fungal cell walls to be vigorously disrupted. Lung A.f. fungal burden has been 
identified in fungal genetic material extracted via the blunt-crush method (manually 
grinding tissue with a pestle) and the homogenising method (using a tissue 
homogeniser for ~10 seconds at ~1200rpm). From this comparison, homogenising lung 
tissue resulted in a more sensitive RNA extraction. However, a noted drop in fungal 
burden at 24 hours was associated with the incomplete homogenisation of large 
hyphae [254]. This suggests both these methods do not fully disrupt tissue. Recently, 
0.5mm3 glass beads (Biospec) have been used to disrupt lung tissue and fungal cell 
walls increasing the yield of extracted fungal genetic material in clinical samples [255] 
and in vivo [256, 257]. In order to achieve high fungal burden assay sensitivity a 
comparison of homogenising A.f. against bead-beating A.f. to obtain fungal genetic 
material was completed.  
 
A.f. RC PBS solutions were generated at concentrations from 109 A.f. RC/ml to 102 A.f. 
RC/ml. To compare the extraction sensitivity of fungal RNA against fungal DNA, A.f. 
PBS solutions were homogenised (10 seconds at 1200rpm) and either fungal RNA or 
DNA extracted. Fungal RNA was used to generate cDNA before the A.f. 18S rRNA was 
quantified by qPCR. The A.f. 18S rRNA was quantified by qPCR directly in extracted 
fungal DNA samples. To compare whether tissue homogenisation or bead beating 
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yielded the most fungal genetic material, A.f. PBS solutions were homogenised (10 
seconds at 1200 rpm) or bead beat (4.5m/s for 4 x 30 seconds with 5 minutes at 4oC 
between cycles) before fungal RNA was extracted and the A.f. 18S rRNA quantified by 
qPCR. 
 
 
 
Figure 4.4: Extracting fungal RNA by bead beating is the optimum method of 
obtained fungal genetic material. A) A.f. fungal RNA and DNA were extracted from 
homogenised 109 to 102 A.f. RC in 1ml PBS using MasterPure RNA Purification Kit 
(Epicentre). Extracted fungal RNA was used to generate cDNA. The quantity of A.f. 18S 
rRNA was determined within extracted fungal DNA and generated cDNA samples by 
qPCR using a Taqman probe (Thermofisher). B) A.f. fungal RNA was extracted after 
homogenisation or bead beating with 0.5mm3 glass beads. Extracted fungal RNA was 
used to generate cDNA. The quantity of A.f. 18S rRNA was determined within 
generated cDNA samples by qPCR using a Taqman probe. This experiment was 
undertaken as part of the optimisation protocol. Data is representative of two 
independent experiments.  
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Figure 4.4 identifies extracting fungal RNA after bead beating tissue samples as the 
most sensitive method of obtaining fungal genetic material. Therefore, all standard 
curve samples and experimental samples were processed following this protocol.  
 
Ideally, the same A.f. standard curve would be used to analyse all in vivo experimental 
samples; however, A.f. standard curves are often produced alongside each experiment 
[258]. To address the long-term stability of A.f. extracted RNA a standard curve was 
produced and cDNA generated. The quantity of A.f. 18S rRNA was determined from 
this cDNA immediately by qPCR. The RNA sample was then stored for 12 weeks at -
80oC before being used to generate new cDNA and the A.f. 18S rRNA qPCR reaction 
was repeated. A HPRT control was used as a reference gene to calculate ΔΔCt for both 
qPCR experiments and allow the comparison of A.f. standard curve quantification 
values.  
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Figure 4.5: The A.f. standard curve degrades and loses sensitivity over time and 
through freeze-thaw cycles. A.f. fungal RNA was extracted from bead beat 109 to 102 
A.f. RC in 1ml PBS using MasterPure RNA Purification Kit (Epicentre). Extracted fungal 
RNA was used to generate cDNA. (Black line) The quantity of A.f. 18S rRNA was 
determined immediately within extracted fungal RNA samples by qPCR using a 
Taqman probe (Thermofisher). (Blue line) After the first, immediate qPCR reaction, 
fungal RNA was stored at -80oC for 12 weeks before fresh cDNA was generated and 
the quantity of A.f. 18S rRNA again determined by qPCR. A HPRT control was included 
on both qPCR plates to permit the ΔΔCt comparison of A.f. 18S rRNA Ct values. This 
experiment was undertaken as part of the optimisation protocol. Data is 
representative of one independent experiment. 
 
 
Figure 4.5 indicates A.f. extracted RNA degrades over time. Therefore, standard curves 
were newly generated alongside each experiment. Having identified the most 
sensitive method of extracting fungal genetic material, generating A.f. standard curves 
and quantifying fungal burden in vivo, the A.f. infection protocol was next optimised. 
The well described A.f. infection protocol as previously mentioned was again used as 
a starting point for our A.f. infection experiments [100].  
 
The A.f. intra-tracheal infection procedure required the A.f. PBS solution being 
pipetted in to the upper trachea of each mouse. If the pipette was placed too far down 
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the trachea, past the carina and accessing the bronchi, the A.f. solution may only 
inoculate one lung. In order to verify both lungs were being inoculated with A.f., mice 
were infected for 24 hours with 5x107 A.f. RC in PBS before both lungs were harvested 
and fungal burden quantified independently from each lung.  
 
Usually between 12-20 mice were used for A.f. infection experiments. Infected-lung 
samples were harvested sequentially but only processed once all samples had been 
obtained. The protocols that were optimised for our facility incubated extracted lung 
samples on ice until all samples were harvested and processed together [100, 174]. 
This often meant the first extracted lung sample would not be processed for 4-6 hours 
as the remaining lung samples were obtained. The duration samples remained 
unprocessed may impact the integrity of fungal RNA. Therefore, a comparison of 
sample collection in PBS or RNAlater was completed. RNAlater (Thermo Fisher 
Scientific, Massachusetts, USA) rapidly penetrates tissues and stabilises RNA in an 
intermediary solution preserving the integrity of RNA within tissues. Mice were 
infected for 24 hours with 5x107 A.f. RC in PBS before both lungs were harvested. Left 
lung was stored in PBS at 4oC for 24 hours before fungal RNA was extracted. Right lung 
was stored in RNAlater at RT for 24 hours before fungal RNA was extracted. Fungal 
burden was quantified from each lung in PBS and RNAlater.  
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Figure 4.6: A.f. fungal RNA can be extracted from right or left lung and stored in PBS 
or RNALater.  (A) Animals were infected with 5x107 A.f. RC for 24 hours before left and 
right lungs were harvested. A.f. fungal RNA was extracted from bead beat lung tissue 
using the MasterPure RNA Purification Kit (Epicentre). Extracted fungal RNA was used 
to generate cDNA and the quantity of A.f. 18S rRNA determined by qPCR. No significant 
difference was attained when quantifying fungal burden from left or right lung. (B) 
Animals were infected with 5x107 A.f. RC for 24 hours before left and right lungs were 
harvested. Right lung was collected in RNA later and stored for 24 hours at RT before 
A.f. fungal RNA was extracted. Left lung was collected in PBS at 4oC and stored for 24 
hours before A.f. fungal RNA was extracted. After incubation fungal RNA was extracted 
from bead beat lung tissue using the MasterPure RNA Purification Kit (Epicentre). 
Extracted fungal RNA was used to generate cDNA and the quantity of A.f. 18S rRNA 
determined by qPCR. No significant difference was attained when quantifying fungal 
burden from RNAlater stored left lung or PBS stored right lung. 6 mice were used for 
this experiment. This experiment was undertaken as part of the optimisation protocol. 
Graph displays mean +/- s.e.m.. (A) Data collated from 5 mice. (B) Data collated from 
6 mice. These experiments were completed once.   
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No significant difference was attained in figure 4.6 comparing the fungal burden 
quantified from left and right lung. This suggests the protocol technique was 
successfully inoculating both lungs with an equal dose of A.f.. For consistency, left lung 
was used in all future experiments to quantify fungal burden. No significant difference 
was attained in figure 4.6 when comparing the impact storing lungs in RNAlater or PBS 
had on the quantification of fungal burden. This implies fungal RNA is stable within 
lung tissue when stored in RNAlater at RT or PBS at 4oC for up to 24 hours. RNAlater 
was used for the temporary storage of left lung lobes in all future experiments 
quantifying A.f. fungal burden.  
 
 
4.3.3: What role do CLRs play in the anti-A.f. immune response in vivo? 
 
Having optimised the in vivo assay protocols, the role CLRs play in the anti-A.f. 
response in vivo could be investigated.  
 
Experiments were first designed to elicit the impact A.f. dose had on fungal burden 
and survival of WT, Dectin-1 KO and Mincle KO mice. Current literature describes a 
range of A.f. doses used to intra-tracheally infect and challenge in vivo. Doses as low 
as 5x106 and as high as 2x108 have been used [2, 259, 260]. The majority of 
experiments investigating the impact CLR KO or TLR KO have on the anti-A.f. immune 
response used doses in the region of 5x107 through to 9x107 [99, 100]. Therefore, 
initial experiments were completed using A.f. at a low dose 5x107, intermediate dose 
7x107 and high dose 9x107. WT, Dectin-1 KO and Mincle KO mice were infected with 
low, intermediate or high dose A.f. RC in PBS for 10 days. After 10 days (or before if 
mice reached humane end point, see scoring sheet in chapter 7.6) left lungs were 
harvested and fungal burden determined. 
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Figure 4.7: Increasing the dose of A.f. did not increase CLR KO mortality or fungal burden. WT, Dectin-1 KO and Mincle KO mice were 
infected with A) 5x107, B) 7x107 or C) 9x107 A.f. RC in PBS for 10 days before left lungs were harvested. A.f. fungal RNA was extracted 
from bead beat lung tissue using the MasterPure RNA Purification Kit (Epicentre). Extracted fungal RNA was used to generate cDNA and 
the quantity of A.f. 18S rRNA determined by qPCR. Each data point represents one mouse. Each column bar represents mean of results. 
Red data points indicate mice taken before the experiment end point. This experiment was undertaken as part of the optimisation 
protocol. A) Comprises of 5 WT, 5 Dectin-1 KO and54 Mincle KO mice. B) Comprises of 10 WT, 5 Dectin-1 KO and 5 Mincle KO mice. C) 
Comprises of 4 WT, 4 Dectin-1 KO and 4 Mincle KO mice. Each dose experiment was completed once. 
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Figure 4.7 demonstrates that increasing the infection dose of A.f. from 5x107 through 
to 9x107 decreased mortality and had no impact on fungal burden at 10-days. 
Independent of the A.f. dose used for infection, WT mice consistently displayed higher 
mortality than the Dectin-1 KO and Mincle KO mice. No Dectin-1 KO mouse succumbed 
to infection and only one Mincle KO mouse succumbed to infection whereas 7 WT 
mice succumbed to the infection. Here, the CLR KO models may be protective due to 
their impaired inflammatory response reducing the development of cytokine 
storm/sepsis disease, this is further discussed in 4.4.2. Fungal burden quantification 
indicated the A.f. infection had been cleared after 10 days irrespective of CLR status. 
Therefore, in order to ascertain the impact the A.f. dose has on fungal burden and the 
anti-A.f. chemokine and cytokine response, high 9x105 and low 5x105 dose 2-day 
experiments were completed.  
 
WT, Dectin-1 KO and Mincle KO mice were infected with low or high dose A.f. RC in 
PBS for 2 days. After 2 days (or before if the mice reached a humane end point, see 
scoring sheet in chapter 7.6) both lungs were harvested. Fungal burden was 
determined from the left lung and the anti-A.f. cytokine and chemokine response 
determined from the right lung. 
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Figure 4.8: The lower dose 5x107 A.f. infection model yields greater differences in chemokine 
and cytokine response between WT, Dectin-1 KO and Mincle KO mice without impacting 
fungal burden. WT, Dectin-1 KO and Mincle KO mice were infected with A) 5x107 or B) 9x107 
A.f. RC in PBS for 2 days before both lungs were harvested. A.f. fungal RNA was extracted from 
bead beat left lung tissue using the MasterPure RNA Purification Kit (Epicentre). Extracted 
fungal RNA was used to generate cDNA and the quantity of A.f. 18S rRNA determined by qPCR. 
Anti-A.f. cytokine and chemokine response was determined from homogenised right lung by 
ELISA. All cytokine/chemokine results are pg/ml. Each data point represents one mouse. Each 
column bar represents mean of results. Red data points indicate mice taken before the 
experiment end point. This experiment was undertaken as part of the optimisation protocol. 
A) Comprises of 6 WT, 6 Dectin-1 KO and 6 Mincle KO mice. B) Comprises of 3 WT, 3 Dectin-1 
KO and 3 Mincle KO mice. Each dose experiment was completed once.   
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The results displayed in figure 4.8 compare the high and low A.f. dose 2-day infection 
experiment. These data describe an increased fungal burden and greater cytokine and 
chemokine response difference between WT and CLR KO mice when the lower, 5x105 
A.f. dose was used.  
 
Having determined the optimal dose required to elicit differences between fungal 
burden and anti-A.f. cytokine and chemokine response in WT and CLR KO mice, 
experiments were completed using this protocol. Figure 4.8 displays preliminary 
results suggesting there are differences in the anti-A.f. response and fungal burden 
between WT and CLR KO mice at 48 hours. Therefore, initial experiments were 
completed at this time point.  
 
WT, Dectin-1 KO, Mincle KO, MD1 DKO and MD2 DKO mice were infected with 5x107 
A.f. RC in PBS for 2 days. After 2 days (or before if mice reached a humane end point, 
see scoring sheet in chapter 7.6) both lungs were harvested. Fungal burden was 
determined from the left lung and the anti-A.f. cytokine and chemokine response 
determined from the right lung. 
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Figure 4.9: Dectin-1 KO mice lack a robust anti-A.f. cytokine and chemokine response although this does not impair their A.f. clearance up to 48 
hours.  WT, Dectin-1 KO, Mincle KO, MD1 DKO and MD2 DKO mice were infected with 5x107 A.f. RC in PBS for 2 days before both lungs were harvested. 
A) A.f. fungal RNA was extracted from bead beat left lung tissue using the MasterPure RNA Purification Kit (Epicentre). Extracted fungal RNA was used 
to generate cDNA and the quantity of A.f. 18S rRNA determined by qPCR. B & C) Anti-A.f. cytokine and chemokine response was determined from 
homogenised right lung by ELISA. All cytokine/chemokine results are pg/ml. Each data point represents one mouse. Each column bar represents mean 
of results. Data is from 7 independent experiments containing different numbers of WT, CLR KO and CLR DKO mice. A one-way analysis of variance 
with Bonferonni’s post-test was used to determine statistical significance. *p<0.05, **p<0.005, ***p<0.0005. 
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The results displayed in figure 4.9 align with previously published work describing 
Dectin-1 KO’s impaired anti-A.f. cytokine and chemokine response in vivo [2, 100]. 
Dectin-1 KO mice significantly lack a robust cytokine and chemokine anti-A.f. response; 
however, in these experiments no significant difference was attained when 
quantifying fungal burden. Results from the other CLR KO or CLR DKO mice were not 
expected. Fungal burden between WT, CLR KO and CLR DKO was similar, suggesting all 
these mice irrespective of their CLR status cleared A.f. from the lung. This was not what 
we expected. The differences between CLR KO and CLR DKO are subtle; due to the low 
mice numbers it is difficult to draw firm conclusions from these experiments.  
 
As differences in the anti-A.f. cytokine and chemokine response had been attained at 
48 hours, an earlier 24-hour experiment was completed. At 24 hours the mice may not 
have cleared the A.f. infection, but due to their varying cytokine and chemokine 
response, differences in fungal burden may be present. 
 
WT, Dectin-1 KO, Mincle KO, MD1 DKO and MD2 DKO mice were infected with 5x107 
A.f. RC in PBS for 24 hours. After 24 hours (or before if mice reached a humane end 
point, see scoring sheet in chapter 7.6) both lungs were harvested. Fungal burden was 
determined from the left lung and the anti-A.f. cytokine and chemokine response 
determined from the right lung. 
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Figure 4.10: WT, CLR KO and CLR DKO mice all generate a robust anti-A.f. response and have partially cleared A.f. from the lung at 24 hours. WT, 
Dectin-1 KO, Mincle KO, MD1 DKO and MD2 DKO mice were infected with 5x107 A.f. RC in PBS for 24 hours before both lungs were harvested. A) A.f. 
fungal RNA was extracted from bead beat left lung tissue using the MasterPure RNA Purification Kit (Epicentre). Extracted fungal RNA was used to 
generate cDNA and the quantity of A.f. 18S rRNA determined by qPCR. B & C) Anti-A.f. cytokine and chemokine response was determined from 
homogenised right lung by ELISA. All cytokine/chemokine results are pg/ml. Each data point represents one mouse. Each column bar represents mean 
of results. N.D. represents no result detected. Data is from 6 independent experiments containing different numbers of WT, CLR KO and CLR DKO 
mice. A one-way analysis of variance with Bonferonni’s post-test was used to determine statistical significance.  
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Figure 4.10 displays no significant difference between the ability of WT, CLR KO and 
CLR DKO mice to generate an anti-A.f. cytokine and chemokine response. There is also 
no significant difference when comparing fungal burden between the WT, CLR KO and 
CLR DKO mice. Fungal burden at this time-point is low indicating these animals are 
clearing the infection rapidly.  
 
The Dectin-1 KO deficient response trend identified in figure 4.9 is present without 
significance in the 24-hour IL-6 response but is not conserved in the 24-hour 
chemokine response. The quantities of cytokine and chemokine produced from all WT, 
CLR KO and CLR DKO mice are reduced when compared to the later 48-hour results. 
Chemokine production is very tightly controlled and resolved abruptly upon 
completion of the immune response [261]. This, along with the fact fungal burden may 
increase from 24 to 48 hours suggests these mice are still actively responding to A.f..  
 
Although the significant differences between WT, CLR KO and CLR DKO mice anti-A.f. 
cytokine and chemokine response was not present at 24 hours, fungal burden was 
increased at this time point. In order to identify whether any fungal burden difference 
was at all present between WT, CLR KO and CLR DKO groups a 12-hour experiment 
was completed. 
 
WT, Dectin-1 KO and Mincle KO mice were infected with 5x107 A.f. RC in PBS for 12 
hours. After 12 hours (or before if mice reached a humane end point, see scoring sheet 
in chapter 7.6) both lungs were harvested. Fungal burden was determined from the 
left lung and the anti-A.f. cytokine and chemokine response determined from the right 
lung. 
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Figure 4.11: WT and CLR KO mice all generate a robust anti-A.f. response and have partially cleared A.f. from the lung at 12 hours. WT, Dectin-1 KO 
and Mincle KO mice were infected with 5x107 A.f. RC in PBS for 12 hours before both lungs were harvested. A) A.f. fungal RNA was extracted from 
bead beat left lung tissue using the MasterPure RNA Purification Kit (Epicentre). Extracted fungal RNA was used to generate cDNA and the quantity 
of A.f. 18S rRNA determined by qPCR. B & C) Anti-A.f. cytokine and chemokine response was determined from homogenised right lung by ELISA. All 
cytokine/chemokine results are pg/ml. Each data point represents one mouse. Each column bar represents mean of results. N.D. represents no result 
detected. Data is from 2 independent experiments containing different numbers of WT and CLR KO mice. A one-way analysis of variance with 
Bonferonni’s post-test was used to determine statistical significance.  
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Figure 4.11 displays no significant difference between the ability of WT and CLR KO 
mice to generate an anti-A.f. cytokine and chemokine response. There is also no 
significant difference when comparing fungal burden between the WT and CLR KO 
mice. Fungal burden at this time-point is lower than the fungal burden results attained 
for 24 hours and 48 hours infection. This indicates these animals rapidly clear a large 
quantity of A.f. before A.f. begins to germinate and replicate within the lung, 
increasing in number over a 48-hour period. Earlier experiments displayed in figure 4.7 
suggest A.f., after increasing in quantity up to 48 hours is cleared by 10 days.  
 
No significant difference in WT, CLR KO or CLR DKO mice fungal burden has been 
obtained at multiple time points. Although a significant Dectin-1 KO reduction of anti-
A.f. cytokine and chemokine response was identified at 48 hours, this had no bearing 
over the ability of mice to clear A.f.. This was not what we expected and not what 
published research suggests. The lack of impact Mincle KO has individually or alongside 
Dectin-1 was also not hypothesised. The reason underlining the differences between 
our in vivo A.f. model and other published research was not clear. Therefore, a 
different approach was taken aiming to align our model with that described in 
published research. Initially, the differences between WT, CLR KO and CLR DKO 
microbiomes were investigated as possibly being responsible for our unexpected 
results. 
 
 
4.3.4: What impact is the microbiome conferring over experimental results? 
 
Recently the impact of the microbiome on the development, maintenance and 
function of the immune response has begun to be understood [262, 263]. The 
homeostatic role the microbiome plays within the pulmonary immune system has also 
been investigated. In this setting the microbiome has been implicated to direct 
immune development and function and set the threshold for immune responses. A 
key role for the microbiome maintaining the balance between immune tolerance, 
acute lung inflammation and chronic lung inflammation was highlighted [264]. 
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Controlling and minimising the impact the microbiome has on WT and KO mice can 
reduce, or even nullify, a previously observed disease phenotype [265]. 
 
The mice used in the previous 48-hour, 24-hour and 12-hour experiments were males 
derived from separate genetic lineages. Males were not co-housed prior to, or 
throughout, experiments. Therefore, the impact each genotype’s microbiome may be 
bearing over their immune response was investigated. Addressing and rectifying any 
microbiome irregularities may restore the previously described Dectin-1 KO increased 
fungal burden. This would allow investigation into anti-A.f. response between WT, CLR 
KO and CLR DKO and may uncover novel fungal burden and anti-A.f. response 
differences. 
 
To address any microbiome discrepancies, male mice underwent a minimum of 2 
weeks of cage bedding swapping between the ages of 4-8 weeks when their 
microbiome retained plasticity [266]. This process involved moving mice between 
cages containing a WT, CLR KO or CLR DKO genotype without changing the bedding in 
that cage. This protocol is used routinely to address microbiome differences between 
groups of mice that are not co-housed. The transfer of microbiome from one genotype 
to another using this protocol has a profound impact on disease pathogenesis, in some 
cases resulting in the loss of a KO phenotype [265, 266].  
 
In order to examine the impact the microbiome confers over the previously displayed 
A.f. infection results, mice from each genotype were cohoused as described above 
before being used in A.f. infection experiments.  
 
After the co-housing protocol was completed for a minimum of 2 weeks, WT, Dectin-
1 KO, MD1 DKO and MD2 DKO mice were infected with 5x107 A.f. RC in PBS for 24 or 
48 hours. Mincle mice were not available for use in these experiments. After 24 or 48 
hours (or before if mice reached a humane end point, see scoring sheet in chapter 7.6) 
both lungs were harvested. Fungal burden was determined from the left lung and the 
anti-A.f. cytokine and chemokine response determined from the right lung. 
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Figure 4.12: Microbiome-controlled WT, CLR KO and CLR DKO mice all generate a robust anti-A.f. response and have partially cleared A.f. from the 
lung at 48 hours. WT, Dectin-1 KO, MD1 DKO and MD2 DKO mice were infected with 5x107 A.f. RC in PBS for 48 hours before both lungs were 
harvested. A) A.f. fungal RNA was extracted from bead beat left lung tissue using the MasterPure RNA Purification Kit (Epicentre). Extracted fungal 
RNA was used to generate cDNA and the quantity of A.f. 18S rRNA determined by qPCR. B & C) Anti-A.f. cytokine and chemokine response was 
determined from homogenised right lung by ELISA. All cytokine/chemokine results are pg/ml. Each data point represents one mouse. Each column 
bar represents mean of results. Data is from 2 independent experiments containing different numbers of WT, CLR KO and CLR DKO mice. A one-way 
analysis of variance with Bonferonni’s post-test was used to determine statistical significance.  
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Figure 4.13: Microbiome-controlled WT, CLR KO and CLR DKO mice all generate a robust anti-A.f. response and have partially cleared A.f. from the 
lung at 24 hours. WT, Dectin-1 KO, MD1 DKO and MD2 DKO mice were infected with 5x107 A.f. RC in PBS for 24 hours before both lungs were 
harvested. A) A.f. fungal RNA was extracted from bead beat left lung tissue using the MasterPure RNA Purification Kit (Epicentre). Extracted fungal 
RNA was used to generate cDNA and the quantity of A.f. 18S rRNA determined by qPCR. B & C) Anti-A.f. cytokine and chemokine response was 
determined from homogenised right lung by ELISA. All cytokine/chemokine results are pg/ml. Each data point represents one mouse. Each column 
bar represents mean of results. Data is from 2 independent experiments containing different numbers of WT, CLR KO and CLR DKO mice. A one-way 
analysis of variance with Bonferonni’s post-test was used to determine statistical significance.  
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Figure 4.12 and 4.13 display the results from microbiome controlled A.f. infection 
experiments. These two figures were compared with their respective non-
microbiome-controlled experiments described in figures 4.9 and 4.10. The quantity of 
cytokines and chemokines produced in the microbiome-controlled experiments were 
reduced when compared to non-microbiome-controlled experiments. Interestingly, 
the quantity of cytokines and chemokines produced in the non-microbiome-controlled 
experiments increased from 24 to 48 hours, suggesting the A.f. infection and immune 
response were active and increasing in magnitude. This trend was not present in the 
microbiome-controlled experiments, suggesting the infection and immune response 
were being rapidly cleared and resolved.  
 
Comparing fungal burden results from the microbiome and non-microbiome-
controlled experiments indicates that controlling the microbiome improves the ability 
of WT, CLR KO and CLR DKO to clear A.f. infection. Fungal burden results were 
consistently increased when the microbiome was not controlled. The previously 
identified Dectin-1 KO and MD1 DKO impaired cytokine and chemokine anti-A.f. 
responses were not conserved in the microbiome-controlled experiments.  
 
The microbiome-controlled experiment results displayed in figure 4.12 and 4.13 were 
not hypothesised. Furthermore, these results have not been previously identified in 
published research using similar A.f. infection models. Therefore, a different approach 
was again taken aiming to align our model with that described in published research. 
Finally, the differences between the gender of WT, CLR KO and CLR DKO mice was 
investigated as possibly being responsible for our unexpected results. 
 
 
4.3.5: What impact is gender conferring over experimental results? 
 
The genetic and hormonal difference between males and females of the same species 
and the subsequent impact this has on their immune response is well described [267-
269]. The immune response between males and females of the same species has been 
established to significantly differ when animals are challenged with LPS, self-antigen, 
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or foreign-antigen from fungi, bacteria and viruses [270]. In order to determine 
whether the sex of the mice was impacting our WT, CLR KO and CLR DKO A.f. infection 
results, 48-hour and 24-hour A.f. infection experiments were completed in females. 
To address any microbiome discrepancies within these experiments female mice were 
co-housed as previously described.  
 
After the co-housing protocol was completed for a minimum of 2 weeks, WT, Dectin-
1 KO, Mincle KO, MD1 DKO and MD2 DKO female mice were infected with 5x107 A.f. 
RC in PBS for 24 or 48 hours. After 24 or 48 hours (or before if mice reached a humane 
end point, see scoring sheet in chapter 7.6) both lungs were harvested. Fungal burden 
was determined from the left lung and the anti-A.f. cytokine and chemokine response 
determined from the right lung. 
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Figure 4.14: Microbiome-controlled female WT, CLR KO and CLR DKO mice all generate a robust anti-A.f. response and have partially cleared A.f. 
from the lung at 48 hours. WT, Dectin-1 KO, Mincle KO, MD1 DKO and MD2 DKO mice were infected with 5x107 A.f. RC in PBS for 48 hours before 
both lungs were harvested. A) A.f. fungal RNA was extracted from bead beat left lung tissue using the MasterPure RNA Purification Kit (Epicentre). 
Extracted fungal RNA was used to generate cDNA and the quantity of A.f. 18S rRNA determined by qPCR. B & C) Anti-A.f. cytokine and chemokine 
response was determined from homogenised right lung by ELISA. All cytokine/chemokine results are pg/ml. Each data point represents one mouse. 
Each column bar represents mean of results. Data is from 1 independent experiment containing different numbers of WT, CLR KO and CLR DKO mice. 
A one-way analysis of variance with Bonferonni’s post-test was used to determine statistical significance.   
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Figure 4.15: Microbiome-controlled female WT, CLR KO and CLR DKO mice all generate a robust anti-A.f. response but have not cleared A.f. from 
the lung at 24 hours. WT, Dectin-1 KO, Mincle KO, MD1 DKO and MD2 DKO mice were infected with 5x107 A.f. RC in PBS for 24 hours before both 
lungs were harvested. A) A.f. fungal RNA was extracted from bead beat left lung tissue using the MasterPure RNA Purification Kit (Epicentre). Extracted 
fungal RNA was used to generate cDNA and the quantity of A.f. 18S rRNA determined by qPCR. B & C) Anti-A.f. cytokine and chemokine response was 
determined from homogenised right lung by ELISA. All cytokine/chemokine results are pg/ml. Each data point represents one mouse. Each column 
bar represents mean of results. Data is from 1 independent experiment containing different numbers of WT, CLR KO and CLR DKO mice. A one-way 
analysis of variance with Bonferonni’s post-test was used to determine statistical significance.  
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Figure 4.15 displays our initially hypothesised fungal burden results; as CLRs are 
knocked-out fungal burden increases. However, this data is derived from a limited 
number of mice and is not significant. Figure 4.14 shows fungal burden decreasing 
from 24 to 48 hours suggesting these mice, independent of their CLR expression can 
clear the A.f. infection rapidly.  
 
The quantity of anti-A.f. cytokine and chemokines produced from female mice is 
similar to that obtained from male microbiome-controlled male experiments. The 
previously described Dectin-1 KO impaired cytokine and chemokine response was not 
conserved in the 48 hour female mice experiment displayed in figure 4.14. Female 
Dectin-1 KO mice may have a subtly reduced anti-A.f. cytokine and chemokine 
response at 24 hours, as displayed in figure 4.15, but this is not significant.  
 
It is clear the microbiome and gender of mice used in A.f. infection experiments has a 
key role controlling these mice anti-A.f. immune response. In order to clarify the 
impact gender and the microbiome conferred over our CLR KO and CLR DKO A.f. 
infection model, results from figures 4.9, 4.10, 4.12, 4.13, 4.14 and 4.15 were collated 
and analysed.  
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Increased at 48 hours 24 hours 
 
48 hours 
Decreased at 48 hours TNF IL-6 MIP-1 MIP-2 KC Fungal 
burden 
TNF IL-6 MIP-1 MIP-2 KC Fungal 
burden 
 
Male WT N.D. 1028 2688 8966 4374 1.31x107 2568 4579 12660 15603 9500 1.55x107 
Dectin-1 KO N.D. 383 2278 8830 4022 0.66x107 1049 2921 6649 6947 6079 1.18x107 
Mincle KO N.D. 1369 3702 7799 4158 0.83x107 3220 7244 12357 13835 8207 0.75x107 
MD1 DKO N.D. 484 2343 5431 1987 0.49x107 498 4062 12118 11693 11617 0.70x107 
MD2 DKO N.D. N.D. 1901 9303 4392 1.16x107 587 3707 10549 5655 8796 1.16x107 
 
Male  
microbiome-
controlled 
WT 175 521 840 1117 338 0.73x107 200 1164 588 151 69 0.63x107 
Dectin-1 KO 204 569 936 978 646 1.55x107 307 447 555 122 259 0.84x107 
MD1 DKO 314 524 604 1008 422 N.D. 299 799 753 254 265 N.D. 
MD2 DKO 195 923 947 1096 449 1.48x107 159 64 464 106 295 1.39x107 
 
Female  
co-housed 
WT 59 3010 577 5274 10661 1.05x107 131 165 1303 934 953 2.15x107 
Dectin-1 KO 79 1716 457 4051 7182 2.78x107 289 379 1582 1069 1238 2.95x107 
Mincle KO 54 3802 718 6399 15407 3.46x107 231 471 1326 851 840 1.17x107 
MD1 DKO 36 1398 500 4988 6894 2.84x107 35 228 919 827 837 1.01x107 
MD2 DKO 50 2338 232 4122 8066 2.55x107 69 412 1074 719 532 0.78x107 
 
Figure 4.16: Co-housing mice prior to A.f. infection radically alters the anti-A.f. cytokine and chemokine response and fungal burden. 
The data in this figure is collated from the experiments displayed in figure 4.9, 4.10, 4.12, 4.13, 4.14 and 4.15. The cytokine, chemokine 
and fungal burden values from each WT, CLR KO and CLR DKO experiment were averaged and added to this figure. All cytokine/chemokine 
results are pg/ml. Results highlighted in green indicate this value increased from 24 to 48 hours. Results highlighted in red indicate this 
value decreased from 24 to 48 hours. N.D. represents no result detected. See individual experiment figures for the number of independent 
experiments completed and mice used.  
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Figure 4.16 displays the large influence gender and the microbiome have on the 
capability of mice to generate robust anti-A.f. immune responses.  
 
Male mice that were not co-housed generated large anti-A.f. cytokine and chemokine 
responses that increased from 24 to 48 hours. This suggests these animals were 
actively responding against A.f. through to the 48-hour experiment end point. Fungal 
burden had not decreased at 48 hours indicating the infection was ongoing and not 
completely cleared. 
 
Results from the microbiome controlled male and female experiments were very 
different to the previously described male experiments. Co-housing mice resulted in 
much smaller anti-A.f. cytokine and chemokine responses at 24 hours; this response 
had typically decreased by 48 hours. Fungal burden in both co-housed males and co-
housed females mainly reduced from 24 to 48 hours. This suggests these mice 
generated an appropriate immune response that led to A.f. clearance. At 48 hours A.f. 
fungal burden was similar or reduced and the anti-A.f. cytokine and chemokine 
response had begun to resolve.  
 
In order to highlight the stark difference co-housing mice and using male and female 
mice had the anti-A.f. cytokine and chemokine response, data collated in figure 4.16 
was graphically displayed. The anti-A.f. MIP-1 response at 24 hours and 48 hours was 
displayed for male, male microbiome-controlled and co-housed female mice of each 
WT, CLR KO and CLR DKO genotype. 
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Figure 4.17: Co-housing animals to control the microbiome prior to A.f. infection drastically alters anti-A.f. MIP-1 response. A) The data 
in this figure is collated from the experiments displayed in figure 4.9, 4.10, 4.12, 4.13, 4.14 and 4.15. The MIP-1 pg/ml response values 
from each WT, CLR KO and CLR DKO experiment were added to this figure. Graph displays mean +/- s.e.m. See individual experiment 
figures for the number of independent experiments completed and mice used.  
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Figure 4.17 highlights the challenges identified aiming to determine the impact CLR KO 
and CLR DKO has on the anti-A.f. immune response. Although initial experiments were 
promising, the results obtained in figures 4.9 and 4.10 were not expected. When 
examining the influence each genotype’s microbiome may confer over the anti-A.f. 
immune response a drastic alteration of results was attained. When examining the 
gender of mice used for CLR KO and CLR DKO A.f. infection experiments, a similarly 
drastic alteration of results was attained. This role the microbiome and gender of mice 
has on their ability to respond against A.f. has not been published. Here, we show both 
these factors have a crucial role influencing the anti-A.f. response. Unfortunately, the 
requirement for Dectin-1, Dectin-2 and Mincle expression and signalling was not 
determined. Before these experiments could be accurately and appropriately 
completed, a better understanding of microbiome and gender influence is required. 
Here, I describe the ability of immune-competent mice to clear A.f. infection 
irrespective of CLR status. In order to identify the true role of CLRs during A.f. infection 
mice may have to be immune-suppressed. 
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4.4: Discussion 
 
 
The aims of this chapter were centered on identifying the importance of CLRs when 
generating anti-A.f. immune responses. Initially, I aimed to elicit the impact CLR 
expression had on the ability of alveolar macrophages to respond against A.f.. Once 
these experiments were completed, a well-described in vivo model of A.f. infection 
was optimised for our facility before being used to infect WT, CLR KO and CLR DKO 
mice. Only Dectin-1 has a defined role during alveolar macrophage anti-A.f. responses 
and during in vivo A.f. challenge. The role of Dectin-2 and Mincle during the anti-A.f. 
alveolar macrophage and in vivo response are unknown. 
 
I was particularly interested in identifying CLR collaboration within this model. I 
hypothesised that CLRs collaboratively recognise and respond to A.f. enhancing the 
immune response. This project aims to describe anti-A.f. immune-enhancing CLR 
collaboration that could be therapeutically boosted to improve the anti-A.f. response 
resulting in clearance of A.f. disease. 
 
 
4.4.1: What role do CLRs play in the alveolar macrophage anti-A.f. response? 
 
Alveolar macrophages act as the first responder during A.f. infection. A.f. RC are 
regularly inhaled and rapidly cleared without pathology by alveolar macrophages. The 
efficient recognition and phagocytosis of inhaled A.f. RC is exclusively undertaken by 
lung-resident alveolar macrophages [1, 87, 250].  
 
Dectin-1 has a clearly described role on macrophages during the anti-A.f. immune 
response. Research has demonstrated the murine peritoneal macrophage 
phagocytosis of A.f. SC and EG required Dectin-1. Blocking Dectin-1 using antibody 
significantly reduced A.f. phagocytosis in these experiments [98]. RAW 264.7 
macrophages over-expressing Dectin-1 generated a significantly increased cytokine 
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and chemokine response when stimulated for 24 hours with A.f. This increased 
response from over-expressed Dectin-1 could be completely abrogated with the 
addition of 2A11 blocking antibody [2]. The requirement for Dectin-1 expression on 
alveolar macrophages during anti-A.f. responses is also well described. When A.f. was 
incubated with alveolar macrophages from WT and Dectin-1 KO mice for 24 hours an 
80% decrease in cytokine and chemokine response was attained from Dectin-1 KO 
alveolar macrophages [2]. Here, the Dectin-1 KO A.f. cytokine and chemokine response 
(displayed in figure 4.3) aligns with published research highlighting the importance of 
Dectin-1 expression on alveolar macrophages. Lacking Dectin-1 expression 
significantly impairs the early anti-A.f. inflammatory response. The impact Mincle and 
Dectin-2 convey on the alveolar macrophage anti-A.f. response is not well described.  
 
The expression of Mincle on alveolar macrophages is poorly defined. However, Mincle 
expression is well described on macrophages and neutrophils in response to several 
inflammatory stimuli including LPS, TNF and IFN-γ [271, 272]. Mincle expression on 
alveolar macrophages has been induced after stimulation with Mycobacterium bovis 
bacillus Calmette-Guérin. The induction of Mincle in these experiments was very 
delayed and often required >24 hours of alveolar macrophage stimulation [192]. Here, 
I have shown, in figure 4.2, that Mincle expression is induced on alveolar macrophages 
by stimulating with 2μg/ml LPS for 4 hours.  
 
The role of Mincle during the alveolar macrophage anti-A.f. response has not been 
identified. The receptor binds fungal pathogens and induces intracellular signalling 
culminating in the production of cytokines and chemokines including TNF, IL-6, MIP-1, 
MIP-2 and KC [136]. Some research has elicited a pro-inflammatory role for Mincle on 
alveolar macrophages; stimulating Mincle KO alveolar macrophages with TDM 
resulted in a significantly impaired TNF, MIP-2 and KC response [192]. Here a similar 
pro-inflammatory role for Mincle expressed on alveolar macrophages during the anti-
A.f. response was not identified. My experiments show the Mincle KO anti-A.f. 
cytokine and chemokine response was not significantly different to the response from 
WT mice. These experiments also included a Mincle Dectin-1 DKO model. The Dectin-
1 KO impaired anti-A.f. cytokine and chemokine response is conserved within the MD1 
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DKO. This further suggests Mincle KO has a limited impact on the ability of alveolar 
macrophages to recognise and produce anti-A.f. responses during early A.f. infection.  
 
An immune evasion role for pathogens engaging Mincle has been described. The 
fungal pathogen Fonsecaea monophora engages Mincle to avoid interaction with 
Dectin-1 and a subsequent pro-inflammatory response. Engaging Mincle results in the 
induction of the E3 ubiquitin ligase Mdm2-dependent degradation pathway. This 
culminates in the loss of IRF1 impairing the pro-inflammatory immune response [157]. 
An evasion role for A.f. engaging Mincle is not present in my alveolar macrophage 
response results. Mincle KO does not increase the anti-A.f. cytokine and chemokine 
response. Mincle KO does not alter the Dectin-1 KO impaired cytokine and chemokine 
response when both receptors are knocked-out together.  
 
The expression of Dectin-2 on alveolar macrophages has not been clearly described. 
Dectin-2 expression was identified on large, scattered lung cells but these cells were 
CD11clow. The majority of CD11chigh lung cells did not express Dectin-2 [176]. Murine 
alveolar macrophages are typically defined by CD11chigh expression [273]. Dectin-2 
expression at mRNA level in alveolar macrophages has been described although the 
presence of the receptor at the cell surface was not confirmed [178]. Here, (as shown 
in figure 4.2) I show that Dectin-2 expression is induced on alveolar macrophages 
stimulated with 2μg/ml LPS for 4 hours. 
 
The role of Dectin-2 during the early, alveolar macrophage driven anti-A.f. response is 
not described. However, the receptor has been implicated in the neutrophil and 
monocyte derived, later anti-A.f. response. Dectin-2 recognises hyphal morphologies 
of A.f. and is essential when producing robust cytokine and chemokine responses 
against A.f. HY [185]. Therefore, it is possible that the impact that Dectin-2 has in the 
alveolar macrophage-driven early A.f. response may be minimal [183].  
 
A role for Dectin-2 expression on alveolar macrophages has been described in a house 
dust mite ex vivo model. The release of cysteinyl leukotrienes (potent inflammatory 
lipid mediators associated with allergic inflammation) following house dust mite 
	 177	
challenge was dependent on alveolar macrophage Dectin-2 expression. Interestingly, 
stimulating alveolar macrophages with house dust mite also resulted in the production 
of TNF and KC but this was independent of Dectin-2 [274]. Here, while I did not have 
access to alveolar macrophages from Dectin-2 KO, I show that Mincle Dectin-2 DKO do 
not display any defects in cytokine and chemokine production. This suggests Dectin-2 
is not required for the early anti-A.f. immune response and may only be important if 
A.f. persists and germinates into HY. 
 
Here I clearly demonstrate our Dectin-1 KO alveolar macrophage A.f. experiments 
align with published research. My results describing the limited impact Dectin-2 
expression has on the alveolar macrophage anti-A.f. response was expected. Dectin-2 
likely plays a role during the later anti-A.f. response against extensively developed A.f. 
infections. The role of Mincle during alveolar macrophage anti-A.f. responses appears 
to be minimal. 
 
 
4.4.2: What roles do CLRs play in the anti-A.f. immune response in vivo? 
 
The role of CLRs during the complicated and multi-faceted in vivo anti-A.f. response is 
not well described. The experiments completed and results displayed in figures 4.9, 
4.10 and 4.11 were based on similar experiments used to identify the importance of 
Dectin-1 during in vivo A.f. infection. This protocol challenged mice with the same dose 
as my experiments, 5x107 A.f. RC, for 5 days, 48 hours and 24 hours. In these 
experiments Dectin-1 KO mice experienced significantly decreased survival, 
significantly impaired anti-A.f. cytokine and chemokine responses and significantly 
increased lung fungal burden [100]. The impact Mincle and Dectin-2 have during A.f. 
in vivo challenge has not been identified.  
 
An anti-fungal in vivo role for Mincle has been described. Mincle enhances in vivo 
Candida albicans infection clearence. When Mincle KO mice were intravenously 
challenged with Candida albicans a significant increase in kidney fungal burden was 
obtained; however, this did not result in decreased survival at 5 days. Increased fungal 
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burden was thought to arise from an impaired TNF inflammatory response produced 
by Mincle KO mice [190]. The role Dectin-2 plays during in vivo fungal challenge has 
also been described. Dectin-2 KO mice were more susceptible to systemic Candida 
albicans infection, generating an impaired pro-inflammatory immune response and 
possessing an elevated fungal burden in the kidney [180]. Dectin-2 KO mice also 
produced an impaired pro-inflammatory response when challenged with 
Pneumocystis lung infection [275]. 
 
Here, the anti-A.f. cytokine and chemokine results shown in figure 4.9 align with 
previous research clarifying the importance of Dectin-1 during in vivo A.f. challenge. A 
significant reduction in TNF, MIP-1 and MIP-2 response was observed at 48 hours from 
Dectin-1 KO mice. However, no significant difference was attained between WT and 
Dectin-1 KO fungal burden. Contrary to published research, our model suggests high 
Dectin-1 redundancy in vivo in this immune-competent model. Although Dectin-1 KO 
mice lack a robust cytokine and chemokine response, they still efficiently clear A.f.. 
 
Figure 4.10 displays the 24-hour A.f. infection results in which the Dectin-1 KO 
impaired cytokine and chemokine response is not present. This was not expected and 
may arise from the large, single dose of A.f. masking early, subtle CLR-dependent 
differences. At 24 hours Dectin-1 KO fungal burden appears to be lower than WT 
fungal burden. A very robust anti-A.f. response in WT mice may impair their early 
fungal clearance. The reduced cytokine and chemokine response exhibited by Dectin-
1 KO mice is potentially, in this model at least, protective.  
 
Further to WT mice possessing increased 24-hour fungal burden, WT mice also 
experienced decreased survival in figure 4.7. The robust cytokine and chemokine 
response of WT mice may lead to systemic inflammatory response syndrome or sepsis 
culminating in mice succumbing to the resulting pathology [276, 277]. A recent 
publication suggests infection with higher doses of A.f. results in efficient fungal killing; 
lower A.f. doses increase the likelihood of developing persistent, invasive disease 
[278]. This may explain the reduced survival elicited from mice infected with lower 
doses of A.f. shown in figure 4.7. 
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Here, in figures 4.9, 4.10 and 4.11 I describe the ability of Mincle KO mice to 
successfully respond to and clear A.f. infection. Unlike Mincle’s pro-inflammatory role 
during Candida albicans infection, Mincle KO mice did not possess significantly 
increased or decreased anti-A.f. cytokine or chemokine response at 12, 24 or 48 hours. 
However, the earlier mentioned Mincle KO reduced TNF response against Candida 
albicans was attained from BMDMs and not in vivo experiments. Mincle does not 
appear to have a role in controlling A.f. fungal burden, as was found in the Candida 
albicans in vivo experiments [190].  
 
I can also speculate Dectin-2 has a limited role during in vivo A.f. infection. The Dectin-
2 KO model was not available so all Dectin-2 results are extrapolated from MD2 DKO 
mice. As mentioned, Mincle does not play a significant role during A.f. in vivo infection. 
The results from MD2 DKO suggest Dectin-2 also does not contribute to the anti-A.f. 
cytokine and chemokine response and has limited impact controlling A.f. fungal 
burden. No significant change in results was obtained with MD2 DKO mice. Either 
Dectin-2 does not play a crucial role, or Mincle KO when alongside Dectin-2 KO 
restores the immune response back to WT levels. The subtle or lack of CLR importance 
may be due to the immune-competent model used here. Immune-suppressing mice 
may identify much clearer CLR roles.   
 
CLRs likely collaborate during the anti-A.f. response, I hypothesised this collaboration 
enhances the immune response and promotes A.f. clearance. Many examples of CLR 
TLR collaboration have been described. Dectin-1 collaborates with TLR2 and TLR4 to 
enhance LPS and Pam3CSK4 cytokine responses [279], Dectin-1, mannose receptor 
and TLR2 collaborate to enhance inflammatory responses and drive TH17 immunity 
against Paracoccidioides brasiliensis [280] and Mincle and TLR collaborative signalling 
results in clearance of Fonsecaea perdrosi infection [187]. These examples of CLR TLR 
signalling highlight the importance of receptor collaboration during immune 
responses. Recently, a similar collaboration involving multiple CLRs was identified. 
Dectin-1 and Dectin-2 collaboratively promote control of Trichophyton rubrum. Both 
CLRs were demonstrated to recognise the fungal pathogen and were required for 
robust TNF, IL-1β, IL-10 and IL-6 responses. Dectin-1 and Dectin-2 DKO impaired fungal 
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clearance to a greater extent than the sum of individually lacking both CLRs [221]. CLR 
collaboration when recognising and responding to A.f. infection has not been 
described; although, the complex anti-A.f. response likely requires CLR collaboration. 
 
Interestingly, the significantly impaired anti-A.f. cytokine and chemokine response 
identified in Dectin-1 KO and MD1 DKO alveolar macrophages was not conserved 
within the in vivo A.f. infection. Only the Dectin-1 KO impaired response was 
maintained in the in vivo infection results. This suggests a pro-inflammatory role for 
Mincle during the anti-A.f. cytokine and chemokine response in vivo. However, this 
role may be complicated, Mincle KO alone does not alter the anti-A.f. response. Here, 
I describe a protective role for Mincle KO recovering the Dectin-1 KO impaired anti-
A.f. cytokine and chemokine response in MD1 DKO mice.  
 
Mincle may act as an A.f. immune evasion target in a similar mechanism to Fonsecaea 
monophora [157]. The A.f. engagement of Mincle may aid the evasion of pro-
inflammatory responses. When Mincle is knocked out, A.f.-Mincle evasion cannot 
occur and the pro-inflammatory response is restored. This may be the mechanism by 
which Mincle KO recovers the Dectin-1 KO impaired anti-A.f. pro-inflammatory 
responses. However, an enhanced anti-A.f. response is not present in Mincle KO 
suggesting the reason MD1 DKO responds robustly to A.f. when Dectin-1 KO does not, 
may be more complicated than this. 
 
The results displayed in figures 4.9 through 4.11 begin to describe the complex role 
each CLR plays in the collaborative and complex anti-A.f. response. However, the A.f. 
fungal burden results and anti-A.f. cytokine and chemokine results from these 
experiments were not expected. Dectin-1 KO mice only produced an impaired cytokine 
and chemokine response after 48 hours and this did not impact their ability to clear 
A.f. infection. No other CLR KO or CLR DKO produced an enhanced or impaired anti-
A.f. response. The fact WT mice experienced the highest mortality was also not 
expected. Therefore, the impact the microbiome may be conferring over WT, CLR KO 
and CLR DKO mice ability to mount an immune response was examined.  
 
	 181	
 
4.4.3: What impact was the microbiome conferring over the ability of WT, CLR KO 
and CLR DKO mice to generate immune responses against A.f.? 
 
The role the microbiome controls over the development, function and threshold of 
immune response is starting to be understood [262, 263]. The microbiome directs 
immune development and function and sets the threshold for immune responses. An 
important homeostatic role for the microbiome maintaining the balance between 
immune tolerance, acute lung inflammation and chronic lung inflammation has been 
described [264]. Controlling and minimising microbiome variation between mice can 
reduce, or even nullify, a previously observed disease phenotype [265]. The 
experiment results displayed in figures 4.12 and 4.13 suggest controlling the WT, CLR 
KO and CLR DKO microbiome through co-housing mice dramatically alters the anti-A.f. 
response in these animals. 
 
The results from figure 4.12 and 4.13 are summarised alongside non-microbiome 
controlled experiments in figure 4.16 and 4.17. These figures describe the decreased 
fungal burden and reduced anti-A.f. cytokine and chemokine response attained from 
microbiome-controlled experiments. Controlling the microbiome appears to impact 
the duration of the anti-A.f. response. Non-microbiome-controlled WT, CLR KO and 
CLR DKO mice possessed higher fungal burden and produced greater quantities of 
cytokines and chemokines at 48 hours. Controlling the microbiome appears to 
enhance A.f. clearance as WT, CLR KO and CLR DKO mice fungal burden was reduced 
at 48 hours and their inflammation was resolving.  
 
Here, in the experiments displayed in figures 4.12 and 4.13, I demonstrate the 
profound impact altering the microbiome can have on the host immune system and 
disease susceptibility. The results attained from controlling the microbiome align with 
other research highlighting the dramatic implications the microbiome can convey 
during immune responses. An example of this was described within a Clostridium 
difficile infection model. Mice lacking one single gut bacteria (often destroyed by the 
therapeutic administration of a specific antibiotic class) were highly susceptible to a 
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resistant strain of C. difficile. When this bacterium was added back into the 
microbiome a dramatic reduction in susceptibility to C. difficile infection was attained 
[281]. A similar mechanism may be present in my experiments. Upon switching the 
bedding from WT, CLR KO and CLR DKO mice around each cage, I may have introduced 
new bacteria into the gut of mice that resulted in an enhanced anti-A.f. response and 
promotion of A.f. clearance. 
 
Furthermore, CLRs play a role within gut immunity contributing to the maintenance 
and homeostasis of the microbiome. The CLRs I am investigating are present on many 
gut-resident cells [282]. Many of these cells are responsible for controlling intestinal 
infections [283]. Therefore, although forcibly controlling the microbiome radically 
alters the anti-A.f. immune response, the microbiome differences between WT, CLR 
KO and CLR DKO may naturally result from their CLR expression impacting their gut 
immunity. 
 
Controlling the microbiome did drastically alter the anti-A.f. immune response; 
however, not in the way I expected or hypothesised. This moved the Dectin-1 KO 
results further away from published research. Therefore, the impact the gender of WT, 
CLR KO and CLR DKO mice had on the anti-A.f. response was examined. 
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4.4.4: What impact was gender conferring over the ability of WT, CLR KO and CLR 
DKO mice to generate immune responses against A.f.? 
 
Gender has a significant influence on the generation of anti-fungal immune responses 
[270]. This is thought to be associated with the genetic and hormonal differences 
between males and females [267]. Here, the experiments displayed in figure 4.14 and 
4.15 align with this research, as the female anti-A.f. response is very different to the 
male and male microbiome-controlled experiments.  
 
Interestingly, the fungal burden results obtained from female mice at 24 hours agree 
with our initial hypothesis that as more CLRs are knocked out fungal burden increases. 
At 48 hours, inflammation had started to resolve and aside from WT mice, fungal 
burden was similar or had decreased. This suggests female mice may clear A.f. more 
efficiently than males. Research examining the influence of age and gender when mice 
were challenged with Crytococcus neoformans concluded female mice produce more 
robust immune responses and experience increased survival when compared to male 
mice. Interestingly, young male mice (6-8 weeks) possessed the shortest survival and 
highest infection burden [284]. The mice used for my in vivo A.f. challenge experiments 
were 8-12 weeks of age. 
 
The Dectin-1 KO impaired chemokine response may be subtly present at 24 hours, 
however; the low number of mice used reduces the female experiment results power. 
At 48 hours the chemokine response was similar across all WT, CLR KO and CLR DKO 
mice. The significant Dectin-1 impaired 48-hour chemokine response attained in males 
was not present in females. As previously described in males, WT mice possessed the 
highest fungal burden at 48 hours. This is potentially due to their robust response 
inhibiting A.f. clearance. Female mice were co-housed before being used in 
experiments. As with the male microbiome-controlled experiments, this may have 
radically altered their anti-A.f. response. 
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4.5: Conclusions  
 
 
The results displayed in these experiments highlight the complex and poorly 
understood anti-A.f. immune response. Alveolar macrophages require Dectin-1 to 
appropriately recognise and respond to A.f.. Dectin-2 and Mincle may not be involved 
in the early, alveolar macrophage driven anti-A.f. response. The response in vivo is 
much more difficult to interpret. The microbiome may have an important role defining 
the capability of each animal’s anti-A.f. response. The microbiome appears to 
modulate the anti-A.f. cytokine and chemokine response irrespective of CLR status or 
gender; ultimately impacting how efficiently A.f. infections are cleared.  
 
My experiments identified no significant difference in fungal burden between WT, CLR 
KO and CLR DKO mice. This suggests high levels of CLR redundancy during the anti-A.f. 
response in an immune-competent model. However, an interesting role for Mincle 
recovering the Dectin-1 impaired anti-A.f. cytokine and chemokine response has been 
identified. This recovery does not involve Mincle’s alveolar macrophage action but 
likely requires Mincle’s presence and anti-A.f. impact on other cell types. Here, 
alongside the microbiome, I also show the gender of the animal has an impact on the 
anti-A.f. response. Female mice cleared the A.f. infection faster than male mice; 
however, initially hypothesised differences between WT, CLR KO and CLR DKO fungal 
burden were identified in females at 24 hours.  
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4.6: Further experiments 
 
 
The clinical course of A.f. infection typically involves a high level of immune-
suppression, low dose inoculation and A.f. growth resulting from an impaired immune 
response. This is very different to the single, high-dose A.f. infection model used for 
the experiments described in this chapter. Switching to an immune-suppression A.f. 
infection in vivo model involving a low-dose A.f. infection and extensive A.f. growth 
within the lung may more closely reflect clinical disease course. An immune-
suppression model may also exacerbate the subtle differences I have identified 
between WT, CLR KO and CLR DKO mice anti-A.f. response. The course of infection 
during an immune suppression model would permit longer experiments and A.f. 
growth, not simply a robust A.f. immune response leading to rapid clearance. This may 
help attain differences between WT, CLR KO and CLR DKO fungal burden. 
 
In order to identify the mechanism by which MD1 DKO recovers the Dectin-1 KO 
deficient anti-A.f. cytokine and chemokine response, the influx of cells into the lung 
could be examined alongside the ability of those cells to respond against A.f.. 
Determining the Mincle-expressing cell-type with the ability to recover the Dectin-1 
deficient response may be very interesting. This cell-type may provide a therapeutic 
target enhancing the anti-A.f. response. 
 
Here, I begin to describe the important impact the microbiome has in controlling host 
immunity in the lung, but only in males. In order to identify the role of the microbiome 
in females, experiments without co-housing females could be completed. 
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Chapter 5 
 	
Using CLR status and functional response capability to stratify 
haematology patients according to their A.f. disease susceptibility 
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5.1: Aims 
 
I. Determine patient’s CLR status 
 
II. Determine patient’s functional immune response capability 
 
III. Identify novel risk factors that can be used to stratify patients according to their 
A.f. disease susceptibility  
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5.2: Introduction 
 
 
Before the clinical use of immune suppressing therapeutics, A.f. infections were 
uncommon and rarely serious. Typically, a mild allergic-type disease would present 
after the repeated and regular inhalation of A.f. spores. Only individuals with pre-
existing lung cavities that were exposed to high doses of A.f. would experience A.f. 
growth within the lung; however, even in this scenario A.f. could not grow outside of 
the cavity and cause serious disease. As the use of immune suppressing therapeutics 
has become more prevalent, the incidence of serious and invasive A.f. infections has 
increased [1].  
 
The immune response against A.f. is rapid and robust; however, when the anti-A.f. 
immune response is impaired, A.f. growth and disease may ensue. Two different types 
of immune suppression give rise to two different A.f. disease courses. Patients with 
cancers including AML often become neutropenic during chemotherapy and 
radiotherapy treatments. Neutropenia is a significant risk factor for developing A.f. 
infections [7]. Neutropenic patients with A.f. infections are subject to systemic, 
invasive A.f. disease [285].  
 
Patients undergoing corticosteroid therapy for graft versus host disease experience a 
different A.f. disease course. These patients do not lack immune cells but their anti-
A.f. immune response is impaired. For example, macrophages treated with 
corticosteroids display significantly reduced A.f. RC phagocytosis [14]. Corticosteroid 
therapy patients contain A.f. infections within the lung but suffer from chronic lung 
inflammation. This often results in scarring, lung fibrosis and a reduced lung capacity. 
 
Current diagnostic and therapeutic clinical tools used for A.f. infections are 
insufficient. Patients are diagnosed with a proven A.f. infection only when histological 
evidence is available, probable disease relies on radiological changes and biomarkers. 
The diagnostic procedure is often a slow process with inaccurate results and many 
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patient’s A.f. infections are only confirmed post-mortem [286]. Poor A.f. infection 
diagnosis culminates in the widespread empirical use of anti-fungal therapies at the 
first suspicion of infection. Therefore, many patients are inappropriately treated with 
anti-fungal therapies. PCR and galactomannan ELISA can be used to screen patients at 
high risk where negative tests can be used to rule out A.f. infection and multiple 
positive results can suggest A.f. infection [287-289]. 
  
Currently used anti-fungal therapeutics are inadequate to deal with complex patient’s 
fungal disease. Voriconazole and liposomal amphotericin B are the most frequently 
used therapeutics for A.f. infection. These drugs are toxic to the liver and kidneys, 
adversely interact with other drugs and acquisition costs are high [59]. Furthermore, 
some A.f. strains have become resistant to azole treatment [290]. The widespread use 
of prophylactic and empirical anti-fungal treatment and the complex issues this 
causes, suggest a better approach to diagnosis and treatment is required.  
 
Stratifying patients according to their risk of developing A.f. infections would reduce 
unnecessary treatment, limit further fungal resistance and allow low risk patient’s 
primary disease treatment to be prioritised. Currently, neutropenia is the only widely 
accepted risk factor for the development of A.f. infections. Identifying more risk 
factors may further aid patient stratification. I aim to investigate associations between 
the incidence of IA and patient’s CLR status and patient’s functional immune response 
capability.  
 
Many CLRs integral to anti-fungal immunity signal using the CARD9 complex, 
individuals possessing mutated CARD9 are at significantly greater risk of developing 
invasive fungal infections [159]. Individuals with mutated Dectin-1 are at risk of 
developing invasive fungal infections even without immune suppression [291]. The 
Dectin-1 mutation Y238X, leading to an early stop codon and truncated Dectin-1, has 
been associated with an increased susceptibility to A.f. infection in hematopoietic 
transplant patients [292]. Y238X Dectin-1 resulted in an impaired peripheral 
mononuclear cell IFN-γ, IL-10, IL-1β, IL-6 and IL-17A response [293]. Recently, 
mutations in Dectin-1 and DC-SIGN, respiratory viral infection, allogeneic stem cell 
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translation and A.f. PCR positivity were used to stratify patients in a predictive disease 
model. Patients with no risk factors had a 2.4% probability of developing an A.f. 
infection whilst patients with four or more risk factors had a 79% probability of 
developing an A.f. infection. This study begins to identify patient stratification risk 
factors permitting the implementation of a personalised medicine approach [67]. 
 
Here, I aim to examine the expression levels of Dectin-1, Dectin-2, Mincle and Mcl and 
determine the prevalence of mutations in these CLRs. Identifying correlation between 
CLR expression or mutation and the incidence of A.f. disease may identify novel risk 
factors. Currently, CLR status has not been linked to an increased susceptibility to A.f. 
disease beyond the previously described Dectin-1 and DC-SIGN mutations. It may also 
be possible to identify patient’s CLR co-expression and determine whether this 
impacts A.f. disease susceptibility. 
 
I also aim to determine the ability of patient’s PBMCs to respond to inflammatory 
stimuli; this has not been used to stratify patients before. If successful, these CLR 
expression and functional assays may be used in healthcare centers to stratify patients 
according to their A.f. disease susceptibility. This would permit a personalised 
medicine approach to treating A.f. disease in complex haematology patients. 
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5.3: Results 
 
 
A prospective cohort of 43 patients with haematological malignancies admitted for 
stem cell transplantation (23 patients) or remission-induction therapy for AML (19 
patients) were studied. Of the 23 SCT patients included in this study, 5 developed 
proven IA and 1 developed probable IA. Of the 19 AML patients included in this study 
4 developed proven IA.  
 
Blood samples collected in PAXgene blood RNA tubes and EDTA tubes were 
transferred to the laboratory within 24 hours. Patients were screened throughout 
their hospital stay for IA using Aspergillus PCR and galactomannan Platelia assay [288]. 
IA was diagnosed using EORTC/MSG criteria [294]. See 2.1.3 for ethical approval 
statement.  
 
The results throughout this chapter include varying numbers of patients. Due to 
limited sample for some patients, not all CLR status and functional results were 
determined for each patient. Patient 18’s blood samples were not processed. CLR 
expression results were not attained from five patients; four of these were SCT and 
one AML. Functional results were not attained from two patients; these were both 
AML. 
 
 
5.3.1: Determination of patient CLR status 
 
CLRs are crucial for anti-fungal immune responses. The requirement for CARD9 
complex signalling and Dectin-1 signalling during A.f. infection has been well 
described. Similar roles for Dectin-2, Mincle and Mcl during A.f. infection have not 
been described.  
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Here, the expression and genetic sequence of Dectin-1, Dectin-2, Mincle and Mcl was 
examined, I also investigated CLR co-expression. Identifying CLR expression 
deficiencies, mutations and receptor collaboration may provide novel risk factors 
aiding patient stratification according to A.f. infection risk.  
 
Patient RNA was obtained from 2ml whole blood using the PAXgene Blood RNA 
equipment and standard protocol (PreanalytiX). The integrity of extracted RNA was 
examined. Patient’s CLR status could only be determined from highly intact RNA. RNA 
was extracted from Patients 1, 2 and 3, and was separated by gel electrophoresis.  
 
 
 
 
 
Figure 5.1: Whole blood extracted RNA is intact and suitable for further analysis. RNA 
was extracted from whole blood collected in PAXgene RNA blood tubes. Patient 1, 2 
and 3 blood-extracted RNA samples were separated by gel electrophoresis. A 1kb 
ladder was included. This experiment was undertaken as part of the optimisation 
protocol. Data is representative of one independent experiment. 
 
 
Figure 5.1 displays clear 28S ribosomal bands at 4kb and 18S ribosomal bands at 2kb 
in each patient sample. This indicates intact RNA was extracted from blood and this 
RNA is suitable for further experimental analysis [295]. In order to identify the 
2Kbp 
4Kbp 
PS1 PS2 PS3 
A 
	 193	
presence of mutations in the coding region of patients’ CLRs, Dectin-1, Dectin-2, 
Mincle and Mcl genes were amplified by PCR. The product of each PCR reaction was 
examined; the presence of a single, correctly sized band for each CLR gene was 
confirmed.  
 
cDNA was generated from Patient 1, 2 and 3’s extracted RNA and PCR was used to 
amplify each CLR gene. After PCR amplification, CLR samples were purified and 
separated by gel electrophoresis.  
 
 
 
 
 
Figure 5.2: Dectin-1 Isoform A and Isoform B, Dectin-2, Mincle and Mcl were 
successfully amplified from patient cDNA. A) Amplification of Patient 1’s CLR genes 
produced correctly sized (~600bp) PCR product. Two bands were attained from Dectin-
1 amplification B) Patient 1, 2 and 3’s Dectin-1 PCR amplification samples were 
separated by 3% gel electrophoresis. Dectin-1 Isoform A is ~600bp in size, Dectin-1 
Isoform B is ~500bp in size, both CLR isoforms were amplified. A 100bp ladder was 
included. This experiment was undertaken as part of the optimisation protocol. Data 
is representative of one independent experiment.  
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Figure 5.2 (A) displays the successful amplification of Dectin-2, Mincle and Mcl genes 
from patient cDNA. This permitted the sequencing of these genes for each patient. 
Figure 5.2 (B) identifies both Dectin-1 Isoform A and Dectin-1 Isoform B were amplified 
from patient cDNA. In order to determine the presence of any isoform-specific 
mutations or splice-variants, both Dectin-1 isoforms were separately excised, purified 
and sent for sequencing. 
 
Two CLR mutants were detected in this cohort, a novel Dectin-2 mutation and a 
previously identified Mcl mutation. 
 
 
 
 
Figure 5.3: Dectin-2 mutant C505X results in an early stop codon and loss of Dectin-
2 ligand-recognition domain. Purified CLR PCR product from each patient was 
sequenced and the presence of CLR mutations determined. Red X indicates mutated 
residue. Dectin-2 C505X mutant was identified from patient 25. Four Dectin-2 primers 
were used for complete and thorough gene sequencing coverage. This Dectin-2 
mutation was sequenced twice with all four primers. Key residues and domains 
highlighted in Dectin-2 were attained from [296].  
D2      1 MMQEQQPQSTEKRGWLSLRLWSVAGISIALLSACFIVSCVVTYHFTYGET     50 
          |||||||||||||||||||||||||||||||||||||||||||||||||| 
Mutant  1 MMQEQQPQSTEKRGWLSLRLWSVAGISIALLSACFIVSCVVTYHFTYGET     50 
 
 
   51     GKRLSELHSYHSSLTCFSEGTKVPAWGCCPASWKSFGSSCYFISSEEKVW    100 
          |||||||||||||||||||||||||||||||||||||||||||||||||| 
   51     GKRLSELHSYHSSLTCFSEGTKVPAWGCCPASWKSFGSSCYFISSEEKVW    100 
 
 
  101     SKSEQNCVEMGAHLVVFNTEAEQNFIVQQLNESFSYFLGLSDPQGNNNWQ    150 
          |||||||||||||||||||||||||||||||||||||||||||||||||| 
  101     SKSEQNCVEMGAHLVVFNTEAEQNFIVQQLNESFSYFLGLSDPQGNNNWQ    150 
 
 
  151     WIDKTPYEKNVRFWHLGEPNHSAEQCASIVFWKPTGWGWNDVICETRRNS    200 
          |||||||||||||||||||X                     
  151     WIDKTPYEKNVRFWHLGEPIILQSNVLQ----------------------    178 
 
 
  201     ICEMNKIYL-      209 
                                    
  178     ----------      178 
 
 
 
 
YELLOW = CRD key fold residues 
GREEN = Residues that interact with Ca2+ 
BLUE = Residues that interact with adjacent Ca2+  
PURPLE = Secondary sugar binding residues 
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Figure 5.4: Mcl A94G mutant identified in patient populations results in an amino 
acid substitution from serine to glycine. Purified CLR PCR product from each patient 
was sequenced and the presence of CLR mutations determined. Red X indicates 
mutated residue. Mcl A94G mutant was identified from 17 of 42 patients. Four Mcl 
primers were used for complete and thorough gene sequencing coverage. Key 
residues and domains highlighted in Mcl were attained from [197]. 
 
  
Mcl     1 MGLEKPQSKLEGGMHPQLIPSVIAVVFILLLSVCFIASCLVTHHNFSRCK     50 
          |||||||||||||||||||||||||||||||X|||||||||||||||||| 
Mutant  1 MGLEKPQSKLEGGMHPQLIPSVIAVVFILLLGVCFIASCLVTHHNFSRCK     50 
 
 
   51     RGTGVHKLEHHAKLKCIKEKSELKSAEGSTWNCCPIDWRAFQSNCYFPLT    100 
          |||||||||||||||||||||||||||||||||||||||||||||||||| 
   51     RGTGVHKLEHHAKLKCIKEKSELKSAEGSTWNCCPIDWRAFQSNCYFPLT    100 
 
 
  101     DNKTWAESERNCSGMGAHLMTISTEAEQNFIIQFLDRRLSYFLGLRDENA    150 
          |||||||||||||||||||||||||||||||||||||||||||||||||| 
  101     DNKTWAESERNCSGMGAHLMTISTEAEQNFIIQFLDRRLSYFLGLRDENA    150 
 
 
  151     KGQWRWVDQTPFNPRRVFWHKNEPDNSQGENCVVLVYNQDKWAWNDVPCN    200 
          |||||||||||||||||||||||||||||||||||||||||||||||||| 
  151     KGQWRWVDQTPFNPRRVFWHKNEPDNSQGENCVVLVYNQDKWAWNDVPCN    200 
 
 
  201     FEASRICKIPGTTLN    215 
          ||||||||||||||| 
  201     FEASRICKIPGTTLN    215 				
YELLOW = CRD key fold residues 
GREEN = Residues that interact with Ca2+ 	
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Having identified CLR mutations and their incidence within the patient cohort, it was 
next important to determine CLR expression for each patient. This was achieved using 
Real-Time qPCR analysis of CLR expression. Although CLR mutations have previously 
been associated with an increased incidence of A.f. disease, CLR expression has not 
been investigated in the same manner [67, 293, 297]. 
 
A limited quantity of RNA was extracted from each patient and used to generate cDNA. 
In order to maximise the use of patient RNA, an experiment was completed comparing 
the sensitivity of qPCR CLR reactions dependent on the quantity of patient cDNA used. 
20ng of cDNA was appropriate for the detection of each CLR gene by qPCR analysis 
using Taqman qPCR pimer/probe sets.  
 
CLR qPCR reactions on a control sample were included on every 96/384-well qPCR 
plate used during this study. HPRT expression was measured for every sample and 
used as the endogenous control. Taken together, a control patient sample and 
endogenous control (HPRT) in every sample permitted the comparison of all patients 
CLR gene expression using the ΔΔCt method. 
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Figure 5.5: Patient CLR expression profiles are highly variable and do not clearly predict A.f. disease. Each patient’s CLR expression was 
determined by qPCR using Taqman probes against each CLR. Alongside each patient qPCR reaction, a control sample and HPRT gene was 
analysed. Data shown from patient samples was calculated using ΔΔCt comparison against control sample and HPRT gene. Each patient 
CLR sample was assayed in duplicate. Red data points indicate incidence of IA, yellow data points indicate likely incidence of IA. 
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The results displayed in figure 5.5 highlight the range of CLR expression identified in 
patients. No clear high or low CLR expression was consistently identified in patients 
with A.f. disease. 
 
Patients enrolled in this study had different types of myeloid cancer and highly variable 
blood cell counts. White blood cell counts ranged from 0.9 to 16.5 x 109 cells/l and 
neutrophil counts ranged from 0.6 to 14.2 x 109 cells/l.  
 
The CLR expression results displayed in figure 5.5 were determined from 20ng cDNA 
generated from each patient sample. These results did not account for the quantity of 
cells and cell types present in each patient’s blood. Cells that do not express CLRs may 
have contributed towards patient’s CLR expression. Therefore, the results from figure 
5.5 were adjusted and normalised against each patient’s blood cell count data. 
Patient’s CLR expression was calculated from 20ng cDNA extracted from whole blood 
and normalised to account for cells present in whole blood able to express CLRs. 
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Figure 5.6: Patient CLR expression profiles normalised to patient cell counts are highly variable and do not clearly predict A.f. disease. 
Each patient’s CLR expression was determined by qPCR using Taqman probes against each CLR. Alongside each patient qPCR reaction, a 
control sample and HPRT gene was analysed. Data shown from patient samples was calculated using ΔΔCt comparison against control 
sample and HPRT gene and was normalised to patient cells that express CLRs using patient’s blood cell count results. Each patient CLR 
sample was assayed in duplicate. Red data points indicate incidence of IA, yellow data points indicate likely incidence of IA. 
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Figure 5.5 and figure 5.6 suggest there is no clear association between CLR expression 
and incidence of A.f. disease. The impact CLR expression has on the ability of patients 
to respond to inflammatory stimuli and ultimately their susceptibility to A.f. disease 
will be discussed later in this chapter.  
 
The anti-fungal immune response requires collaboration from a multitude of immune 
receptors including TLRs and CLRs. Recently, CLR:CLR enhancing collaboration has 
been identified involving Dectin-1 and Dectin-2 [221]. Patient’s CLR expression results 
provided an opportunity to determine CLR co-expression within this patient cohort. 
The presence of CLR co-expression may suggest CLR collaboration as was found with 
Mincle and Mcl [298]. CLR co-expression may also enhance the anti-A.f. immune 
response; therefore, patients with less co-expression may be more susceptible to A.f. 
disease. 
 
In order to identify any CLR co-expression, patient’s CLR expression results were 
plotted on an XY graph.  
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Figure 5.7: Moderate correlation between the expression of Mincle and Dectin-1, 
and Mincle and Mcl. CLR co-expression does not clearly predict A.f. disease. Each 
patient’s CLR expression was determined by qPCR using Taqman probes against each 
CLR. Alongside each patient qPCR reaction, a control sample and HPRT gene was 
analysed. Data shown from patient samples was calculated using ΔΔCt comparison 
against control sample and HPRT gene and was normalised to patient’s cells that 
express CLRs using patient’s blood cell count results. A Pearson r test was used to 
identify statistical significance. Pearson r results were interpreted as > 0.3 negligible, 
0.3 to 0.49 low, 0.5 to 0.69 moderate and > 0.7 high [299]. Red data points indicate 
incidence of IA, yellow data points indicate likely incidence of IA. 
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Figure 5.7 suggests positive or negative CLR co-expression does not clearly identify 
patients at risk of developing A.f. disease. Although moderate CLR co-expression was 
identified between Dectin-1 and Mincle, and Mincle and Mcl, IA positive patients were 
equally distributed within total patient results. Similarly, a lack of CLR co-expression 
does not clearly identify patients at risk of developing A.f. disease. 
 
 
5.3.2: Determination of patient’s functional immune response capabilities 
 
Patients with myeloid cancers are complex and their ability to appropriately respond 
to pathogen challenge is not well understood. Acute myeloid leukaemia patient’s 
adaptive immune systems recover slowly after chemotherapy. A study showed only 
two out of ten patients post-chemotherapy generated protective immunity when 
vaccinated against influenza; this was associated with disrupted B-cell expansion 
[300]. Furthermore, acute myeloid leukaemia has been demonstrated to disrupt 
natural killer cell activating receptors reducing the cytotoxic effect of these cells [301]. 
A similar, slowly recovering immune system has been described in stem-cell transplant 
patients. Innate immunity is thought to fully recover within months of transplantation 
but T cell and B cell populations were compromised for years after transplant therapy 
[302].  
 
Previous studies aiming to elicit risk factors associated with increased A.f. disease 
susceptibility have not investigated patient’s functional responses against 
inflammatory stimuli. Research aiming to identify patients that respond well to 
immunotherapy has extracted PBMCs and analysed their functional capabilities. 
However, this was done retrospectively after all patients had received treatment [303, 
304]. Stimulating patient’s PBMCs ex vivo with inflammatory stimuli such as LPS and 
live A.f. may provide insight into how patients respond when challenged with fungal 
pathogens. This could aid patient stratification according to A.f. disease susceptibility.  
 
LPS induces a robust pro-inflammatory response from PBMCs [305]. PBMCs when 
stimulated with A.f.-extracted chitin or live A.f. produce pro-inflammatory cytokines 
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and drive TH1 immunity [306, 307]. In order to determine the ability of patients to 
respond against inflammatory and fungal stimuli, PBMCs were extracted and 
stimulated with LPS or live A.f. for 24 hours. ELISA was used to elicit TNF and IL-6 
cytokine responses. 
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Figure 5.8: IA patients may lack a specific anti-A.f. TNF and IL-6 cytokine response. Patient PBMCs were isolated from whole blood and 
stimulated with (A i & B i) 1μg/ml LPS or (A ii & B ii) 5x106 A.f. RC/ml for 24 hours. After stimulation, supernatant was removed and the 
concentration of TNF and IL-6 determined by ELISA. Red data points indicate incidence of IA, yellow data points indicate likely incidence 
of IA. 
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Figure 5.8 shows the majority of patient’s PBMCs produce TNF and IL-6 cytokine 
responses when stimulated with LPS; however, not all patients produce anti-A.f. TNF 
and IL-6 responses. These results suggest IA patients may lack a specific anti-A.f. TNF 
and IL-6 response. Only two of nine patients and two of eight patients generated anti-
A.f. IL-6 and TNF responses respectively.  
 
Figure 5.8 displays all patient results irrespective of their primary disease. In order to 
determine whether IA patient’s lack of anti-A.f. response is linked to their primary 
disease, patients were separated in AML and SCT groups and the same data displayed. 
Two of four AML patients produced anti-A.f. cytokine responses; therefore, only SCT 
patient’s functional response results were displayed. 
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Figure 5.9: SCT IA patients may lack a specific anti-A.f. TNF and IL-6 cytokine response. SCT patient PBMCs were isolated from whole 
blood and stimulated with (A i & B i) 1μg/ml LPS or (A ii & B ii) 5x106 A.f. RC/ml for 24 hours. After stimulation supernatant was removed 
and the concentration of TNF and IL-6 determined by ELISA. Red data points indicate incidence of IA, yellow data points indicate likely 
incidence of IA. 
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Figure 5.9 displays the stark difference in anti-A.f. cytokine response between patients 
who developed A.f. disease and patients who did not develop A.f. disease. Patients 
who produced an anti-A.f. TNF and IL-6 response did not develop A.f. disease. 
Conversely, the majority of patients who produced an anti-LPS cytokine response but 
lacked an anti-A.f. cytokine response did develop A.f. disease. Here, a novel risk factor 
identifying SCT patients at high risk of developing A.f. disease may have been 
identified.  
 
PBMCs produce robust MIP-1 and KC responses against inflammatory stimuli such as 
LPS [308, 309]. As the patient PBMC stimulation results had proven so interesting 
when examining cytokines, MIP-1 and KC chemokines were quantified. Identifying a 
similar trend in chemokines would only further enhance the power of the potential 
novel risk factor.  
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Figure 5.10: The majority of patients generated an anti-A.f. chemokine response irrespective of their A.f. disease status. Patient PBMCs 
were isolated from whole blood and stimulated with (A i & B i) 1μg/ml LPS or (A ii & B ii) 5x106 A.f. RC/ml for 24 hours. After stimulation, 
supernatant was removed and the concentration of MIP-1 and KC determined by ELISA. Red data points indicate incidence of IA, yellow 
data points indicate likely incidence of IA. 
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5.3.3: Patient stratification system 
 
I have identified patient’s CLR status including their CLR expression and the presence 
of CLR mutations, and I have elicited patient’s functional response capabilities. It was 
next important to determine whether any of these results could be used to stratify 
patients according to their likelihood of developing A.f. disease. The identification of 
novel risk factors would allow for a personalised medicine approach towards treating 
A.f. disease. 
 
Initially, correlation between CLR expression and incidence of IA was examined. CLR 
expression was categorised into high or low for each patient. All CLR expression values, 
after being normalised to patient cell number, were averaged. Patients with CLR 
expression above the mean were classed as high, patients with CLR expression below 
the mean were classed as low.  
 
The following results figures contain varying numbers of patients; this is due to a 
limited quantity of cells and RNA being extracted from patient samples. CLR status and 
functional response results were not attained from all patients. 
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Figure 5.11: No significant 
association between CLR 
expression and incidence of 
A.f. disease. This data was 
produced from a contingency 
multivariate statistical 
analysis of CLR expression 
against incidence of IA. CLR 
expression, normalised to 
each patient’s cell counts and 
relative to a HPRT control, 
was used for analysis. NEF 
represents no evidence of 
fungal disease. Fisher’s exact 
test was used to identify 
statistical significance. As two 
variables were examined, 
statistical significance was set 
at *p<0.05.  
 
 
Patient group 
 
Parameter IA NEF Odds 
ratio 
95% CI Significance 
P value 
 
         
Total (37) Low Dectin-1 expression 6/9 18/28 1.111 0.22 to 5.43 1  
AML (18) Low Dectin-1 expression 3/3 7/15 7.933 0.34 to 180.1 0.215  
SCT (19) Low Dectin-1 expression 3/6 11/13 0.181 0.02 to 1.63 0.261  
        
Total (37) Low Dectin-2 expression 6/9 18/28 1.111 0.22 to 5.53 1  
AML (18) Low Dectin-2 expression 2/3 10/15 1 0.07 to 13.88 1  
SCT (19) Low Dectin-2 expression 4/6 8/13 1.25 0.16 to 9.54 1  
        
Total (37) Low Mcl expression 5/9 20/28 0.5 0.1 to 2.35 0.43  
AML (18) Low Mcl expression 3/3 10/15 3.667 0.15 to 84.58 0.521  
SCT (19) Low Mcl expression 2/6 10/13 0.15 0.017 to 1.26 0.128  
        
Total (37) Low Mincle expression 3/9 18/28 0.277 0.05 to 1.358 0.135  
AML (18) Low Mincle expression 1/3 9/15 0.333 0.024 to 4.55 0.558  
SCT (19) Low Mincle expression 2/6 9/13 0.222 0.028 to 1.75 0.319  
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Figure 5.11 displays no significant association between patient’s CLR expression status 
and incidence of A.f. disease. However, low Dectin-1 expression and high Mcl 
expression may increase the risk of developing IA in AML and SCT patients respectively. 
AML patients with low Dectin-1 expression were 7.9 times more likely to develop A.f. 
disease. SCT patients with low Mcl expression were 6.6 times less likely to develop A.f. 
disease. 
 
I have previously identified two CLR mutants in this cohort, one in Mcl and one in 
Dectin-2. The Mcl mutation was present in ~40% of patients; the Dectin-2 mutation 
was only identified in one patient. The patient possessing the Dectin-2 mutation was 
a proven IA case and did not survive. Unfortunately, as the mutation was only detected 
in one patient, association between mutated Dectin-2 and incidence of A.f. disease is 
not statistically appropriate.  
 
Association between mutant Mcl and the incidence of IA was examined; the impact 
mutant Mcl had on Mcl expression was also examined. 
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Figure 5.12: Mutant Mcl does not significantly impact incidence of IA or Mcl expression. This data was produced from a contingency 
multivariate statistical analysis of incidence of Mcl mutant against incidence of IA, and incidence of Mcl mutant against Mcl expression. 
CLR expression normalised to each patient’s cell counts and relative to a HPRT control, was used for analysis. NEF represents no evidence 
of fungal disease. Fisher’s exact test was used to identify statistical significance. As two variables were examined, statistical significance 
was set at *p<0.05. 
 
Patient group 
 
Parameter IA NEF Odds ratio 95% CI Significance 
P value 
       
Total (42) Mcl A94G mutant  5/10 12/32 1.667 0.39 to 6.97 0.714 
AML (19) Mcl A94G mutant 2/4 5/15 2 0.21 to 18.7  0.603 
SCT (23) Mcl A94G mutant 3/6 7/17 1.429 0.22 to 9.26 1 
       
Patient group 
 
Parameter Low Mcl 
expression 
High Mcl 
expression 
Odds ratio 95% CI Significance 
P value  
 
       
Total (36) Mcl A94G mutant 9/24 3/12 1.8 0.38 to 8.45 0.709 
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Figure 5.12 displays no significant association between mutant Mcl and the incidence 
of IA. There is also no association between mutant Mcl and Mcl expression; although, 
CLR expression was determined at RNA level and so the impact the mutant may have 
on Mcl cell surface expression cannot be determined.  
 
In figure 5.11 high Mcl expression was loosely associated with an increased risk of IA 
in SCT patients. Here, mutant Mcl does not alter Mcl expression or the incidence of IA. 
This may suggest the Mcl mutant identified resulting in an amino acid substitution has 
little impact on the expression and function of Mcl.  
 
In this small patient study, CLR status alone does not provide any novel and significant 
risk factors that could be used to stratify patients according to their risk of A.f. disease. 
Next, patient’s functional response results were associated with incidence of IA. This 
would determine whether patient’s PBMC stimulation results could be used as an A.f. 
disease risk factor.  
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Patient group 
 
Parameter IA NEF Odds ratio 95% CI Significance 
P value 
       
Total (40) No A.f. TNF response 8/10 11/30 6.909 1.23 to 38.53 *0.0281 
Total (40) No A.f. IL-6 response 8/10 11/30 6.909 1.23 to 38.53 *0.0281 
       
AML (17) No A.f. TNF response 2/4 6/13 1.167 0.12 to 11 1 
AML (17) No A.f. IL-6 response 2/4 7/13 0.857 0.09 to 8.07 1 
       
SCT (23) No A.f. TNF response 6/6 5/17 29.55 1.40 to 622 **0.0046 
SCT (23) No A.f. IL-6 response 6/6 4/17 39 1.81 to 839 **0.0021 
SCT LPS responders (21) LPS TNF response  
No A.f. TNF response 
6/6 3/15 46.63 2.06 to 1043 **0.0015 
       
 
 
Figure 5.13: Patients who lack an anti-A.f. TNF or IL-6 PBMC response are significantly more likely to develop A.f. disease. This data 
was produced from a contingency multivariate statistical analysis of PBMC anti-LPS and anti-A.f. cytokine response against incidence of 
IA. NEF represents no evidence of fungal disease. Fisher’s exact test was used to identify statistical significance. Where two variables 
were examined, statistical significance was set at *p<0.05, **p<0.005; significant values are highlighted bold. Where more than two 
variables were examined, Bonferroni’s correction was applied; significant values are highlighted bold and italic.  
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Figure 5.13 highlights the significant association between patient’s anti-A.f. TNF or IL-
6 PBMC response and incidence of IA. Here, a novel risk factor identifying patients with 
an increased likelihood of developing A.f. disease has been identified. This risk factor 
is particularly appropriate for use in SCT patients.  
 
SCT patients are 29.5 times more likely to develop IA if they do not produce an anti-
A.f. TNF response and 39 times more likely if they do not produce an anti-A.f. IL-6 
response. Interestingly, if SCT patients produce a response against LPS but not against 
A.f. their risk of developing IA is 46.6 times higher when compared to SCT patients who 
generated both an anti-LPS and anti-A.f. responses. This novel risk factor is not present 
or significant in the AML patient cohort. 
 
It was important to determine whether patient’s lack of anti-A.f. response was specific 
for predicting A.f. disease or was a more general indicator of patients responding 
poorly. Therefore, the incidence of IA and lack of TNF/IL-6 anti-A.f. response was 
associated with mortality in the patient cohort.  
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Patient group 
 
Parameter Mortality Survival Odds ratio 95% CI Significance 
P value 
       
Total (40) IA 4/15 6/25 1.152 0.26 to 4.99 1 
AML (17) IA 1/6 3/11 0.533 0.04 to 6.65 1 
SCT (23) IA 3/9 3/14 1.833 0.27 to 12.07 0.643 
       
Total (40) No A.f. TNF response 5/15 14/25 0.392 0.10 to 1.49 0.204 
Total (40) No A.f. IL-6 response 6/15 13/25 0.615 0.16 to 2.25 0.526 
SCT (23) No A.f. TNF response 3/9 8/14 0.375 0.06 to 2.15 0.40 
SCT LPS responders (21) LPS TNF response  
No A.f. TNF response 
3/9 8/12 0.25 0.03 to 1.56 0.198 
       
 
 
Figure 5.14: No significant association between IA and mortality, and a lack of anti-A.f. TNF or IL-6 PBMC response and mortality. This 
data was produced from a contingency multivariate statistical analysis of IA incidence against incidence of mortality and PBMC anti-LPS 
and anti-A.f. cytokine response against incidence of mortality. NEF represents no evidence of fungal disease. Fisher’s exact test was used 
to identify statistical significance. Where two variables were examined, statistical significance was set at *p<0.05; significant values are 
highlighted bold. Where more than two variables were examined, Bonferroni’s correction was applied; significant values are highlighted 
bold and italic.  
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Figure 5.14 demonstrates there is no association between IA and mortality, and no 
association between lacking an anti-A.f. TNF/IL-6 response and mortality. This suggests 
the results displayed in figure 5.13 relate to a novel and A.f. disease specific risk factor. 
This risk factor does not simply discriminate against patients who are responding 
poorly and experience higher mortality; this risk factor specifically identifies SCT 
patients at increased risk of developing IA.  
 
Finally, it was important to use the data displayed in figures 5.11 to 5.14 to generate 
a model that predicts incidence of A.f. disease according to the risk factors identified 
in this research. The results displayed in the following figures are limited to the 
patients recruited in this clinical study; therefore the maximum number of patients 
used to generate IA incidence predictions is 43. 
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Primary disease + Risk factor 
 
Incidence in  
Patient cohort 
Incidence of IA Odds ratio Significance 
P value 
     
SCT + No A.f. TNF response 11/23  6 (54%) 29.55 **0.0046 
SCT + No A.f. IL-6 response 10/23 6 (60%) 39 **0.0021 
SCT + LPS TNF/IL-6 response  + no A.f. TNF/IL-6 response 9/21 6 (66%) 46.63 **0.0015 
     
     
SCT + High Mcl expression 7/19 4 (57.2%) 6.67 0.128 
SCT + High Mcl expression + 
LPS TNF/IL-6 response + no A.f. TNF/IL-6 response 
5/19 4 (80%) 311.02 **0.001 
     
AML + no A.f. TNF response 8/17 2 (25%) 1.167 1 
AML + no A.f. IL-6 response 9/17 2 (22%) 0.857 1 
AML + Low Dectin-1 expression 10/18 3 (30%) 7.933 0.215 
AML + Low Mcl expression 13/18 3 (23%) 3.667 0.521 
AML + Low Dectin-1 expression + Low Mcl expression 9/18 3 (33%) 29.09 0.206 
 
Figure 5.15: An anti-A.f. cytokine response and Mcl expression can be used to stratify SCT patients according to their risk of developing A.f. infection. Previously 
identified risk factors were used to stratify patients before the incidence of IA was calculated within this stratified group. Incidence of IA as a percentage relates to 
the number of IA positive patients stratified by the risk factor parameter. Contingency multivariate statistical analysis of each set of risk factor parameters and their 
association with IA incidence was used to determine statistical significance. A Chi-squared test was used to identify statistical significance where multiple parameters 
were associated with IA incidence. Where two variables were examined, statistical significance was set at *p<0.05, **p<0.005; significant values are highlighted 
bold. Where more than two variables were examined, Bonferroni’s correction was applied; significant values are highlighted bold and italic.  
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The results from figure 5.15 display the incidence of IA within patient groups that were 
stratified using risk factors from this study. This stratification could be applied to 
patients as they undergo treatment for haematological malignancies as described in 
figure 1.4. The presence or absence of risk factors would allow patients to be stratified 
into high, intermediate and low risk groups’ dependent on their risk of developing A.f. 
disease. From this stratification, their anti-fungal diagnosis and treatment regime 
could be modified accordingly.  
 
The data from figure 5.15 was used to generate a flow diagram clearly defining 
patients at low, intermediate or high risk of developing A.f. disease. Patients were 
stratified according to the risk factors identified within this research. 
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Figure 5.16: System to stratify SCT patients according to risk factors identified within this research. Data collated from figure 5.15 was 
used to describe risk factors leading patient stratification into low, intermediate and high-risk of A.f. disease cohorts.  
 
RNA	extracted	
from	blood	
SCT	patients	
Low	Risk	
	
•  A.f.	TNF/IL-6	response	–	IA	risk	0%	
•  Low	Mcl	expression	–	IA	risk	16%	
	
	
PBMCs		
extracted	
CLR	status	
	determined	
Functional	response	
	determined	
Stratification 
Intermediate	Risk	
	
•  High	Mcl	expression	–	IA	risk	57.2%	
•  No	A.f.	TNF	response	–	IA	risk	54%	
•  No	A.f.	IL-6	response	–	IA	risk	60%	
	
	
High	Risk	
	
•  LPS	TNF/IL-6	response	+	No	A.f.	TNF/IL-6	
response	–	IA	risk	66%	
•  High	Mcl	expression	+	LPS	TNF/IL-6	response	+	
No	A.f.	TNF/IL-6	response	–	IA	risk	80%	
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Figure 5.16 provides the final stratification protocol that can be drawn from this 
research. These results and protocol could be used to apply a personalised medicine 
approach to haematology SCT patients at risk of developing A.f. disease.  
 
As previously described in figure 1.4, high risk patients may be given prophylactic anti-
fungal therapy and their primary disease treatment modulated to reduce the risk of 
A.f. disease. Intermediate risk patients may be given prophylactic anti-fungal therapy 
but their primary disease treatment prioritised, this cohort may undergo regular 
fungal infection screening. Low risk patients primary disease may be prioritised 
without the requirement of prophylactic anti-fungal therapy.  
 
Although the patient cohort was small in size, this study has identified significant novel 
risk factors associated with an increased susceptibility to A.f. disease. 
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5.4: Discussion 
 
 
The aims of this research focussed on identifying risk factors associated with an 
increased susceptibility to A.f. disease in haematology patients. The determination of 
patient’s CLR status and their functional immune response capabilities has led to 
multiple novel risk factors being described. These risk factors can be used to stratify 
SCT patients according to their risk of developing A.f. disease; therefore, driving a 
personalised medicine approach to anti-fungal therapy.  
 
The requirement for improving current anti-fungal treatment strategies is clear. A.f. as 
a pathogen is responsible for a rapidly increasing disease burden in immune-
compromised patients. The prevalence of A.f. disease within patients diagnosed with 
hematologic malignancies is around 10-15%; this high disease prevalence is 
accompanied by an unacceptably severe mortality rate ranging from 38-80% [7, 40-
42]. The incidence of A.f. disease in the study centre has been as high as 27%, this 
study attained A.f. incidence of 20.9%. 
 
Current anti-fungal therapeutics are expensive, toxic and highly interactive with other 
drugs. This often means patient’s primary treatments must be modified to allow anti-
fungal therapeutics to be administered [56, 57, 60]. Resistance issues are also 
emerging, rendering front-line anti-fungal therapeutics redundant [58]. These 
therapeutic insufficiencies, alongside increasing disease burden and high mortality 
rates highlight the necessity for improvements in anti-fungal therapy. Identifying 
patients at high risk of developing A.f. disease would permit the targeting of anti-
fungal therapies; therefore, reducing unnecessarily treated patients, reducing the risk 
of fungal resistance and reducing the high cost burden associated with anti-fungal 
therapies.  
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5.4.1: Determining patients CLR status. 
 
CLRs are crucial during anti-fungal and anti-A.f. immune responses. This is highlighted 
by the increased susceptibility to fungal infection experienced by individuals with 
defective CARD9 [159]. Recently, mutations in Dectin-1 and DC-SIGN have also been 
associated with an increased A.f. disease susceptibility [67, 292]. Therefore, identifying 
patient’s CLR expression and sequence may have elicited novel risk factors associated 
with developing A.f. disease. 
 
Here, two CLR mutants were identified within the patient cohort, a novel Dectin-2 
mutation and Mcl mutation. The Dectin-2 C505X mutant has not been previously 
described and is a very interesting CLR mutant. The patient with this mutation 
developed A.f. disease and did not survive. Information regarding the cause of death 
is unavailable and death may or may not have resulted from A.f. disease. 
 
Dectin-2 is important during established A.f. infection, the CLR recognises larger 
hyphal morphologies of A.f. and generates robust cytokine and chemokine responses 
driving protective immunity [183, 185]. The mutation in Dectin-2 described in figure 
5.3 results in an early stop codon and premature termination of protein translation. 
This likely severely disrupts the tertiary structure of the CLR and impairs Dectin-2’s 
recognition of A.f. [296]. This mutation may be particularly relevant for haematology 
patients with A.f. disease. 
 
Haematology patients experience drastic immune suppression and are at high risk of 
developing A.f. infections [38, 39]. The adaptive immune response recovers slowly 
after chemotherapy whereas the innate immune response can recover within months 
[302]. Lacking a crucial CLR such as Dectin-2, involved in the recognition of developed 
A.f. structures, may reduce the capability of patients to generate robust anti-A.f. 
immune responses. If patients are infected with A.f. during their treatment, even when 
their innate immune response recovers they may not be able to appropriately 
recognise and respond against developed A.f. infections.  
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The mutation identified in 17/43 patient’s Mcl gene has been previously described. 
This missense mutation results in the substitution of serine to glycine at amino acid 
position 32. Although these two amino acids have different charge, my research 
suggests this substitution does not impact the expression or function of Mcl. 
 
Figure 5.7 permits the identification of CLR co-expression using patient’s CLR 
expression results displayed in figure 5.6. The requirement for collaborative CLR and 
TLR responses against A.f. infections has been extensively described. This figure 
highlights moderate correlation between the expression of Dectin-1 and Mincle, and 
Mincle and Mcl.  
 
Collaborative signalling between Mincle and Mcl has been previously identified. A role 
for both receptors heterodimerising and enhancing the recognition of carbohydrate 
and lipid containing molecules has been demonstrated [298]. Research describing Mcl 
facilitating Mincle expression and signalling provides further evidence of Mincle and 
Mcl collaboration [310]. However, the functional consequence of Mincle and Mcl 
engagement during fungal infections has not been described. Patients that developed 
A.f. disease did not possess more or less Mincle and Mcl co-expression when 
compared to the total patient cohort; therefore, minimal functional conclusions can 
be drawn from Mincle and Mcl co-expression. 
 
A role for Dectin-1 and Mincle collaborating has not been identified. The two CLRs do 
appear to be linked as the fungal engagement of Mincle can block Dectin-1 induced 
anti-fungal TH1 immunity [157]. However, this research does not demonstrate physical 
CLR interaction or mention CLR co-expression. Interestingly, Dectin-1 can produce 
robust responses against mycobacteria but what the CLR recognises on the pathogen 
is unknown. It is suggested both Dectin-1 and Mincle may be required to recognise 
and respond against mycobacteria. Both receptors were demonstrated to signal via 
Syk/CARD9 and generate inflammatory cytokines driving TH1 and TH17 immunity upon 
mycobacterial recognition [311].  
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No correlation was attained between the expression of Dectin-1 and Dectin-2. The 
recently described role for Dectin-1 and Dectin-2 enhancing Tricophyton rubrum 
clearance suggests these receptors can collaborate but may not directly impact the 
others expression [221].  
 
Here, a novel Dectin-2 mutation was identified and the CLR status of 43 patients 
determined. Although no clear association between CLR expression and incidence of 
IA was attained, when these results are collated with patient’s functional capabilities 
risk factors aiding in the stratification of patients according to risk of A.f. disease may 
be identified.  
 
 
5.4.2: Determining patient’s functional response capabilities  
 
This research begins to describe a novel risk factor that may identify patients 
susceptible to A.f. disease. Almost all patient’s extracted PBMCs generated anti-LPS 
TNF and IL-6 responses. Interestingly, the majority of patients who did not produce 
anti-A.f. TNF and IL-6 responses developed A.f. disease. This trend was not conserved 
in patient’s MIP-1 and KC chemokine responses. The total patient results displayed in 
figure 5.8 and then narrowed to SCT patients in figure 5.9 highlight the absence of 
specific anti-A.f. cytokine response produced by IA positive SCT patients. Therefore, 
this potential risk factor may be most appropriate for stratifying SCT patients.  
 
Haematological malignancies and SCT therapy are well known to impair the immune 
response. However, the explanation for patient’s specific lack of anti-A.f. cytokine 
response is not clear, especially when anti-LPS cytokine responses are produced. Why 
this trend is not conserved in patient’s chemokine response is also unknown. 
 
Innate immune responses against LPS require TLR4 and some CD14 signalling and are 
driven by myeloid immune cells. The immune response against LPS is extremely robust 
and results in a range of pro-inflammatory cytokines and chemokines being produced 
[312, 313]. Furthermore, LPS stimulation of PBMCs up-regulates TLR4 expression, 
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enhancing LPS signalling and cytokine production [314]. Although stem cell transplant 
therapy impairs the innate immune response, TLRs can still signal post-treatment and 
are one of the main immune drivers of allograft rejection [315]. Similarly, although 
chemotherapy and radiotherapy treatments impair the innate immune system, TLRs 
in the gut can still signal post-treatment, often being linked with gut toxicity and 
chronic pain [316].  
 
Each patient blood cell count was taken at the same time their functional assays were 
performed. The blood count data suggests almost all patients possessed some myeloid 
cells within their blood. This, alongside TLRs sustained impact despite stem cell 
transplant, chemotherapy or radiotherapy treatment may suggest why the majority of 
patients generated anti-LPS TNF and IL-6 responses.  
 
The reason underlining patient’s specific lack of an anti-A.f. response and subsequent 
enhanced risk of A.f. disease is more challenging. A role for CLRs during anti-cancer 
responses have been described with CLRs expressed on DCs responsible for cancer 
antigen presentation [317]. However, the presence of CLRs post-stem cell transplant, 
chemotherapy or radiotherapy has not been clarified. It may be the case that CLR 
expression is disrupted by these treatments, consequently impairing the anti-fungal 
immune response without altering patient’s LPS response. 
 
In order to generate a robust anti-A.f. immune response a complex and multifaceted 
recognition and signalling sequence must occur. This involves multiple immune cell 
types and receptors. In contrast the LPS immune response is driven almost exclusively 
by TLR4 [318]. Patients may produce only anti-LPS cytokine responses, as this immune 
response requires fewer components and less collaboration. Patients that produce 
both an anti-LPS and anti-A.f. immune response may possess a more intact and better 
functioning immune system.  
 
The functional PBMC stimulation experiments were completed for 24 hours with LPS 
and live A.f.. These experiments may have primitively, yet accurately reflected what 
occurred in patients infected with A.f.. Patient PBMCs when challenged with LPS 
	 227	
simply had to recognise and respond to the stimulant within 24 hours. However, 
patient PBMCs when challenged with live A.f. had to rapidly recognise and respond 
against A.f. to avoid being killed. If PBMCs did not recognise and respond against A.f. 
no cytokine response would be detected. Therefore, this experiment does not 
discriminate against anti-A.f. cytokine responders or non-responders but stratifies 
patients according to the ability of their PBMCs to respond against A.f. before they 
were killed. This may be why this assay is so selective for patients highly susceptible to 
A.f. disease. 
 
Finally, an explanation as to why this functional assay stratifies patients according to 
their anti-A.f. cytokine response and not their chemokine response is challenging. 
PBMCs produce chemokines in much greater quantities than cytokines, especially 
when stimulated with LPS [319, 320]. Patients susceptible to A.f. disease may rapidly 
produce some chemokines but not cytokines, before their PBMCs are killed by A.f.. 
 
 
5.4.3: Patient stratification system 
 
This research has identified multiple novel risk factors that can be used to stratify 
patients according to their risk of developing A.f. disease. These risk factors add to the 
already described genetic and diagnostic risk factors currently used in healthcare 
centers to stratify patients [65, 67, 321]. Here, I identify SCT patient’s ability to 
generate an anti-A.f. TNF and IL-6 response as a significant risk factor. Furthermore, 
when patients are stratified according to their Mcl expression and their functional 
response, as shown in figure 5.16, the incidence of IA goes up to 80%. When used 
together these parameters represent a novel and significant stratification protocol.  
 
The diagnosis of A.f. infections is challenging and relies on the outcome of multiple 
diagnostic tests including PCR positivity, A.f. antibody ELISA and lung scans. Here, this 
research describes clear and novel risk factors that can be used to stratify high-risk 
patients and drive a personalised medicine approach. Interestingly, this research also 
permits the stratification of patients at low risk of developing A.f. disease. All patients 
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that generated anti-A.f. TNF and IL-6 responses did not develop A.f. disease. This 
provides a robust strategy to rule out patients at risk of developing A.f. disease. 
 
Finally, the experiments undertaken in this research are not impractical to complete 
on a larger scale and could with some planning, be implemented into the current 
diagnostic strategy employed in healthcare centers. Before patient’s treatment 
commences, blood could be extracted and used to determine their functional 
response capabilities and CLR expression status. This is no more intensive than 
multiple and regular PCR testing, ELISA testing and analysing lung scans.  
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5.5: Conclusions 
 
 
The requirement to improve the diagnosis and treatment strategy of A.f. infections 
has been thoroughly discussed in 5.1. The incidence of A.f. disease is increasing, 
mortality is unacceptably high and current therapeutics are toxic, drug interactive, 
expensive and encountering resistance problems. Therefore, patients are 
prophylactically treated with anti-fungal therapeutics at the slightest suspicion of A.f. 
disease. This typically results in the modulation of their primary disease therapies and 
even then, IA is often fatal. 
 
The requirement to stratify patients according to their risk of developing A.f. infections 
is clear. This would allow high-risk patients to be regularly screened and 
prophylactically treated reducing their risk of A.f. disease. Crucially, this would also 
permit low-risk patients primary disease to be prioritised whilst their A.f. disease 
status was closely monitored.  
 
This research adds multiple novel risk factors to the growing number of genetic, 
functional and diagnostic risk factors currently used in healthcare centers to stratify 
patients according to their A.f. disease susceptibility. 
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5.6: Future experiments 
 
 
The Dectin-2 mutation identified in a patient from this study requires further 
investigation. This early stop codon mutation likely renders Dectin-2 redundant, which 
would drastically impair the anti-fungal immune response. The prevalence of this 
mutation within the population, and patient cohorts at-risk of fungal infection, must 
be determined. Following this, the mutation must be associated with incidence of 
fungal disease. This Dectin-2 mutant may increase patient’s susceptibility to fungal 
infection.  
 
The research undertaken within this study was completed using a patient cohort size 
of 43, of which 10 patients developed A.f. disease. Although some of the conclusions 
drawn from this research were statistically significant, the patient cohort size is small. 
In order to increase the statistical significance and test the risk factors identified here, 
more patients could be enrolled. Similar cohorts of patients at-risk of fungal infection 
could also be retrospectively examined for some of the genetic risk factors identified 
here.  
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Chapter 6 		
General discussion 
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6.1: Earlier research  
 
C-type lectin receptors comprise a large and diverse family of proteins. CLRs are 
defined by their possession of a CTLD, a domain that can recognise a multitude of 
different ligands including carbohydrates, proteins and lipid components [151]. CLRs 
are predominantly expressed on myeloid cells where their primary function involves 
pattern recognition. Upon recognition, CLRs drive immune responses against PAMPs, 
damage associated molecular patterns, and most recently described, tumour 
associated molecular patterns [317, 322]. CLRs have been demonstrated to drive 
phagocytic, endocytic, pro-inflammatory and anti-inflammatory responses. This range 
of CLR-derived responses relies on a complex signalling system comprising of tyrosine-
based signals that recruit kinases and phosphatases, and non-tyrosine based signals 
that typically require coupling to adjacent pathways [323]. 
 
Fungal immunity is primarily mediated by CLRs that recognise fungal cell wall 
carbohydrates acting as PAMPs. Dectin-1 is the best characterised CLR during anti-
fungal immune responses [245]. The CLR Dectin-1 recognises β-glucans and is essential 
for generating protective immune responses against fungal pathogens such as Candida 
albicans [171]. Dectin-2 also plays a crucial role in anti-fungal immunity recognising 
high mannose structures widely found on fungal cell walls. Dectin-2 is important when 
generating protective immune responses against Candida albicans [180]. The CLR 
Mincle has a complicated role during anti-fungal immune responses. Mincle was found 
to be beneficial during Malassezia challenge, driving pro-inflammatory cytokine 
responses [188]. Conversely, the engagement of Mincle by Fonsecaea monophora 
suppressed Dectin-1 protective responses, suggesting a pathogen immune evasion 
role for Mincle [157]. The anti-fungal capability of Mcl is not well understood. The CLR 
can mediate immune responses against mycobacterial cord factor and Mcl deficient 
mice are more susceptible to Candida albicans infection [158, 199]. 
 
A.f. is a complicated pathogen with a severe disease burden. The fungus causes a 
variety of invasive and allergic type diseases dependent on the host’s immune status. 
Immune suppressed individuals are highly susceptible to invasive A.f. infections and 
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experience unperturbed systemic A.f. growth that is associated with an unacceptably 
high mortality rate [324]. Individuals with compromised immune systems such as 
those with CF do not experience systemic A.f. disease but often struggle with chronic 
A.f. infections in the lung. Persistent A.f. infections retained in the lung cause chronic 
local inflammation; this culminates in tissue scarring and reduced lung capacity [19]. 
Anti-A.f. therapeutics are insufficient at clearing A.f. infections and have a range of 
severe side effects [1, 324].  
 
The anti-A.f. immune response likely requires extensive collaboration between PRRs. 
A.f. is a complicated pathogen with multiple morphological states and many immune 
evasion strategies [128]. Collaboration between CLRs and TLRs has long been 
understood. Stimulating Dectin-1 and TLR2 with β-glucan and Pam3CSK4 produced a 
synergistic inflammatory response when compared to stimulating each PRR 
individually [279]. Immune clearance of Fonsesaea pedrosoi was found to require CLR 
and TLR signalling despite exclusive recognition of the pathogen by a CLR [187]. 
Recently, CLR:CLR collaboration between Dectin-1 and Dectin-2 was identified. An 
enhanced response against Trichophyton rubrum was demonstrated when both CLRs 
were engaged; this resulted in reduced fungal burden in vivo [221]. 
 
Here, I investigated the role of Dectin-1, Dectin-2, Mincle and Mcl during anti-A.f. 
immune responses in immune-compromised, immune-competent and immune-
suppressed disease settings. 
 
 
6.2: CLRs and A.f. in the immune-compromised 
 
Individuals with compromised immune systems such as those with CF are susceptible 
to A.f. disease. CF patients typically suffer from repeated lung infections and chronic 
airway inflammation [19]. The most common cause of death in CF patients is 
respiratory failure, often resulting from chronic lung infection. A.f. is regularly isolated 
from CF patient respiratory secretions [325]. CF patient’s defective mucociliary 
escalator does not clear A.f. that has been inhaled and deposited in the lung; 
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therefore, the A.f. infection persists. Furthermore, the disrupted mucociliary escalator 
impairs the airway immune response. Recruited, activated immune cells get stuck in 
mucus and contribute to local inflammation further impairing of the immune response 
[18]. Poorly challenged A.f. exacerbates lung inflammation by providing a persistent 
stimulus for the defective immune response. However, the underlying reason CF 
patients are so susceptible to A.f. infection and their lack of A.f. clearance is not well 
understood. CLRs drive anti-fungal immunity and their requirement for generating 
robust immune responses is becoming clear. Here in chapter 3, I identify NE induced 
cleavage of Dectin-1 and suggest why this may enhance CF patient’s susceptibility to 
A.f. infection. 
 
Dectin-1 expressed on alveolar macrophages, monocytes and neutrophils recognises 
A.f. and generates pro-inflammatory cytokine responses. These cell types are present 
in the CF airway and contribute to the local anti-A.f. immune response. Dectin-1 has 
been demonstrated to bind A.f. SC with particularly high affinity, suggesting the 
receptor is important for early immune responses as conidia are inhaled and begin to 
germinate [2]. My research demonstrates that NE-induces cleavage of Dectin-1 and 
therefore likely impairs A.f. recognition. I showed that NE-induced cleavage of Dectin-
1 resulted in recognition and functional defects in response to zymosan, a β1-3 glucan 
ligand for Dectin-1. Zymosan has extensively been used as a sterile model of fungal 
infection [326]. Zymosan engagement of Dectin-1 triggered NFAT activation in 
macrophages to the same extent that Candida albicans stimulation achieved [327]. In 
the seminal study showing that Dectin-1 KO mice displayed increased susceptibility to 
Candida albicans infection, Dectin-1 KO macrophages were initially stimulated with 
zymosan to confirm reduced β1-3 glucan recognition [171]. These data suggest 
zymosan is an useful model of fungal infection/responses and impaired zymosan 
recognition is often associated with impaired fungal immunity in vivo.  
 
Furthermore, the production of cytokines and chemokines such as TNF, IL-6, MIP-1 
and KC in response to zymosan or A.f. was found to be dependent on Dectin-1 
expressed on macrophages [2, 328]. A lack of Dectin-1 engagement reduced the 
cytokine and chemokine response and increased A.f. in vivo fungal burden [2]. In 
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chapter 3, I demonstrate NE-induced cleavage of Dectin-1 and highlight the 
recognition and functional deficiency resulting from this cleavage event using zymosan 
and A.f.. Losing Dectin-1’s anti-A.f. impact in the CF airway would likely drastically 
increase susceptibility to fungal disease. Dectin-1 KOs impact in vivo against fungal 
pathogens has been thoroughly explored with almost all models experiencing 
significantly increased mortality resulting from impaired anti-fungal responses [171, 
173, 174, 329]. 
 
My results and the above comparisons with others research suggest the action of NE, 
present in high concentrations in the CF airway, inducing cleavage of Dectin-1 would 
drastically reduce A.f. recognition and result in an impaired anti-A.f. immune response. 
Poorly challenged A.f. would persist in the CF airway and contribute to the local 
chronic inflammatory setting. This may describe why CF patients have such high A.f. 
disease incidence and suffer from chronic A.f. infection. Furthermore, this research 
not only describes a role for NE inducing Dectin-1 cleavage but also suggests NE may 
cleave other CLRs important during anti-A.f. immune responses [330]. 
 
As NE has such a devastating impact when inappropriately regulated in the CF airway, 
NE-inhibitors are an attractive therapeutic target. Here, my research suggests blocking 
the action of NE in the CF airway would restore Dectin-1 expression and likely recover 
the anti-A.f. immune response. Dectin-1 generates robust anti-A.f. immune responses 
and is almost exclusively required for clearing early A.f. infection [2, 174]. NE-inhibitor 
therapeutics are a very real possibility with multiple patent applications accepted 
within the last 8 years [331-334].  
 	
6.3: CLRs and A.f. in the immune-competent 
 
The majority of research investigating CLRs during A.f. infection has been undertaken 
using immune-competent in vivo models. Although this does not provide an accurate 
representation of what occurs in humans, these models have elicited CLRs impact in 
other fungal diseases. Previous research has identified a controversial role for Dectin-
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1 during in vivo fungal challenge. Immune-competent Dectin-1 KO in vivo models were 
used to determine the requirement of Dectin-1 during Candida albicans infection 
[171]. Conversely, research from another lab showed Dectin-1 deficient mice possess 
the same susceptibility to Candida albicans as WT mice. This suggests a lesser role for 
the CLR or extensive CLR redundancy; however, this reduced Dectin-1 impact was 
associated with the use of a different Candida albicans strain [172, 173]. Blocking 
Dectin-1 signalling in vivo before A.f. challenge resulted in significantly impaired 
cytokine and chemokine production [2]. The production of IL-22 following A.f. 
challenge was found to be dependent on Dectin-1; furthermore, mice lacking IL-22 
possessed significantly higher A.f. fungal burden [174]. Crucially, Dectin-1 deficient 
mice were significantly more susceptible to A.f. infection, produced impaired cytokine 
and chemokine responses and experienced increased mortality [100].  
 
Here, my research in chapter 4 aligns with previous work highlighting the impaired 
anti-A.f. cytokine and chemokine response resulting from Dectin-1 KO mice. However, 
my research suggests this does not translate into an increased susceptibility to A.f. 
infection. The results displayed in chapter 4 indicate this reduced Dectin-1 impact may 
result from microbiome and/or gender discrepancies between WT and each CLR KO or 
DKO strain. Several laboratories have demonstrated the immune controlling impact of 
the microbiome, particularly relevant in lung immunity [262, 263]. There are many 
examples of microbiome bacteria modulating inflammatory immune responses, often 
using the ubiquitin system. Iκβ, a crucial signalling component of the NFκβ pathway, 
can be targeted for degradation by numerous gut bacteria [335-337]. Recently, the 
influence the microbiome controls over host immunity was clearly demonstrated using 
Clostridium difficile. Adding a single gut bacteria into the microbiome restored bile 
acid-mediated resistance to the pathogen and cleared infection [281]. Differences in 
the immune systems of males and females have long been described, with genetic 
variation and different sex hormones predominantly being responsible [338]. The 
influence microbiome and gender have during in vivo anti-fungal immune responses 
have not been previously identified. Here, my research suggests both have significant 
roles controlling host anti-fungal immunity and require further investigation. 
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The role of Dectin-2 during anti-fungal immune responses is becoming clearer. Dectin-
2 deficient mice were more susceptible to Candida albicans and Candida glabrata 
infection than WT mice [180, 339]. This was associated with reduced phagocytosis and 
impaired ROS production [340]. Dectin-2 recognises larger hyphal morphologies of A.f. 
generating cytokines, chemokines and extracellular traps [185]. Although this receptor 
is likely involved in anti-A.f. immunity, limited in vivo research has investigated this 
CLR’s role. The impact Mincle has on the anti-A.f. in vivo immune response is also 
unclear. Mincle has been shown to have pro-inflammatory and pathogen immune 
evasion roles during in vivo fungal challenge [157, 188]. Here, my research suggests a 
limited role for Dectin-2 and Mincle influencing the in vivo anti-A.f. immune response. 
It appears when the host is immune competent there is enough CLR redundancy to 
cope with the loss of these CLRs. Dectin-2 and Mincle may have more impact during 
extensive A.f. infections found in immune suppressed patients.  
 
The alveolar macrophage experiments for both these receptors also suggested they 
had limited impact during anti-A.f. immunity. The alveolar macrophage experiments 
were completed for 24 hours with live A.f., this allowed alveolar macrophages to 
experience all A.f. morphologies. Despite this, 24 hours is still an early time-point and 
A.f. growth was not extensive. It may be the case that Mincle and Dectin-2 recognise 
larger HY morphologies of A.f. and possess limited impact on the alveolar macrophage-
driven early response. Dectin-1 has been identified as the crucial CLR during early, anti-
A.f. alveolar macrophage responses [98]. Although I show Dectin-2 and Mincle are 
expressed on alveolar macrophages, these CLRs may have more anti-A.f. impact on 
cells recruited to combat extensive A.f. infection. 
 
My research did identify an interesting result from Mincle Dectin-1 DKO. The alveolar 
macrophage MD1 DKO cytokine and chemokine response was similar to the reduced 
response attained from Dectin-1 KO. However, the reduced cytokine and chemokine 
response observed in Dectin-1 KO mice in vivo was recovered when Mincle and Dectin-
1 were knocked out together. This again suggests that Mincle has limited impact on 
alveolar macrophages but may have some role during in vivo A.f. infection. A.f. may 
engage Mincle on recruited immune cells to evade engagement from other CLRs. 
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When Mincle is also knocked out alongside Dectin-1, A.f. cannot engage Mincle or 
Dectin-1 and the pathogen is likely recognised by other CLRs. A pathogen evasion role 
for Mincle engagement has previously been described. Mincle engagement was found 
to impair Dectin-1 induced IL-12 production blocking TH1 protective immunity [157]. 
Helicobacter pylori was demonstrated to up-regulate and engage Mincle driving anti-
inflammatory immune responses and avoiding clearance [194]. Here, my research 
aligns with other published results suggesting Mincle not only has a complicated 
immune role but may be engaged by pathogens to evade protective immunity.  
 
Unfortunately, this chapter of research did not follow my hypothesis, where I expected 
the anti-A.f. response to be significantly reduced in the absence of one or more CLRs. 
As highlighted in this chapter, the microbiome and sex of the mice impacted results. 
The differences between WT, CLR KO and CLR DKO mice may be subtle and difficult to 
extrapolate when mice are otherwise immune competent. The immune competent 
model used here appears to result in the rapid and robust clearance of A.f. before 
larger hyphae germinate and A.f. invades tissues. CLRs likely have clearer roles in 
immune suppressed models where extensive A.f. growth occurs and the different role 
of each CLR, along with CLR collaboration, is essential for fungal clearance. Immune-
competent models may be more appropriate for examining allergic-type A.f. disease 
where chronic A.f. exposure results in airway sensitisation rather than this acute 
infection model where A.f. is cleared quickly. The allergic chronic exposure models 
require mice to be inoculated with A.f. multiple times per week for multiple weeks to 
generate persistent A.f. disease [341]. Further study into the role of these CLRs during 
acute A.f. infection in an immune-suppressed model is required. 
 
6.4: CLRs and A.f. in the immune-suppressed 
 
A.f. is responsible for a significant disease burden in immune suppressed individuals. 
Patients with neutropenia or patients receiving corticosteroid therapy for graft versus 
host disease are at significant risk of developing A.f. infection [321, 342]. This is 
associated with a lack of robust anti-A.f. immune response and poor fungal clearance. 
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The CLR-driven anti-A.f. immune response during periods of immune suppression is 
not well understood.  
 
Depleting macrophages and neutrophils in zebra fish attained significantly enhanced 
susceptibility to A.f. disease [343]. In mice, glucocorticoid treatment accelerated the 
growth rate of A.f. in vivo; this was associated with an impaired macrophage and 
neutrophil response [344]. The depletion of neutrophils in mice reduced the required 
lethal dose of A.f. by 1 log (10); however, this research found the immune-suppression 
regime, mouse strain and A.f. strain significantly influenced the in vivo anti-A.f. 
response and survival outcome [345]. Despite research demonstrating enhanced in 
vivo susceptibility to A.f. following immune suppression, the impact immune 
suppression has on CLRs and their anti-A.f. impact is not understood. Lacking 
macrophages and neutrophils, significantly impairs the anti-A.f. response; however, 
the definitive impact losing CLRs during A.f. challenge has not been thoroughly 
investigated. 
 
Here, my research in chapter 5 investigates CLR status and functional immune 
response capability in a cohort of patients at high risk of developing A.f. disease. These 
results were then associated with the incidence of A.f. disease. Initially, this research 
identified the expression of patient’s CLRs at haematological malignancy treatment 
initiation. I demonstrated at this point, patients possessed some myeloid cells and the 
majority of patients expressed CLRs, although at highly variable expression levels. Due 
to the small patient cohort size, limited deductions can be attained from this research. 
However, patient’s Dectin-1 expression and Mcl expression were loosely associated 
with incidence of A.f. disease. The Dectin-1 mutation Y238X has been identified to 
increase susceptibility to A.f. disease. This early stop-codon mutation was found to 
functionally impair anti-A.f. cytokine and chemokine responses [292]. My research 
suggesting Dectin-1 expression impacts A.f. susceptibility was therefore expected. So 
far, Mcl has only been implicated in protective anti-fungal immunity, although the 
evidence for this is limited. Why patients with high Mcl expression are at greater risk 
of A.f. disease in my model is not clear. This patient cohort is small in size and the 
impact Mcl expression has may have not been detected.  
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My research also identified a novel Dectin-2 mutation that results in an early stop 
codon and loss of CRD. One patient was homozygous for this novel CLR mutation. This 
patient did not produce an anti-A.f. cytokine and chemokine response and developed 
a lethal A.f. infection. This mutation may have similar impact to the Dectin-1 Y238X 
early stop codon mutation that was associated with an increased susceptibility to A.f. 
disease. Dectin-1 Y238X resulted in an impaired anti-A.f. cytokine and chemokine 
response likely due to the loss of A.f. recognition [292]. Multiple mutations in Dectin-
1 and DC-SIGN have been associated with an increased susceptibility to A.f. disease 
[67, 346]. The Dectin-2 mutant may provide a novel risk factor identifying patients 
susceptible to A.f. disease; this mutation requires further investigation.  
 
This research also determined the ability of patient’s to generate functional anti-fungal 
immune responses during periods of immune-suppression. Interestingly, lacking a 
specific anti-A.f. cytokine response was identified as a novel risk factor that could be 
used to stratify patients according to their A.f. disease susceptibility. The anti-A.f. 
response is complex and likely requires CLR and TLR collaboration, and multiple 
components; where as the anti-LPS response is almost exclusively driven by TLR4 
[318]. Patients who generated anti-A.f. cytokine and chemokine responses may have 
more intact and capable immune systems able to generate protective immune 
responses. Patients that only generated anti-LPS responses may lack key anti-fungal 
immune components and are therefore more susceptible to A.f. disease. In this 
research I have only identified patients CLR expression at RNA level and sequenced 
CLR exon regions. It is possible that CLR protein expression deficiencies, CLR intron 
mutations, CLR splice deficiencies or CLR signalling deficiencies may be present in this 
cohort, however due to limited sample size these properties have not been examined. 
These aspects of each patient’s CLR status may provide further insight as to why 
patients susceptible to A.f. disease lack a specific anti-A.f. cytokine response. Here, in 
a small patient cohort I have identified a combination of novel risk factors that can be 
used to stratify patients according to their A.f. disease susceptibility. Further study in 
a larger patient cohort is warranted to thoroughly test the ability of these risk factors 
to successfully stratify patients.  
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6.5: Conclusions 
 
Understanding the individual and collaborative role of CLRs during the complex anti-
A.f. immune response may allow the generation of novel therapeutics that enhance 
the CLR-driven anti-A.f. immune response. The exogenous administration of TLR 
ligands restored impaired PRR co-stimulation and enhanced clearance of Fonsecaea 
perdrosoi [187]. In a similar mechanism, exogenously administering ligands that 
restore or enhance CLR collaboration may generate more robust anti-A.f. immunity. 
 
This research describes a clear role for NE inducing Dectin-1 cleavage and impairing 
the anti-A.f. immune response. This is particularly relevant for CF patients who 
experience a severe A.f. disease burden and possess high concentrations of NE within 
their airway. Blocking the action of NE in the CF airway, alongside the administration 
of therapeutics that enhances the CLR-driven anti-A.f. response may reduce CF 
patient’s A.f. morbidity and mortality. This research also identifies novel risk factors 
that can be used to stratify patients according to their susceptibility to A.f. infection. 
Determining patient’s CLR status and functional immune response capability upon 
initiation of their primary disease treatment would allow the stratification of patients 
at high risk of A.f. disease. Therefore, a personalised medicine approach could be 
implemented and the empirical prophylactic use of inadequate anti-fungal 
therapeutics reduced.  
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Chapter 7 
 
 
Appendix 
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          Table 7.1: Cell media used in this research 
Media Quantity/ 
Concentration 
Constituent  Company 
BMDM  DMEM LifeTechnologies 
10% Fetal bovine serum LifeTechnologies 
5% Horse serum LifeTechnologies 
2mM L-glutamine LifeTechnologies 
1% Penicillin  
Streptomycin 
LifeTechnologies 
25mM  HEPES LifeTechnologies 
10ng/ml final M-CSF Peprotech 
 
Alveolar 
macrophage 
 IMDM LifeTechnologies 
 
Neutrophil/ 
Monocyte 
 RPMI 1640 LifeTechnologies 
10% Fetal bovine serum LifeTechnologies 
1% Penicillin  
Streptomycin 
LifeTechnologies 
 
NIH-3T3  DMEM LifeTechnologies 
10% Fetal bovine serum LifeTechnologies 
2mM L-glutamine LifeTechnologies 
1% Penicillin  
Streptomycin 
LifeTechnologies 
For selection 0.5mg/ml final G418 LifeTechnologies 
 
Ecopack  DMEM LifeTechnologies 
10% Fetal bovine serum LifeTechnologies 
 
FACS buffer  PBS LifeTechnologies 
0.1%  Bovine serum albumin Sigma 
0.05% Sodium azide Sigma 
 
NE assay  
buffer 
 PBS LifeTechnologies 
0.1%  Bovine serum albumin Sigma 
5mM  EDTA Fisher Scientific 
 
PBMC  RPMI 1640 LifeTechnologies 
10% Fetal bovine serum LifeTechnologies 
2% Human serum Sigma 
10mM L-glutamine LifeTechnologies 
10mM Sodium pyruvate LifeTechnologies 
100μg/ml final Gentamicin LifeTechnologies 
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          Table 7.2: Antibodies used in this research 
Antibody Fluorophore Species Final concentration Clone Company 
CD11b APC-Cy7 Mouse 2μg/ml M1/70 BioLegend 
CD11b PerCP-Cy5.5 Mouse 4μg/ml M1/70 BioLegend 
CD11c PE-Cy7 Mouse 2μg/ml N418 BioLegend 
F4/80 PB Mouse 4μg/ml BM8 BioLegend 
Ly6G PE Mouse 4μg/ml 1A8 BioLegend 
Dectin-1 APC Mouse 2μg/ml MCA228 Bio-Rad 
Dectin-2 Biotin Mouse 4μg/ml ILE4 Homemade 
Mincle Biotin Mouse 4μg/ml 4A9 Homemade 
Streptavidin PE  4μg/ml  BioLegend 
          Table 7.3: ELISA kits used in this research 
ELISA target Species Product Company 
TNF Mouse 14-7423-68A eBioscience 
IL-6 Mouse 14-7061-68 eBioscience 
Mip-1 Mouse DuoSet DY450 R & D Systems 
Mip-2 Mouse DuoSet DY452 R & D Systems 
KC Mouse DuoSet DY453 R & D Systems 
TNF Human DuoSet DY210 R & D Systems 
IL-6 Human DuoSet DY206 R & D Systems 
Mip-1 Human DuoSet DY270 R & D Systems 
KC Human DuoSet DY275 R & D Systems 
245	
          Table 7.4: qPCR probes used in this research 
qPCR Probe target Species Product Company 
HPRT Human 02800695 m1 ThermoFisher 
Dectin-1 Human 00224028 m1 ThermoFisher 
Dectin-2 Human 01073951 m1 ThermoFisher 
Mcl Human 01073582 m1 ThermoFisher 
Mincle Human 00372017 m1 ThermoFisher 
A.f. 18S rRNA A.f. Custom probe  
GenBank accession reference AB008401 
ThermoFisher 
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Figure 7.5: CLR sequences and PCR primers used in this research 
 
 
A) Human Dectin-1 
 
atggaatatcatcctgatttagaaaatttggatgaagatggatatactcaattacacttcgact 
ctcaaagcaataccaggatagctgttgtttcagagaaaggatcgtgtgctgcatctcctccttg 
gcgcctcattgctgtaattttgggaatcctatgcttggtaatactggtgatagctgtggtcctg 
ggtaccatgggggttctttccagcccttgtcctcctaattggattatatatgagaagagctgtt 
atctattcagcatgtcactaaattcctgggatggaagtaaaagacaatgctggcaactgggctc 
taatctcctaaagatagacagctcaaatgaattgggatttatagtaaaacaagtgtcttcccaa 
cctgataattcattttggataggcctttctcggccccagactgaggtaccatggctctgggagg 
atggatcaacattctcttctaacttatttcagatcagaaccacagctacccaagaaaacccatc 
tccaaattgtgtatggattcacgtgtcagtcatttatgaccaactgtgtagtgtgccctcatat 
agtatttgtgagaagaagttttcaatgtaa 
 
 
 
Forward Primer 1  atggaatatcatcctgatttagaaa 
Forward Primer 2  ttcagcatgtcactaaattcc 
Reverse Primer 1  ttacattgaaaacttcttctcacaa 
Reverse Primer 2  aggagattagagcccagttg 
 
C203G Forward Primer 
             Reverse Primer 
ggtcctgggtaccatgggtatttggagatccaatt 
aattggatctccaaatacccatggtacccaggacc 
T311G Forward Primer 
             Reverse Primer 
catctttagaagacagtgggactcctaccaaagctgt 
acagctttggtaggagtcccactgtcttctaaagatg 
C326G Forward Primer 
             Reverse Primer 
gtgactcctaccaaaggtgtcaaaaccacaggg 
ccctgtggttttgacacctttggtaggagtcac 
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B) Human Dectin-2 
 
atgatgcaagagcagcaacctcaaagtacagagaaaagaggctggttgtccctgagactctggt 
ctgtggctgggatttccattgcactcctcagtgcttgcttcattgtgagctgtgtagtaactta 
ccattttacatatggtgaaactggcaaaaggctgtctgaactacactcatatcattcaagtctc 
acctgcttcagtgaagggacaaaggtgccagcctggggatgttgcccagcttcttggaagtcat 
ttggttccagttgctacttcatttccagtgaagagaaggtttggtctaagagtgagcagaactg 
tgttgagatgggagcacatttggttgtgttcaacacagaagcagagcagaatttcattgtccag 
cagctgaatgagtcattttcttattttctggggctttcagacccacaaggtaataataattggc 
aatggattgataagacaccttatgagaaaaatgtcagattttggcacctaggtgagcccaatca 
ttctgcagagcaatgtgcttcaatagtcttctggaaacctacaggatggggctggaatgatgtt 
atctgtgaaactagaaggaattcaatatgtgagatgaataagatttacctatga  
 
 
 
Forward Primer 1 atgatgcaagagcagcaa 
Forward Primer 2  cccagcttcttggaagtca 
Reverse Primer 1  tcataggtaaatcttattcatctcacat 
Reverse Primer 2  actcattcagctgctggac 
 
 
 
 
C) Human Mcl 
 
atggggctagaaaaacctcaaagtaaactggaaggaggcatgcatccccagctgataccttcgg 
ttattgctgtagttttcatcttacttctcagtgtctgttttattgcaagttgtttggtgactca 
tcacaacttttcacgctgtaagagaggcacaggagtgcacaagttagagcaccatgcaaagctc 
aaatgcatcaaagagaaatcagaactgaaaagtgctgaagggagcacctggaactgttgtccta 
ttgactggagagccttccagtccaactgctattttcctcttactgacaacaagacgtgggctga 
gagtgaaaggaactgttcagggatgggggcccatctgatgaccatcagcacggaagctgagcag 
aactttattattcagtttctggatagacggctttcctatttccttggacttagagatgagaatg 
ccaaaggtcagtggcgttgggtggaccagacgccatttaacccacgcagagtattctggcataa 
gaatgaacccgacaactctcagggagaaaactgtgttgttcttgtttataaccaagataaatgg 
gcctggaatgatgttccttgtaactttgaagcaagtaggatttgtaaaatacctggaacaacat 
tgaactag  
 
 
 
Forward Primer 1 atggggctagaaaaacctca  
Forward Primer 2  acaagacgtgggctgaga  
Reverse Primer 1  ctagttcaatgttgttccaggtattt  
Reverse Primer 2  ccactgacctttggcatt  
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D) Human Mincle 
 
atgaattcatctaaatcatctgaaacacaatgcacagagagaggatgcttctcttcccaaatgt 
tcttatggactgttgctgggatccccatcctatttctcagtgcctgtttcatcaccagatgtgt 
tgtgacatttcgcatctttcaaacctgtgatgagaaaaagtttcagctacctgagaatttcaca 
gagctctcctgctacaattatggatcaggttcagtcaagaattgttgtccattgaactgggaat 
attttcaatccagctgctacttcttttctactgacaccatttcctgggcgttaagtttaaagaa 
ctgctcagccatgggggctcacctggtggttatcaactcacaggaggagcaggaattcctttcc 
tacaagaaacctaaaatgagagagttttttattggactgtcagaccaggttgtcgagggtcagt 
ggcaatgggtggacggcacacctttgacaaagtctctgagcttctgggatgtaggggagcccaa 
caacatagctaccctggaggactgtgccaccatgagagactcttcaaacccaaggcaaaattgg 
aatgatgtaacctgtttcctcaattattttcggatttgtgaaatggtaggaataaatcctttga 
acaaaggaaaatctctttaa  
 
 
 
Forward Primer 1 atgaattcatctaaatcatctgaaac  
Forward Primer 2  accatttcctgggcgtta  
Reverse Primer 1  ttaaagagattttcctttgttcaaa  
Reverse Primer 2  tcctgctcctcctgtgag  
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Figure 7.6: Animal distress scoring system used in this research 
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1. 
0 
1 
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0 
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3. 
0 
1 
2 
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4. 
0 
1 
2 
3 
 
            
   
5. 
2-4 
            
   
6. 
0-16 
            
 
-20% 
mass             
Exp ID Completed by  Time Date 
 
 
   
Additional 
examination             
Completed by  Time  
1. APPEARANCE 
Normal 
General lack of grooming 
Coat starring, ocular and nasal discharging 
Piloerection, hunched posture 
 
2. FOOD AND WATER INTAKE  
Normal 
5% weight loss 
Upto 15% weight loss 
Over 15% weight loss 
 
3. NATURAL BEHAVIOUR 
Normal respiratory rate and pattern 
Slight changes, increased rate only 
Increased rate with abdominal breathing 
Decreased rate with marked abdominal breating 
 
4. PROVOKED BEHAVIOUR 
Normal 
Minor depression or exaggerated response 
Moderate change in expected behaviour 
Reacts violently, or very weak and precomatose 
 
5. SCORE ADJUSTMENT 
If you have scored 3 more than once add 1 point per 3 score 
 
6. TOTAL 
 
JUDGEMENT 
0-3 Normal  
4-8 Monitor Carefully (daily) 
9-12 Observe regularly 
>13 Kill by schedule 1 
 
COMMENTS: 0-3 = Normal; 4-8 = Monitor Carefully; 9-12 = Provide relief where 
possible, observe regularly, seek advice as appropriate from NACWO and/or NVS; >13  
= Kill by schedule 1 method. Humane-end-point is reached at 20% loss of body weight. 
 
ADDITIONAL COMMENTS: Actual severity: Mild – score 0-4 with up to 15% 
weight loss; Moderate – score >5 and/or >15% weight loss; Severe – moribund or found 
dead 
ANIMAL	DISTRESS	SCORING	SHEET	Aspergillus challenge 15/05/17 (Adapted	from	Wolfensohn	and	Lloyd,	1998)	
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